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Niraja Padmalata Lal 
Abstract 
The role of Placenta growth factor (PlGF) in physiological angiogenesis is quiescent, 
preclinical and human studies have established PlGF angiogenic activity to be regulated in 
pathologies. PlGF elicits its cellular functions via (vascular endothelial growth factor 
receptor) VEGFR-1 alone, and has gained more attention for its safety profile, especially 
when compared to the risks involved in VEGF-derived therapies. Loss and gain studies of 
PlGF function highlight the contribution of PlGF in disease aggravation or alleviation; 
however, factors regulating PlGF expression remains elusive.  
Data from this study demonstrates basic fibroblast growth factor (FGF-2) induced expression 
of PlGF in cultured ECs. FGF-2-amplified PlGF via transcriptional regulation, demonstrated a 
significant increase in both PlGF protein and mRNA levels. Using pharmacological inhibitors 
and adenoviral constructs to modulate signalling enzymes, I established that the FGF-2-
amplified EC expression of PlGF involved multiple signalling cascades; namely the 
Ras/Raf/MAPK, protein kinase C (PKC), and phospholipase D (PLD) signal transduction 
pathways. Functional studies conducted with PlGF gene knock-down in endothelial cells (EC) 
displayed reduced FGF-2-mediated angiogenic activity in invitro tube formation. This finding 
was consolidated using the mouse aortic ring assay; significant reduction in sprouting 
angiogenesis was noted in FGF-2 treated aortic tissue from null mice (plgf
-/-
) compared to 
their wild-type controls.  
Besides being a pro-angiogenic factor, PlGF is also a strong pro-inflammatory mediator. 
Chronic inflammation is a hallmark of several inflammatory disorders and plays a key role in 
the pathogenesis of endothelial dysfunction. In this study, decline in endothelial PlGF protein 
levels in ECs in response to pro-inflammatory cytokines TNF-α, IL-1β, and IFNγ has been 
revealed. Real-time PCR and PlGF promoter activity studies confirmed TNF-α reduced 
endothelial PlGF expression to be transcriptionally regulated. Endothelial dysfunction has 
been reported to be mediated by EC apoptosis that may eventually lead to systemic vascular 
dysfunction (SVD), a common denominator for several inflammatory and chronic disorders.  
Loss of PlGF significantly increased EC apoptosis even in the presence of high serum 
concentrations. Additionally, exogenous growth factors could not rescue EC apoptosis in 
PlGF gene knock-down HUVEC. Data from these studies identified a new pathway leading to 
EC apoptosis, secondary to PlGF loss or inhibition in response to the “alarming cytokines” 
TNF-α, IL-1β. 
Collectively, these data demonstrate the factors that regulate endothelial PlGF expression and 
contribute a vital discovery of new biological functions of endothelial PlGF in FGF-2-
mediated angiogenesis. These findings add new dimensions to the regulatory mechanisms 
governing endothelial PlGF that may have significant implications for therapeutic approaches 
aimed at promoting or disrupting neovascularisation. 
Keywords: PlGF, FGF-2, neovascularisation, VEGFR-1, TNF-α, functional assay, 
endothelial apoptosis, endothelial dysfunction 
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1.1  Neovascularisation 
Vascular endothelial cells form the integral and fundamental constituents of the vascular 
system for growth and survival.  Endothelial cells (ECs) line the inner surface of the blood 
vessels. Neovascularization is an umbrella (or broad) term used to represent physiologically 
complex processes, namely, vasculogenesis, angiogenesis and arteriogenesis (Figure1.1). 
Vasculogenesis is a de novo process solely used to describe the process of blood vessel 
formation in the embryo. In vasculogenesis, undifferentiated endothelial progenitor cells 
(EPCs) migrate to the sites of new vessel growth and then follow on to differentiate into 
mature ECs (Flamme, Frolich et al. 1997). The process is completed by the formation of the 
vascular plexus (Gerhardt and Betsholtz 2003). Recent studies are now asserting that this 
process contributes to the adult blood vessel formation as well (Drake 2003, Eguchi, Masuda 
et al. 2007). Angiogenesis is the development of new microvessels from pre-existing 
vasculature, involving proliferation and migration of the ECs; in short, it is the growth of new 
blood vessels from pre-existing ones. The processes of angiogenesis and vasculogenesis are 
distinct. Despite the differences in the molecular and cellular levels governing the sequence of 
events in both of these processes, an overlap of several genes that are essential for 
angiogenesis are likewise vital for vasculogenesis as well (Folkman and D'Amore 1996, Risau 
1997). The new vessels formed through angiogenesis can either develop via sprouting 
angiogenesis, or non-sprouting (intussusceptive) microvascular growth (IMG) (Ribatti 2006). 
Sprouting angiogenesis is an important and common mechanism of vessel growth coordinated 
by sequential steps (Ribatti and Crivellato 2012). Non-sprouting angiogenesis occurs by 
intussusceptions and vessel elongation from the pre-existing vessel growth. This development 
is achieved either by the merging of the pre-existing capillaries or by the fusion of additional 
ECs into the already existing vessels, consequently increasing the length and the diameter of 
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the tubular structure as well. Non-sprouting angiogenesis was shown to take place in the 
myocardium, skeletal muscle and during the process of wound healing (Patan, Haenni et al. 
1996, Djonov, Baum et al. 2003). Overall, both sprouting and non-sprouting angiogenesis 
occur in the heart, lung and yolk sac (Risau 1997) (Figure 1.2). 
  
 
Figure 1.1 Neovascularisation - The processes of angiogenesis, vasculogenesis, and 
arteriogenesis. Angiogenesis, new microvessels generated from pre-existing vasculature by 
the proliferation and migration of mature ECs in response to agonists of angiogenesis, i.e 
growth factors. In vasculogenesis undifferentiated EPCs circulate to the sites of new vessel 
growth, where they differentiate into mature ECs. Arteriogenesis promotes 
neovascularisation via migration and proliferation of ECs and SMCs forming mature 
collateral arteries. Abbreviations: Ang 1, angiopoietin-1; EC, endothelial cell; EPC, 
endothelial progenitor cell; FGF, fibroblast growth factor; HIF, hypoxia-inducible factor; 
SMC, smooth muscle cell; VEGF, vascular endothelial growth factor (Szoke and Brinchmann 
2012). 
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Arteriogenesis involves the migration and proliferation of two major cell types; ECs and 
smooth muscle cells (SMCs). During this process, the expansive growth of the collateral 
arteries from the sprouting of pre-existing vessels form collateral bridges between the arterial 
networks in response to endogenous growth factors and cytokines, such as VEGF, FGF, TGF, 
Ang 1, which are released secondary to tissue ischemic event.  
 
1.2 Physiological Angiogenesis 
Physiological angiogenesis is fundamental for embryonic development and is characterised by 
tight regulation, both spatially and temporally. Angiogenesis is essential for a healthy adult to 
maintain functions of the female reproductive system, wound and fracture healing, and tissue 
repair.   
1.2.1    Angiogenesis: A Multistep Process 
Angiogenesis is a complex process involving extensive interaction between cells, soluble 
factors and extracellular matrix [ECM] components. The formation of a vascular network, 
subsequent to angiogenesis, requires fine coordination of sequential events regulated by 
antagonistic factors to stimulate and inhibit angiogenesis (Risau 1997). Metabolic demands 
regulate the vascularisation of tissues as well as tumours. The tissue diffusion limit of oxygen 
ranges between 100-200 µm, indicating hypoxia to be the most significant pro-angiogenic 
trigger (Schaafhausen, Yang et al. 2013). Hypoxia induces the regulation of hypoxia-
inducible factor (HIF) protein signalling cascade (Semenza 2001), which in turn up-regulates 
the endogenous release of various growth factors and cytokines, such as VEGF, fibroblast 
growth factor-2 (FGF-2) and placenta growth factor (PlGF) to name a few. These growth 
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factors and cytokines diffuse into the surrounding environment, bind to their specific 
receptors and activate the ECs lining the pre-existing blood vessels. The activated endothelial 
cells loosen their cell contacts and release proteases such as matrix metalloproteinases 
[MMPs], resulting in the degradation of the base membrane surrounding the pre-existing 
vessel. ECs migrate towards angiogenic stimuli into the interstitial spaces. Angiogenesis 
likewise relies on the adhesion receptor integrins such as αvβ3 and αvβ5 that facilitate EC 
migration through their interaction with a variety of ECM components (Cheresh 1991, 
Leavesley, Schwartz et al. 1993). Besides being a fundamental factor for the survival of the 
nascent vessels, via regulating cell adhesion to the matrix, αvβ3 associates in the activation of 
vascular endothelial growth factor receptor 2 (VEGFR-2) triggered by its ligand VEGF 
(Soldi, Mitola et al. 1999, Borges, Jan et al. 2000).  Sprouting ECs proliferate, forming a new 
lumen, and the generation of new basement membrane takes place. These ECs that deposit on 
the new basement membrane, secrete growth factors such as platelet-derived growth factor 
(PDGF), which recruit pericytes in small vessels and SMCs in larger vessels for the structural 
support and vascular integrity of the vessel (Carmeliet 2000). 
Angiogenesis is a highly complex process involving the concerted actions of several other 
factors, such as the angiopoietins and ephrins which regulate vessel stability upon activation 
of their specific receptors (Yancopoulos, Davis et al. 2000). PDGF and the angiopoietins 
complement this process at the later stages of angiogenesis, bridging communications 
between the ECs and the mesenchyme in the surrounding areas (Hammes, Lin et al. 2002, 
Guo, Hu et al. 2003). Finally, the fusion of the newly formed vessels initiates the flow of the 
blood.  
  





Table 1.1 Schematic representation of the key stages in angiogenesis and the relevant 
growth factors involved at each stage. [http://www.cellworks.co.uk/angiogenesis.php].  
Key Stage Markers
Stage One: Endothelial cell 
activation in response to 
angiogenic factors.
Basic Fibroblast Growth Factor (bFGF): a potent 
stimulatory factor for endothelial cell migration and 
proliferation. Vascular Endothelial Growth Factor 
(VEGF): initiates cell proliferation and migration.
Stage Two: Degradation of the 
capillary wall by extracellular 
proteinases.
Matrix Metalloproteinases (MMPs): MMP1 (a 
collagenase) and MMP2 are expressed during 
angiogenesis and act to degrade extracellular matrix 
components.
Stage Three: Formation of a 
branch point in the vessel wall.
Integrins: expressed on newly forming vessels.
Stage Four: Migration of 
endothelial cells into the 
extracellular matrix towards the 
angiogenic stimulus.
Integrins: allow migrating endothelial cells to interact with 
specific components of the surrounding matrix. MMPs and 
urokinase: aid migration of endothelial cells into the 
surrounding matrix.
Stage Five: Re-organisation of 
endothelial cells to form tubules 
with a central lumen.
Angiopoietin (Ang 1): produced by surrounding stromal 
cells; facilitates endothelial cell survival and stabilisation of 
new capillary tubes.
Stage Six: Interconnection of 
the new tubules to form a 
network (anastomosis). 
Platelet Derived Growth Factor (PDGF): produced by 
endothelial cells of the new capillaries; recruits pericytes 
which stabilize the new vessels.




The sequential events involved in vasculogenesis leading to mature circulatory system via 
angiogenesis are tightly regulated by several endogenously released growth factors and 









Figure 1.2 Pictorial illustration representing the sequential events involved in 
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1.2.2  Angiogenesis in female reproductive system 
Angiogenesis is a fundamental process underlying the action and function of the female 
reproductive system; notably the menstrual cycle and the establishment of pregnancy. Rapid 
cyclic growth and shedding of the endometrium take place throughout the reproductive life of 
a female. The process involving the development and function of corpus luteum is largely 
dependent on the growth of new blood vessels (Klauber, Rohan et al. 1997). EC proliferation 
occurs throughout the menstrual cycle, reflecting the continual vascular remodelling 
occurring in the endometrium (Rogers, Donoghue et al. 2009). Studies have demonstrated that 
VEGF, PlGF, FGF-2 and other angiogenesis promoting factors are expressed in human 
endometrium, decidua and placenta (Rogers, Donoghue et al. 2009). Endometrial 
angiogenesis predominantly occurs in the basalis layer, and in the sub epithelial capillary 
plexus of the functionalis layer during the phase of proliferation and early secretion of the 
menstrual cycle. Two distinct peaks of EC migratory activity that correspond to the cyclic 
changes in EC proliferation are apparent in the functionalis region of the endometrium. These 
occur during the post menstrual and mid to late proliferative phases of the cycle (Rogers, 
Lederman et al. 1998). Despite the certainty of angiogenesis in the endometrium during the 
menstrual cycle, reports from several studies in animal models have failed to establish a 
correlation between the factors triggering the angiogenic switch and neovascularisation in the 
endometrium (Weston and Rogers 2000). 
Studies exploring the type of angiogenesis occurring in the endometrium reported that the 
expression of αvβ3 integrin [expressed by ECs during angiogenesis] localised in the ECs 
within the existing vessels and not detected in the vascular sprouts. This observation strongly 
suggests intussusceptions and vessel elongation as the major mechanism of angiogenesis in 
the endometrium (Rogers, Lederman et al. 1998). The uterus is home to circulating 
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endothelial progenitor cells [EPCs] that differentiate into ECs (Asahara, Masuda et al. 1999). 
Dr Shunichiro Miyoshi and the group recently reported how multipotent stem cells derived 
from the menstrual blood exhibited stem cells properties. These precursor cells, when co-
cultured with rat cardiomyocytes, formed sheets of heart muscle tissue (Hida, Nishiyama et al. 
2008).  
Several molecules are involved as mediators in endometrial angiogenesis, including VEGF, 
PlGF, Ang-1 and Ang-2 (Maisonpierre, Suri et al. 1997) and FGF-2 (Gospodarowicz, Cheng 
et al. 1985, Ferrara, Chen et al. 1998, Demir, Yaba et al. 2010). It was reported that a clear 
association exists between the expression of VEGF and angiogenesis occurring in the 
endometrium (Graubert, Ortega et al. 2001). In 1998 Ferrara and group, reported that rats 
treated with soluble receptor VEGFR-1 (sVEGFR-1) demonstrated complete suppression of 
corpus luteum angiogenesis (Ferrara, Chen et al. 1998).  VEGF expression has also been 
correlated with angiogenesis regulated by oestrogen (Shweiki, Itin et al. 1992). Moreover, it 
has been found that the regulatory regions of the VEGF gene harbour oestrogen response 
elements (Mueller, Vigne et al. 2000). The majority of endometrial VEGF appears to be 
secreted by the glandular epithelium when compared to the stromal cells (Nayak, Critchley et 
al. 2000, Bussolati, Dunk et al. 2001). During days 1-3 of the menstrual cycle (Nayak, 
Critchley et al. 2000) maximal expression of VEGF induced by hypoxia following the 
constriction of spiral arterioles in conjunction with the expression of transforming growth 
factor (TGF) α and interleukin (IL)-1β was noticed (Varma and Mascarenhas 2001).  
Collectively, the studies shed light on the multiple factors involved in the tight regultion of 
endometrial angiogenesis.       
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 1.2.3  Wound Healing 
New vessel formation is critical for the process of wound healing. Capillary regression 
followed by the successful healing of the wound and resultant termination of the process takes 
place. Neovascularisation into the wound is fundamental for the provision of oxygen and 
nutrients to the tissue during repair, to promote granulation tissue formation (Schafer, Maier 
et al. 1994) and to clear debris from the wound (Dvorak, Nagy et al. 1988). 
Neovascularisation for the process of wound healing depends on several factors, such as cell 
to cell interactions, cell and ECM interactions, and most importantly the balance between 
agonist and antagonist that have a direct effect on the “angiogenic switch”. The angiogenic 
switch refers to the time restricted event, wherein the balance between the pro- and anti-
angiogenic mediators tilts, resulting in unwanted or unstable cellular events.  Tissue injury is 
followed by plasma exudation, including the degranulation of plasma fibrinogen. Plasma 
fibrinogen then acts as a substrate and generates fibrin-containing matrix, which eventually is 
substituted by the granulation tissue (Schafer, Maier et al. 1994, To and Midwood 2011). 
Degranulation of platelets and release of growth factors are the initial events at the wound site 
(Maloney, Silliman et al. 1998). Granulation involves the process of proteolysis by plasmin, 
which is produced by plasminogen in the interstitial fluid and plasma (Miyashita, Wenzel et 
al. 1988). Recruitment of polymorphonuclear leukocytes [PMNs], monocytes, fibroblasts, and 
capillary endothelial cells organise the primary wound matrix (Dvorak, Nagy et al. 1988). 
Neovascularisation, which plays a critical role in successful wound healing, is predominantly 
regulated by the growth factors FGF-2 (Ortega, Ittmann et al. 1998), VEGF (Nissen, Polverini 
et al. 1998) and PlGF (Carmeliet, Moons et al. 2001). These growth factors are released by 
both endothelial and non-endothelial cells in response to inflammatory mediators. 
Macrophages play a significant role in contributing to the healing process by releasing potent 
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angiogenic factors (Swift, Kleinman et al. 1999). During wound healing, PlGF released by 
vascular and non-vascular cells is known to have an autocrine effect on ECs (Migdal, 
Huppertz et al. 1998, Dewerchin and Carmeliet 2012) as well as a role in recruiting 
macrophages to the site of injury. These inflammatory mediators further release both 
angiogenic and lymphangiogenic (formation of lymphatic vessels from pre-existing lymphatic 
vessels) molecules, in addition to proinflammatory cytochemokines (Selvaraj, Giri et al. 2003, 
Dewerchin and Carmeliet 2012) contributing to the process of wound healing.  
1.3 Pathological Angiogenesis 
Pathological angiogenesis occurs when the dynamic balance between factors that induce the 
formation of blood vessels and those that inhibit the process is obliterated. A distinct margin 
lies between physiological and pathological settings (Folkman 1995). Although many positive 
and negative regulators function in both situations, EC proliferation is firmly controlled in the 
former, whereas in the latter, the unchecked growth of blood vessels lead to several diseases 
in different tissues, some of which illustrated in Figure 1.3  
 
In both normal and pathological angiogenesis, hypoxia is the main driver of the angiogenic 
process via the hypoxia-inducible factor (HIF-1) receptor. Furthermore, growth factors, 
hormones and inflammatory mediators enhance the expression of angiogenic factors, such as 
VEGF, PlGF, FGF and respective receptors, thereby switching on the process of unchecked  
angiogenesis (Galzie, Kinsella et al. 1997, Jiang, Agani et al. 1997, Carmeliet, Dor et al. 
1998, Carmeliet 2005). The remarkable ability of the ECs to divide excessively results in 
excessive angiogenesis, which can lead to pathologies of inflammatory, ocular and 
malignancy disorders (Carmeliet 2005).  Similarly, insufficient angiogenesis can lead to EC 
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dysfunction, vessel regression or malformation, contribute to preeclampsia (PE), ischemic 
heart disease, peripheral vascular disease, and ulcers to name a few (Folkman 1995, Carmeliet 
2005). 
                    
Figure 1.3 Angiogenesis off-balance common denominator for pathologies. Schematic 
representation of excessive angiogenesis leading to inflammatory and/or malignant disorders 
and insufficient angiogenesis giving rise to cardiovascular disease, peripheral vascular 
disease and other pathologies. 
 
 
1.4 Role of growth factors in angiogenesis 
VEGF-mediated angiogenesis is critical for organ formation during embryogenesis. 
Angiogenesis is tightly regulated by a variety of pro- and anti-angiogenic factors involved in 
the stimulation of angiogenesis. The imbalance between pro- and anti-angiogenic factors is 
manifested in pathological conditions, including cardiovascular disorders, tumours and 
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inflammatory cytokine-derived signals, or mutations leads to pathological angiogenesis 
(Malhotra 1989, Velasco 2002, Streit 2003, Yano 2003). A range of pro-angiogenic factors, 
including angiopoietins, FGF, transforming growth factor-β (TGF-β), and the members of the 
VEGF family such as PlGF, play key roles in the regulation of angiogenesis as well as 
lymphangiogenesis (Folkman 1987, Keck 1989, Yang 1990, Suri 1996). 
1.5  Factors regulating angiogenesis 
1.5.1 Vascular Endothelial Growth Factor [VEGF] 
VEGF was initially described as a vascular permeability factor (Brown, Weiss et al. 1980, 
Senger, Galli et al. 1983) that exerted its effects on non-angiogenesis related cellular functions 
as well. The identification of VEGF [or VEGF-A] has revolutionised the understanding of 
angiogenesis and of the prominent role it holds in physiological and pathological events. 
VEGF is a member of the PDGF family of growth factors.  VEGF and PlGF (Maglione, 
Guerriero et al. 1991) are two prominent members of the VEGF family of secreted proteins 
that exert endothelial and non-endothelial cellular mechanisms, along with the others 
members VEGF-B (Olofsson, Pajusola et al. 1996), VEGF-C (Joukov, Pajusola et al. 1996, 
Lee, Gray et al. 1996), VEGF-D (Achen, Jeltsch et al. 1998), VEGF-E (Ogawa, Oku et al. 
1998, Meyer, Clauss et al. 1999) and VEGF-F (Komori, Nikai et al. 1999). The members of 
the VEGF family are structurally related dimeric glycoproteins with different physical and 
biochemical characteristics, functional via three receptor tyrosine kinases (RTKs).  VEGF 
displays the ability to stimulate ECs to proliferate, migrate and survive in serum-deprived 
conditions (Breen 2007). 
VEGF-B, which is also known as VEGF-related factor [VRF], has its gene located on 
chromosome 11q13 (Paavonen, Horelli-Kuitunen et al. 1996). VEGF-B is expressed early in 
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foetal development and is distributed in different types of tissues, specifically in skeletal 
muscle and heart (Olofsson, Pajusola et al. 1996, Aase, Lymboussaki et al. 1999). VEGF-B 
binds to VEGFR-1 [fms-like tyrosine kinase 1/Flt-1], but not VEGFR-2 [kinase domain 
receptor - KDR/ Flk-1] or VEGFR-3 (Olofsson, Korpelainen et al. 1998). Two splice variant 
isoforms VEGF-B167 and VEGF-B186 are produced (Olofsson, Pajusola et al. 1996), which 
bind to heparin and neuropilin-1 respectively (Makinen, Olofsson et al. 1999).  
VEGF-C and VEGF-D act as lymphangiogenic growth factors (Joukov, Pajusola et al. 1996, 
Achen, Jeltsch et al. 1998). VEGF sub-types VEGF-C and D are proteolytically processed; no 
splice variants have been reported in humans yet (Baldwin, Roufail et al. 2001). However, 
two different protein isoforms with distinct C-termini, VEGF-D358 and VEGF-D326, with 
binding capacity for VEGFR-2 and VEGFR-3 have been identified in mice (Baldwin, Catimel 
et al. 2001) 
VEGF-E and VEGF-F are non-mammalian proteins related to VEGF. VEGF-E has been 
identified in the Parapoxvirus genome (Lyttle, Fraser et al. 1994). VEGF-E was identified in 
the genome of various strains of the Orf virus [NZ-2, NZ-7 and D1701], a member of the 
Poxvirus superfamily (Lyttle, Fraser et al. 1994, Ogawa, Oku et al. 1998, Meyer, Clauss et al. 
1999, Wise, Veikkola et al. 1999). Lesions caused by this virus are highly vascularised 
(Larcher, Murillas et al. 1998). Despite low sequence similarity to VEGF-A [16-20 % 
apparent homology], VEGF-E induces comparable levels of cell proliferation and 
permeability to that of VEGF-A165 (Ogawa, Oku et al. 1998, Meyer, Clauss et al. 1999, Wise, 
Veikkola et al. 1999). VEGF-E exerts these cellular activities via VEGFR-2. It was 
hypothesised that VEGF-E may have a phylogenetic origin in the vertebrate genome (Ogawa, 
Oku et al. 1998). 
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VEGF-F is the seventh member of the VEGF family was discovered in recent times. VEGF-F 
was identified in the venom of the snake (viper) (Yamazaki, Takani et al. 2003). VEGF-F 
yields two designated proteins: vammin of 110 residues and VR-1 with 109 residues (Otrock, 
Makarem et al. 2007). VEGF-F shares 50% homology with VEGF165 and selectively binds to 
VEGFR-2 (Otrock, Makarem et al. 2007). 
 
Structure and Functional Properties 
 
VEGF is a basic, heparin-binding, homodimeric glycoprotein of 45,000 Daltons (Ferrara, 
Houck et al. 1992) expressed in different tissues, including the brain, kidney, liver and spleen, 
and by many other cell types (Veikkola and Alitalo 1999). VEGF shares about 20% 
homology of amino acid sequence with PDGF-A and PDGF-B chains (Keck, Hauser et al. 
1989, Tischer, Gospodarowicz et al. 1989, Ferrara, Houck et al. 1992).  
VEGF, a.k.a VEGF-A has received greater attention and is a key mitogen regulating both 
physiological and pathological angiogenesis. VEGF is expressed in nine different isoforms, 
VEGF-A121, VEGF-A145, VEGF-A148, VEGF-A162, VEGF-A165, VEGF-A165b, VEGF-A183, 
VEGF-A189 and VEGF-A206  generated due to alternative mRNA splicing (Tischer, Mitchell et 
al. 1991, Ferrara, Houck et al. 1992, Bates, Cui et al. 2002) [see Figure 1.3]. The human 
VEGF gene is located on chromosome 6p21.3 composed of eight exons (Vincenti, Cassano et 
al. 1996). The N-terminal of VEGFR-binding domain is the common region to all the 
isoforms which is encoded on exons 1-5 (Tischer, Mitchell et al. 1991). VEGF-A165 lacks 
exon six coding regions, physiologically is the most abundant isoform of VEGF-A (Tischer, 
Mitchell et al. 1991) and binds to both VEGFR-1 and VEGFR-2. However, the binding 
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affinity of VEGF-A165 to VEGFR-1 is ten-fold higher than VEGFR-2 (de Vries, Escobedo et 
al. 1992, Terman, Dougher-Vermazen et al. 1992, Quinn, Peters et al. 1993). A new group of 
VEGF-A isoforms generated by the alternative splicing of the distal site at exon eight site 
were identified. Though these isoforms are similar in length to the classic VEGF isoforms, 
they differ in their C-terminal six amino acids. These new isoforms were designated the name 
VEGFxxxb, wherein xxx denoted the amino acid number of the mature protein. Currently, two 
isoforms have so far been identified and assigned as VEGF-A165b and VEGF-A159b. 
VEGFxxxb were reported to inhibit pro-angiogenic functions of VEGF (Bates, Cui et al. 2002). 
The structural variation and the distinct binding patterns of the VEGF subtypes to the 
receptors are illustrated in figure 1.4. 
 
Figure 1.4 Exonic structure of the VEGF gene and the identified splice variants of VEGF-
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The VEGF ligands bind to their specific receptors in a distinct pattern, as illustrated in Figure 
1.5. Each of the VEGF family members selectively bind to the VEGFR-1, 2 and 3 RTKs and 
neuropilin-1, 2 co-receptors, to manifest the diversity of their biological functions (Terman, 
Khandke et al. 1994, Makinen, Olofsson et al. 1999, Veikkola and Alitalo 1999, Breen 2007, 
Grunewald, Prota et al. 2010). VEGF isoforms bind to the cell surface and ECM by 
interacting with heparin sulphate proteoglycans [HSPG] that modulate the interactions of 
VEGFs and their receptors. The alternative splice variants of VEGF-A; VEGF-A121, VEGF-
A145, VEGF-A165, VEGF-A189 and VEGF-A206 have been shown to bind to both VEGFR-1 and 
VEGFR-2 (de Vries, Escobedo et al. 1992, Neufeld, Cohen et al. 1996). VEGF-A121 is a 
highly diffusible weak acidic protein that lacks exons 6 and 7; it neither binds to heparin nor 
neuropilin. VEGF-A189 and VEGF-A206 are retained in the extracellular matrix [ECM] and 
contain residues encoded by 6 and 7. These subtypes bind to heparin containing proteoglycans 
with high affinity (Houck, Leung et al. 1992). The C-terminal region of VEGF-A165 is critical 
for the heparin-binding and mitogenic activities. Exogenous heparin potently inhibited the 
binding of VEGFR-1, with both VEGF-A165 that binds to immobilised heparin, and VEGF-
A121, a splice variant lacking heparin binding affinity (Cohen, Gitay-Goren et al. 1995).  
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  Figure 1.5  Schematic representation of VEGF family/subtype ligand-receptor interactions 
 
Expression and regulation 
 
VEGF is a key regulator of vasculogenesis and angiogenesis (Plate and Warnke 1997, Josko, 
Gwozdz et al. 2000) and is produced by ECs, macrophages, fibroblasts and smooth muscle 
cells (Plate and Warnke 1997). Both in vitro and in vivo studies reported that VEGF binds to 
the specific receptors on ECs and act as a direct inducer of angiogenesis (Risau 1997). The 
two best characterised VEGF receptors, VEGFR-1 and VEGFR-2, are specific RTKs that 
together with PDGF receptors form the subtype III of RTK receptors through which VEGF 
executes cellular activities (Shibuya, Yamaguchi et al. 1990, de Vries, Escobedo et al. 1992, 
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binds to VEGF with substantially higher affinity, most of the biological effects of VEGF 
seem to be VEGFR-2-mediated (Holash, Davis et al. 2002) on ECs. Naturally occurring splice 
variant short soluble protein [sVEGFR-1] of VEGFR-1 retains its high-affinity binding to 
VEGF. sVEGFR-1 is a negative regulator effecting VEGF availability or may prolong the 
different VEGF-induced EC activities (Kendall and Thomas 1993, Plate and Warnke 1997, 
Hornig, Barleon et al. 2000, Hasan and Jayson 2001).  
 
VEGF-A activation of phosphatidylinositol-3 kinase (PI3K) and Bcl-2 signalling pathways 
promotes EC survival by inducing the expression of anti-apoptotic proteins Bcl-2 (Gerber, 
Dixit et al. 1998). VEGF-A mRNA expression is up-regulated by growth factors, 
inflammatory cytokines and hormones (Bates and Harper 2002), with the prime factor being 
hypoxia. Several growth factors like FGF-2 also regulate VEGF mRNA expression in a 
paracrine and autocrine manner, independent of hypoxic microenvironment (Seghezzi, Patel 
et al. 1998). It is now recognised that Hypoxia-inducible factor-1 alpha [HIF-1α] is a key 
mediator of the hypoxic responses. HIF-1α is involved in all vital physiological and 
pathological processes. Hypoxia-induced VEGF regulation elicits physiological responses via 
multiple molecular mechanisms. HIF-1 participates in essential developmental and 
physiological processes, including angiogenesis, energy metabolism, iron homeostasis, cell 
proliferation and viability via transactivation of target genes (Heme Oxygenase 1, Nitric 
Oxide Synthase 2, Plasminogen Activator Inhibitor 1, VEGF, VEGFR-1, Insulin-like Growth 
Factor 2 (IGF-2), Transforming Growth Factor 3 (TGF3), etc.) (Mukhopadhyay, Mazumder et 
al. 2000, Semenza 2000). Additionally, HIF-1 transactivation of target genes leads to either 
protective or pathologic responses in several major disease states, such as myocardial 
ischemia (MI), preeclampsia (PE), intrauterine foetal growth restriction (IUGR), pulmonary 
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hypertension, cerebral ischemia and cancer (Semenza 2000). The role of von Hippel–Lindau 
[VHL], tumour suppressor gene in HIF-1α dependent hypoxic responses, has also been 
described (Tammela, Enholm et al. 2005). Mutations in the VHL gene are allied with 
increased angiogenesis and tumours with VHL mutations that display increased VEGF-A 
expression. VHL targets the degradation of HIF subunits; consequently loss of VHL increases 
HIF1α levels (Ivan, Kondo et al. 2001, Jaakkola, Mole et al. 2001). In hypoxic situations, 
HIF-mediated regulation involved PI3K/Akt signalling mechanism (Semenza 2000) 
modulating VEGF-A expression.  
Biological activity & Role 
VEGF is very critical for the differentiation of ECs and morphogenesis of the vascular system 
during development. During embryogenesis loss of a single vegf allele resulted in the 
substantially deficient vascular network, leading to the death of mice (Carmeliet, Ferreira et 
al. 1996, Ferrara, Carver-Moore et al. 1996). Embryonic lethality is also observed in mice 
following a two-fold over-expression of VEGF, restating the significance of vegf gene dosage 
during development (Miquerol, Langille et al. 2000). 
As a multifunctional cytokine, VEGF is a potent stimulator of angiogenesis in vivo, and 
growth, migration, and differentiation of ECs in vitro (Ferrara, Carver-Moore et al. 1996, 
Terman and Dougher-Vermazen 1996, Shibuya, Luo et al. 1999). VEGF also elicits an 
angiogenic response in a variety of in vivo models including the chick chorioallantoic 
membrane (Leung, Cachianes et al. 1989, Plouet, Schilling et al. 1989), the rabbit cornea 
(Ferrara and Davis-Smyth 1997), the primate iris, and the rabbit bone (Ferrara and Davis-
Smyth 1997). VEGF is named as a key regulator of pathological growth of the blood vessels 
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in many conditions including, inflammation, retinopathies, psoriasis and arthritis (Hicklin and 
Ellis 2005, Dvorak 2006, Folkman 2007). 
The avb3 integrin, an adhesion receptor for extracellular matrix components with an exposed 
Arginine-glycine-aspartic acid (RGD) sequence is an attractive target for anti-angiogenic 
therapy since it is exclusively present on the cell surface of activated ECs but absent in 
quiescent endothelium or other cell types (Eliceiri and Cheresh 2000). Promising results with 
gene therapy have been obtained in therapeutic angiogenesis. Intramuscular gene transfer of 
VEGF165 and intramyocardial administration of an adenoviral vector expressing the VEGF121 
cDNA improved collateral vessel development in patients with critical limb ischemia 
(Arveschoug and Christensen 1999) and coronary artery disease (Rosengart, Lee et al. 1999), 
respectively. Although VEGF improves myocardial blood flow, it produces endothelium-
derived relaxing factor (EDRF)-mediated hypotension (Hariawala, Horowitz et al. 1996), a 
decrease in cardiac output and stroke volume, tachycardia (Yang, Bunting et al. 2000) and, in 
certain studies, the formation of intramural vascular tumours at the implantation site (Lee, 
Springer et al. 2000). In contrast, both PlGF and FGF-2 have drawn the attention of 
researchers as a safer and potential therapeutic target for neovascularisation in animal models 
and trials (Laham, Sellke et al. 1999, Laham, Chronos et al. 2000, Lederman, Mendelsohn et 
al. 2002, Simons, Annex et al. 2002) (Table 1.2 and 1.3).  
1.5   VEGF Receptor Tyrosine Kinases 
1.5.1 VEGFR-1 
VEGFR-1 was the first VEGF receptor identified and originally cloned from a human 
placental cDNA library (Shibuya, Yamaguchi et al. 1990).  VEGFR-1 homologues were 
identified in other mammals including mouse, rat, goat, pig, cow, sheep, and dog (Finnerty, 
                                                                                                                Chapter 1-Introduction 
 
21 
Kelleher et al. 1993, Choi, Wall et al. 1994, Yamane, Seetharam et al. 1994) and VEGFR-1 
gene identified in the chicken (Akimoto, Hashimoto et al. 2002) and in the zebrafish 
(Rottbauer, Just et al. 2005).  
Structure and Function 
The VEGFR-1 human gene is located on chromosome 13q12-13 (Shibuya, Yamaguchi et al. 
1990), and on chromosome 5 for the mouse homologue (Rosnet, Stephenson et al. 1993). 
VEGFR-1 mRNA transcript ensues mainly as a 7.5-8.0 kb transcript. VEGFR-1 is composed 
of seven extracellular immunoglobulins [Ig] homology domains, a single transmembrane 
region and an intracellular tyrosine kinase domain (Shibuya, Yamaguchi et al. 1990). 
VEGFR-1-ligand interaction occurs via the second Ig-like loop (Davis-Smyth, Chen et al. 
1996). VEGFR-1 binds to VEGF-A, VEGF-B and PlGF, with a high affinity. VEGF-B and 
PlGF serve as ligands specific for VEGFR-1 only (Shibuya, Yamaguchi et al. 1990, Park, 
Chen et al. 1994, Olofsson, Korpelainen et al. 1998). 
VEGF and PlGF share a 46.3% homology; however, comparison of the crystal structures of 
VEGF and PlGF in association with the VEGFR-1 demonstrated an identical set of residues 
on PlGF and VEGF contributing towards binding to the receptor. This resemblance suggests 
that the biological events mediated by these two ligands may likely involve complex 
formation with co-receptors such as neuropilin, or heparan sulphate proteoglycans [HSPGs] 
(Christinger, Fuh et al. 2004). 
Expression and Regulation 
Endothelial cell-specific expression of VEGFR-1 occurs in human foetuses (Kaipainen, 
Korhonen et al. 1993) and in adult organs, VEGFR-1 mRNA exists in the quiescent 
endothelium (Peters, De Vries et al. 1993). VEGFR-1 is also expressed by 
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monocytes/macrophages and osteoblasts (Clauss, Weich et al. 1996), placental trophoblasts 
(Charnock-Jones, Sharkey et al. 1994, Ahmed, Dunk et al. 1997), cells of renal mesangial 
origin and in some hematopoietic stem cells (Zachary and Gliki 2001). VEGF and PlGF, both 
stimulate the production of tissue factor and chemotaxis in monocytes (Clauss, Gerlach et al. 
1990) indicating that VEGFR-1 functions as a signalling receptor in this cell type. 
Additionally, VEGFR-1 is present on CD34
+
 cells and has a role in reconstituting 
haematopoiesis after bone marrow depletion (Luttun, Tjwa et al. 2002). VEGFR-1 mRNA 
and protein are expressed by vascular smooth muscle cells [VSMCs]; including human brain 
vascular SMCs (Yang, Yao et al. 2004), human aortic SMCs, uterine myometrial SMCs 
(Grosskreutz, Anand-Apte et al. 1999) and bovine pericytes. 
 
Pathologically, VEGFR-1 and its ligand PlGF were reported to be up-regulated and expressed 
in vessels near healing wounds, suggesting that the PlGF/VEGFR-1 alliance may perhaps 
play a role in the regulation of vascular permeability, vascular repair and maintenance (Peters, 
De Vries et al. 1993). Some melanomas and leukaemias express VEGFR-1 (Cohen, Gitay-
Goren et al. 1995, Fiedler, Graeven et al. 1997, Pisacane and Risio 2005) whereas, VEGF and 
VEGFR-1 via autocrine and paracrine regulation are up-regulated in the vascular endothelium 
of numerous tumours (Shibuya 1995, Hatva, Bohling et al. 1996, Tran, Master et al. 2002). 
Tumour environment is hypoxic, VEGFR-1 expression (as mentioned earlier) is up-regulated 
by hypoxia via HIF-1 dependent mechanism, indicating direct regulation of the gene by 
hypoxia (Ikeda, Wakiya et al. 1996, Gerber, Condorelli et al. 1997), in vivo as well as in vitro 
(Tuder, Flook et al. 1995, Brogi, Schatteman et al. 1996, Li, Brown et al. 1996, Gerber, 
Condorelli et al. 1997, Marti and Risau 1998). Cultured pericytes, under hypoxic conditions, 
express VEGFR-1 (Nomura, Yamagishi et al. 1995). 





The VEGFR-1 cytoplasmic domain is not essential for vasculogenesis during development 
(Hiratsuka, Minowa et al. 1998), and very recent work demonstrated that embryos lacking 
VEGFR-1 displayed an increased outgrowth of ECs and hemangioblast commitment, 
proposing a negative role for VEGFR-1 in angiogenesis (Fong, Zhang et al. 1999). In 
contrast, VEGFR-1 deficient mice developed normal vessels and survived (Hiratsuka, 
Minowa et al. 1998). During embryonic development, VEGF-A-mediated macrophage 
migration was severely suppressed, in truncated membrane bound VEGFR-1 as well as its 
soluble isoform sVEGFR-1, suggesting a possible role for VEGFR-1 as a decoy receptor for 
angiogenesis during embryo development. In this manner, modulating VEGF bioavailability 
and leading to the prevention of EC overgrowth. VEGF-A affinity for VEGFR-1 is stronger 
when compared to VEGFR-2, but VEGFR-1 has a weak signal transducing activity (Park, 
Chen et al. 1994), that negatively regulates VEGF-induced angiogenesis by controlling its 
availability to VEGFR-2. VEGFR-1 is implicated in several pathologies. Anti-VEGFR-1 
suppressed neovascularisation in tumours,
 
ischemic retinae, and prevented inflammatory joint 
destruction
 
in autoimmune arthritis. Since Luttun et al. performed VEGFR-1 studies 
demonstrating it to be a potentially attractive target for modulation
 
of pathological 
inflammation and angiogenesis (Luttun, Tjwa et al. 2002) VEGFR-1 has drawn greater 
attention from researchers. 
 1.7 Soluble Vascular Endothelial Growth Factor Receptor-1 (sVEGFR-1) 
sVEGFR-1 is a naturally occurring, short soluble protein splice variant of VEGFR-1 that 
mediates inhibition of VEGF, as well as PlGF interaction with their receptors (Kendall and 
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Thomas 1993). This soluble receptor occurs as a result of alternative splicing of VEGFR-1 
mRNA and consists of only the extracellular domain of VEGFR-1. As shown in Figure 1.7, 
sVEGFR-1 inhibits the binding of VEGF and PlGF to their respective RTKs and prevents the 
cellular activities elicited by these growth factors. Additionally, sVEGFR-1 acts as a 
dominant-negative inhibitor blocking the formation of VEGFR-1 and -2 homo and 
heterodimers, inhibiting their trans-phosphorylation or activation (Kendall, Wang et al. 1996).  
Levels of sVEGFR-1 are elevated in the placenta (Maynard, Min et al. 2003, Tsatsaris, Goffin 
et al. 2003) and serum (Zhou, McMaster et al. 2002, Koga, Osuga et al. 2003) of women with 
pre-eclampsia (PE). sVEGFR-1 associated with severity of the disease and sVEGFR-1 levels 
stated as a predominant risk factor pertaining to this disorder (Levine, Maynard et al. 2004, 
Thadhani, Mutter et al. 2004). PE mouse model studies reported that TNF-α will increase 
sVEGFR-1 (Sunderland, Thomson et al. 2011). sVEGFR-1 also inhibits wound healing, again 
via prevention of VEGF or PlGF interaction to their receptors by acting as a sink (Carmeliet, 
Moons et al. 2001, Maynard, Min et al. 2003). In summary, sVEGFR-1 can have a beneficial 
or harmful effect, depending on the disorder. 
1.8    Placenta Growth Factor [PlGF] 
1.8.1 Structure and Functional Properties 
PlGF was originally identified in the placenta by Maria Graziella Perisco (Maglione, 
Guerriero et al. 1991).  PlGF is a N-glycosylated, secretory homodimeric protein (Maglione, 
Guerriero et al. 1991, Iyer, Leonidas et al. 2001), belonging to the cysteine-knot super family 
of growth factors, encoding for a protein with an approximately 46.3% homology to VEGF in 
the PDGF-like amino acid sequence (Maglione, Guerriero et al. 1991, Iyer, Leonidas et al. 
2001). The PlGF gene is reported to be mapped 
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 on human chromosome 14q24-q31 (Mattei, Borg et al. 1996) and chromosome 12q in mice 
(DiPalma, Tucci et al. 1996). The human PlGF gene consists of seven exons (Maglione, 
Guerriero et al. 1993). The 3D crystal structure of PlGF illustrated in Figure 1.6.  
                                            
Figure 1.6 Three-dimensional crystal structure of PlGF-1. The structure has been colour-
coded to differentiate between the two subunits: Monomer A has been colour purple, and 
Monomer B is in cyan. The cysteine-knot motif [consists of 3-intra-  and one inter-chain 
disulphide bridge passing through the 8-membered cysteine ring] and the receptor-binding 
region is highlighted at each pole of the dimer (Iyer and Acharya 2002). 
 
The structure of PlGF is remarkably similar to VEGF-A121 (Iyer and Acharya 2002). The 
human genome encodes four isoforms: PlGF-1 [PlGF131], PlGF-2 [PlGF152], PlGF-3 
[PlGF203], and PlGF-4 [PlGF224] (Maglione, Guerriero et al. 1993, Cao, Ji et al. 1997, Yang, 
Ahn et al. 2003). In mice, only one PlGF mRNA encoding a 158 amino acid precursor protein 
has been identified that is equivalent to human PlGF-2 (Fischer, Jonckx et al. 2007, 
Dewerchin and Carmeliet 2012). Little is known about the difference in the functions of PlGF 
isoforms. PlGF-1 is composed of 131 amino acid residues per monomer, PlGF-2 consists of 
170 amino acids and PlGF-3 corresponds to 216 amino acids. A schematic representation of 
the three splice variants of the PlGF gene is illustrated in Figure 1.7. The novel PlGF subtype 
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4 [PlGF-4] consists of the same sequence as PlGF-3, plus the heparin binding domain 
previously thought to be present only in PlGF-2 (Yang, Ahn et al. 2003). PlGF-2 can also 
bind to neuropilin (NRP)-1, and -2 because of an insertion of 21 basic amino acids at the 
carboxyl terminus (Migdal, Huppertz et al. 1998, Persico, Vincenti et al. 1999, Hoffmann, 
Willenborg et al. 2013). PlGF-1 and PlGF-3 are diffusible isoforms, and PlGF-2 and PlGF-4 
have heparin binding domains (Hauser and Weich 1993, Persico, Vincenti et al. 1999, Yang, 
Ahn et al. 2003). PlGF has the natural capacity to form heterodimers with VEGF (DiSalvo, 
Bayne et al. 1995). Little is known about the pro-angiogenic or anti-angiogenic activity of the 






Figure 1.7 A schematic representation of the three spliced variants of the PlGF gene. The 
gene has seven exons [each colour differently]. PlGF-1 and PlGF-3 mRNAs lack exon 6. 
PlGF-3 mRNA has a 216 base insert between exon 4 and 5. The length of the amino acid 
sequence indicated for each isoform corresponds to that of the mature protein [after cleavage 
of the signal peptide]. (Adapted from (Takahashi and Shibuya 2005) and 
ethesis.helsinki.fi/.../pg/jeltsch/intro.html). 
 
1.8.2 PlGF and Receptor Interactions  
PlGF binds to VEGFR-1, NP-1, NP-2 (Migdal, Huppertz et al. 1998, Persico, Vincenti et al. 
1999) and sVEGFR-1; the natural soluble version of the receptor lacking transmembrane and 
intracellular domains (Kendall and Thomas 1993, Errico, Riccioni et al. 2004). One of the 
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glycosylated residues of the two N-linked glycosylation sites, Asn
84
, plays a significant role in 
binding VEGFR-1 distinct to VEGF-A (Errico, Riccioni et al. 2004). PlGF can induce signals 
via VEGFR-1, independent of VEGF (Cai, Ahmad et al. 2003, Ahmad, Hewett et al. 2006).  
PlGF, when bound to VEGFR-1, can indirectly promote EC proliferation via displacement of 
VEGF from VEGFR-1 (decoy receptor), thereby enhancing angiogenesis by liberating VEGF 
for activation of VEGFR-2 (Park, Chen et al. 1994). Binding of PlGF to VEGFR-1 may also 
induce an intermolecular cross talk between VEGFR-1: VEGFR-2 that amplifies 
VEGF/VEGFR-2 signalling and VEGF-driven angiogenesis (Autiero, Waltenberger et al. 
2003). The schematic representation of the receptor competition and receptor cross-talk 
exerted by PlGF binding to VEGFR-1 illustrated in Figure 1.8. 
Activation of VEGFR-1 by either PlGF or VEGF-A induces different gene expression profiles 
and phosphorylation of distinct tyrosine residues in the tyrosine kinase domain of VEGFR-1 
(Autiero, Waltenberger et al. 2003). VEGF: PlGF heterodimers promote the formation of 
RTK receptors VEGFR-1: VEGFR-2 to which they preferentially bind (Autiero, 
Waltenberger et al. 2003), in addition to VEGFR-1: VEGFR-1. However, VEGF: PlGF 
heterodimers do not bind to VEFGR-2: VEGFR-2 homodimers (Eriksson, Cao et al. 2002).  
      
  




Figure 1.8 Molecular mechanisms of PlGF-induced pro-angiogenic signalling. [A] VEGFA 
[VEGF] binds with a higher affinity to [s]VEGFR-1 [designated Flt1in the mouse] than 
toVEGFR-2 [designated Flk2 in the mouse]. Hence, in physiological conditions, when [B] 
PlGF expression is minimal, [s] VEGFR-1 acts as a VEGF trap to prevent excessiveVEGFR-
2 activation. In cancer, PlGF is up-regulated in cancer cells and stromal cells, which leads to 
displacement of VEGF from [s] VEGFR-1, increases its bioavailability and binding 
toVEGFR-2, leading to transmission of a pro-angiogenic signal. B, In addition, PlGF 
transduces its own signal viaVEGFR-1, evidenced by phosphorylation of distinct tyrosine 
residues in the intracellular domain ofVEGFR-1.This signal leads to proliferation and 
migration of tumour cells, ECs, monocytes, and endothelial progenitor cells [EPCs]. 
Moreover, stimulation of VEGFR-1by PlGF amplifies the VEGF-induced signalling of 
VEGFR-2 by transphosphorylation of tyrosine residues of VEGFR-2. As a consequence, 
VEGF-induced angiogenesis, vascular permeability and proliferation, and survival and 
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1.8.3 PlGF – pleiotropic activities  
PlGF is a pleiotropic factor affecting different cell types; vascular (ECs, pericytes/smooth 
muscle cells) as well as non-vascular cell types (macrophages, bone marrow-derived 
progenitors, tumour cells, dendritic cells, fibroblasts, hepatic stellate cells, epithelial cells, 
neurons, Schwann cells, astrocytes) (Dewerchin and Carmeliet 2012). PlGF is a multitasking 
cytokine affecting and regulating various biological responses (Figure 1.9). PlGF originally 
discovered and abundantly expressed in the placenta (Maglione, Guerriero et al. 1991, Hauser 
and Weich 1993, Cao, Ji et al. 1997). Although trophoblasts are the prime site of synthesis 
(Khaliq, Li et al. 1996, Vuorela, Hatva et al. 1997) many other cells produce PlGF including 
ECs, vascular smooth muscle cells, inflammatory cells, neurons, especially when activated 
(Beck, Acker et al. 2002, Iyer and Acharya 2002, Luttun, Tjwa et al. 2002). PlGF is 
significantly detected in several organs, including the heart (Iwama, Uemura et al. 2006), lung 
(Persico, Vincenti et al. 1999), breast (Parr, Watkins et al. 2005), stomach (Chen, Hsieh et al. 
2004), prostate (Matsumoto, Suzuki et al. 2003), retina (Feeney, Simpson et al. 2003), thyroid 
(Viglietto, Maglione et al. 1995) and skin (Failla, Odorisio et al. 2000, Odorisio, Schietroma 
et al. 2002). PlGF mRNA expression was detected abundantly in trophoblastic cells, which 
initiate and coordinate vascularisation in the decidua and placenta during early embryogenesis 
in mice (Achen, Gad et al. 1997). In situ hybridization analysis detected PlGF mRNA 
transcripts extra-embryonically in villous trophoblast, whereas VEGF was expressed in 
mesenchymal cells within the chorionic plate (Vuorela, Hatva et al. 1997). PlGF-1 facilitates 
neovascularisation in vivo (Ziche, Maglione et al. 1997) and the recruitment of monocytes and 
ECs (Clauss, Weich et al. 1996, Ziche, Maglione et al. 1997). Unlike VEGF-A, PlGF mRNA 
expression was not up-regulated by hypoxia in Human Aortic ECs or Human umbilical vein 
ECs (HUVECs) (Gleadle, Ebert et al. 1995, Cramer, Nagy et al. 2005).  
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PlGF expression has been reported in various pathological conditions, including cancers:  
hypervascular renal cell carcinomas, thyroid and germ cell tumours (Takahashi, Sasaki et al. 
1994) and in a subset of human meningiomas (Donnini, Machein et al. 1999). Recently, Adini 
et al. found that overexpression of PlGF leads to tumour growth as well as vascular 
formation. PIGF also induces expression of survival genes and inhibits apoptosis in vitro. 
This study further confirmed that PlGF contributes to tumour angiogenesis by providing 
functions needed for EC survival (Adini, Kornaga et al. 2002). A recent study documented a 
cross-talk between tumour cells. Stroma was found to be present in bone metastases of breast 
cancer and of chronic myeloid leukaemia, in which the tumour cells can educate stroma cells 
to produce PlGF (Coenegrachts, Maes et al. 2010, Schmidt, Kharabi Masouleh et al. 2011). 
Although tumour cells respond to PlGF, and some of them even produce PlGF (such as 
choriocarcinoma cells). Whether tumour cells essentially secrete significant amounts of PlGF 
is controversial. Conditioned-medium from various cancer cell lines were devoid of PlGF 
(Figure 4.1).  
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Figure 1.9 Schematic illustration of the pleiotropic actions of PlGF, including effects on 
survival, migration, proliferation, metabolism, and activation effects on vascular as well as 
non-vascular cells. BM, Bone marrow; SMC, smooth muscle cells; TAM, tumour associated 
macrophage (Dewerchin and Carmeliet 2012). 
 
1.8.4 Biological Activity and Role of PlGF 
PlGF induces various biological activities. PlGF-Knockout (plgf
-/-
) mice exhibit normal 
development and viability with no major vascular defects, indicating that endogenous PlGF is 
not critical for vascular and embryonic development (Carmeliet, Moons et al. 2001). PlGF 
contributes to regulating the angiogenic switch, and its significant role in promoting aberrant 
angiogenesis in a variety of pathologies has gained attention in the past few years (Dewerchin 
and Carmeliet 2012).  
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Like VEGF, PlGF exhibits mitogenic activity on cultured ECs (Maglione, Guerriero et al. 
1991, Hauser and Weich 1993, Ziche, Maglione et al. 1997) and induces angiogenesis in vivo. 
The angiogenic effects induced by PlGF on ECs are similar to those of the potent classical 
angiogenic factors, VEGF and FGF-2 (Ziche, Maglione et al. 1997). The role of PlGF in 
proliferation, migration and permeability of ECs has been controversial; some studies 
reported PlGF to be ineffective in inducing endothelial cell growth and migration in vitro 
(Park, Chen et al. 1994, Cao, Chen et al. 1996, Kurz, Wilting et al. 1998). However, ECs 
produce abundant PlGF in culture (Appendix I) (Yonekura, Sakurai et al. 1999). PlGF-
deficient mice demonstrated regression of neovascular complexes that had minimal effect on 
vascular development or normal embryogenesis, yet such a deficiency could reduce collateral 
vascular growth under pathologic conditions; ischemia, inflammation, and cancer (Carmeliet, 
Moons et al. 2001). Furthermore, studies demonstrate that loss of PlGF reduced endothelial 
cell responses (Carmeliet, Moons et al. 2001, Schmidt, Kharabi Masouleh et al. 2011) and 
ECs from PlGF gene knock-out mice responded to exogenous PlGF (Schmidt, Kharabi 
Masouleh et al. 2011). The reasons for discrepancies in the reported biological activity of 
PlGF are unclear, but factors such as sources of PlGF, target cell heterogeneity, or the end 
points of the assays (Torry, Ahn et al. 1999) could be some of the contributors.  
The modulation of PlGF/VEGFR-1 interaction has been reported to affect VEGFR-1 
expressing ECs, hematopoietic stem cells, SMCs and inflammatory cells including 
macrophages (Carmeliet, Moons et al. 2001, Luttun, Tjwa et al. 2002, Autiero, Waltenberger 
et al. 2003). PlGF stimulates the production of tissue factor and enables chemotaxis in 
monocytes (Clauss, Weich et al. 1996). PlGF heterodimerisation with VEGF (VEGF: PlGF) 
was identified in tumour cell supernatants, though less significant than VEGF (Xu, Cochran et 
al. 2006) (Figure 1.10). 
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VEGFR-1 raises the possibility that PlGF may act in an autocrine manner to modulate normal 
trophoblast function (Khaliq, Li et al. 1996). Prominent secretion of PlGF by trophoblasts and 
the presence of VEGFR-1 receptors on trophoblasts (Shore, Wang et al. 1997) triggered a 
rapid but transient activation of the stress-activated protein kinase [SAPK], c-Jun-N-terminal 
kinase [JNK] and p38 kinase pathways. This activation of the signalling pathways resulted in 
trophoblasts protected from growth factor withdrawal-induced apoptosis (Desai, Holt-Shore et 
al. 1999). PlGF binding to VEGFR-1 in monocytes led to activation of PI3 kinase/AKT and 
extracellular signal-regulated kinase (ERK)-1/2 pathways, leading to chemotaxis and the 
induction of a series of inflammatory cytokines in sickle cell disease (Selvaraj, Giri et al. 
2003). 
  





Figure 1.10 Angiogenic response via receptor activation. Schematic representation of 
receptor activation elicited by the PlGF:PlGF, VEGF:VEGF homodimers and VEGF:VEGF 
heterodimer consequent to activation with corresponding receptors. Abbreviations: 
V=VEGF-A, Pl =PlGF, P= phosphorylation, R1 = VEGFR-1, R2 = VGFR-2, NRP-1 = 
Neuropilin-1 
 
Desai and others have reported that PlGF induced ERK-1/2 activation in porcine aortic ECs 
overexpressing VEGFR-1 (Landgren, Schiller et al. 1998) and in HUVECs (Desai, Holt-
Shore et al. 1999). PlGF and VEGF heterodimers exert a stronger mitogenic activity than 
VEGF homodimers alone in HUVEC (Cai, Ahmad et al. 2003).  
PlGF is expressed by migrating keratinocytes and ECs, acting in a paracrine and autocrine 
fashion on VEGFR-1-expressing endothelium (Failla, Odorisio et al. 2000). Lack of PlGF 
                                                                                                                Chapter 1-Introduction 
 
35 
resulted in delayed wound closure, indicating that it is required for optimal skin repair 
(Carmeliet, Moons et al. 2001). Overexpression of this growth factor accelerates wound 
closure in diabetic mice (Cianfarani, Zambruno et al. 2006).  
PlGF via VEGFR-1 alone (Terman, Khandke et al. 1994)  promotes monocyte migration 
(Clauss, Weich et al. 1996), the release of nitric oxide (Bussolati, Dunk et al. 2001), wound 
healing (Iwama, Uemura et al. 2006) and prolongs survival and stability of capillary-networks 
(Cai, Ahmad et al. 2003). PlGF also plays a vital role in wound healing and potentiates the 
VEGF pro-angiogenic function in a synergistic manner (Brown, Yeo et al. 1992, Failla, 
Odorisio et al. 2000, Carmeliet, Moons et al. 2001). PlGF gene transfer studies into cutaneous 
wounds of mouse stimulated migration of dermal fibroblasts, enhanced granulation tissue 
formation, maturation and vascularisation promoting in wound repair (Cianfarani, Zambruno 
et al. 2006). 
Apart from being a chemoattractant for mononuclear cells, PlGF also acts as a potent 
stimulator of VEGF secretion by monocytes (Bottomley, Webb et al. 2000). PlGF 
significantly increases mRNA levels of the proinflammatory chemokines, namely, Tumour 
necrosis factor-alpha [TNF-α], interleukin-1 beta, [IL-1β], Interleukin-8 [IL-8] and monocyte 
chemoattractant protein-1 [MCP-1] in the peripheral blood mononuclear cells of sickle cell 
patients when compared to healthy subjects (Perelman, Selvaraj et al. 2003). 
1.8.5 Role of PlGF in Pathological angiogenesis 
PlGF and its receptor VEGFR-1 have gained increasing attention for its contribution to 
angiogenesis in pathologies. For example:  revascularisation of ischemic tissues by enhancing 
capillary and collateral vessel formation in the heart, and limb ischemic tissues with PlGF 
treatment (Luttun, Tjwa et al. 2002, Pipp, Heil et al. 2003, Kolakowski, Berry et al. 2006), 
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and inhibition of tumour angiogenesis, arthritis and atherosclerosis using anti-VEGFR-1 
(Carmeliet, Moons et al. 2001, Luttun, Tjwa et al. 2002).  
Analysis of PlGF-deficient mice has revolutionised the understanding of pathological 
angiogenesis in several disorders, including tumour, ischemic retina and arthritis. This 
signifies the central role played by PlGF in angiogenesis associated with pathological events 
(Figure 1.11) (Luttun, Tjwa et al. 2002).  
PlGF levels are variably up-regulated in several cancers, including renal-cell carcinoma 
(Matsumoto, Suzuki et al. 2003), lung cancer (Zhang, Chen et al. 2005), breast cancer (Parr, 
Watkins et al. 2005), colorectal cancer (Wei, Tsao et al. 2005) and gastric cancers (Chen, 
Hsieh et al. 2004). This significant role of PlGF in tumour progression has been pursued 
extensively, in the hope that PlGF might be a useful prognostic marker for cancer progression. 
Carmeliet and the group have demonstrated that embryonic stem (ES) cell-derived tumours 
from PlGF deficient mice with C57Bl6 background were small and poorly vascularised 
(figure 1.9) (Carmeliet, Moons et al. 2001). However, there is no indication that PlGF has a 
role in tumour formation. PlGF and its receptor VEGFR-1 are the therapeutic targets to treat 
pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation 
and/or vascular leakage. The avb3 integrin, an adhesion receptor for extracellular matrix 
components with an exposed Arginine-glycine-aspartic acid (RGD) sequence, is an attractive 
target for anti-angiogenic therapy since it is exclusively present on the cell surface of 
activated ECs but absent in quiescent endothelium or other cell types (Eliceiri and Cheresh 
2000). 
Promising results with gene therapy are obtained in therapeutic angiogenesis. Intramuscular 
gene transfer of VEGF165 and intramyocardial administration of an adenoviral vector 
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expressing the VEGF121 cDNA improved collateral vessel development in patients with 
critical limb ischemia (Arveschoug and Christensen 1999) and coronary artery disease 
(Rosengart, Lee et al. 1999), respectively. Although VEGF improves myocardial blood flow, 
it produces endothelium-derived relaxing factor (EDRF)-mediated hypotension (Hariawala, 
Horowitz et al. 1996), decreases in cardiac output and stroke volume, tachycardia (Yang, 
Bunting et al. 2000) and, in certain studies, formation of intramural vascular tumours at the 
implantation site (Lee, Springer et al. 2000). In contrast, both PlGF and FGF-2 has drawn the 
attention of researchers as a safer and potential therapeutic target for neovascularisation in 
animal models and trials (Laham, Sellke et al. 1999, Laham, Chronos et al. 2000, Lederman, 
Mendelsohn et al. 2002, Simons, Annex et al. 2002) (Table 1.3 and 1.4).  
  




Figure 1.11 Role of PlGF in therapeutic angiogenesis. (A) Impaired tumour angiogenesis in 
Pgf-/-. Macroscopic pictures of wild-type, Pgf–/– [A] ES cell– derived tumours, revealing the 
haemorrhagic [red] appearance of the large wild-type tumour, in contrast to the small 
hypovascular [white] Pgf–/– tumours (Carmeliet, Moons et al. 2001). Laser Doppler 
imaging, revealing that perfusion through the ligated right limb seven days after femoral 
artery ligation is increased by treatment with hPlGF-2 (Luttun, Tjwa et al. 2002). 
 
1.8.5.1 Cardio Vascular Disease (CVD) and PlGF 
Heart failure remains as one of the leading causes of morbidity and mortality in both Western 
and developing countries. Atherosclerosis is the disease of hardening and narrowing of the 
arteries. This progressive disease silently and slowly blocks arteries, putting blood circulation  
at risk. Atherosclerosis is the usual cause of heart attacks, strokes, and peripheral vascular 
disease; together they are called cardiovascular disease (CVD). CVD has been projected as 
the underlying cause for 1 in every 3 deaths in the USA (Roger, Go et al. 2011), and an 
PlGF and Therapeutic angiogenesis
• PlGF plays a vital role in pathological 
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estimated 17.3 million CVD-related deaths in 2011, representing 30% of all global deaths 
(Table 1.2) (WHO 2013). Vascular insufficiency is implicated as the primary cause of a 
number of CVDs, such as myocardial infarction (MI), peripheral vascular disease (PVD), 
stroke and ischaemia.  
MI results in scar formation with ventricular dilatation and eventually heart failure 
(Binsalamah, Paul et al. 2011). Rehospitalisation rates due to congestive heart failure as a 
result of left ventricular dysfunction with MI are still high (Pfeffer and Braunwald 1990). The 
requirement for these disorders is the return of blood supply to the tissue as fast as possible, to 
rescue the myocardium in threat of infarct (Martens, Bottelbergs et al. 2012). 
PlGF (Carmeliet, Moons et al. 2001, Luttun, Tjwa et al. 2002, Iwama, Uemura et al. 2006, 
Kolakowski, Berry et al. 2006) is reported to be both pro-angiogenic and pro-arteriogenic 
without any deleterious side effects, such as hypotension, oedema or hemangio-genesis 
normally accompanied by systemic VEGF therapy (Oura, Bertoncini et al. 2003, Takeda, 
Uemura et al. 2009). PlGF-deficient mice display reduced angiogenesis, and inflammation at 
the border of the infarct after an MI (Carmeliet, Moons et al. 2001).  
Correlation studies in patients and mice indicate high expression of PlGF post-acute 
myocardial infarction (AMI) (Iwama, Uemura et al. 2006). In AMI patients, peripheral 
plasma PlGF levels on day 3 were significantly higher than in control subjects (Iwama, 
Uemura et al. 2006) A. The same research group observed PlGF expression was 26.6-fold 
greater in an AMI model than in sham-operated mice subjected to 40-60 minutes coronary 
artery ligation (Iwama, Uemura et al. 2006) B. The study reported that the endothelium within 
the infarcted region is the major site for elevated PlGF expression (Iwama, Uemura et al. 
2006).  














Table 1.2 Department of Health Statistics and Information Systems WHO, Geneva. June 
2013  
Several animal and pre-clinical studies focussed on the role of PlGF in improving cardiac 
function affected by CVD-related diseases, by promoting wound healing, inducing 
mobilisation of mononuclear cells and enhancing angiogenesis. A list of some of these studies 
summarised in Table 1.3.  
Conversely, studies reported correlations between adverse cardiac outcomes in long-term 
follow-up patients with acute coronary syndrome (ACS) and plasma PlGF levels (Dewerchin 
and Carmeliet 2012). PlGF is a recruiter of macrophages and monocytes, a role that may 
result in on-going inflammatory processes in the coronary artery wall. This on-going process 
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may trigger adverse cardiovascular events (Heeschen, Dimmeler et al. 2004, Lenderink, 
Heeschen et al. 2006, Dewerchin and Carmeliet 2012).  
 
Table 1.3 Role of PlGF in improving cardio-protective function in CVD 
1.8.5.2 PlGF and Preeclampsia (PE) 
PE is a systemic condition of the maternal endothelium, with the clinical presentation of 
hypertension and proteinuria (Friedman, Taylor et al. 1991) that affects 3-7 %  (Enkhmaa, 
Wall et al. 2016) of all pregnancies. PE remains one of the leading causes of maternal-foetal 
mortality and morbidity (Schaap, van der Wal et al. 1993, Brewster, Orsi et al. 2008) even in 
developed countries. Numerous studies have reported an imbalance of angiogenic and anti-
angiogenic proteins to be a key influence leading to the maternal symptoms of PE (Ivan, 
Kondo et al. 2001, Maynard, Min et al. 2003, Ahmad and Ahmed 2004, Levine, Maynard et 
al. 2004, Levine, Lam et al. 2006, Chaiworapongsa, Romero et al. 2008). Endothelial 
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dysfunction is responsible for the clinical symptoms of the disorder (Ueda, Hirai et al. 1996) 
include poor placental vascular remodelling and subsequent placental hypoxia (Schaap, van 
der Wal et al. 1993), oxidative stress  (Roberts and Redman 1993, Schaafhausen, Yang et al. 
2013) and excessive inflammation (Redman, Sacks et al. 1999).  
Circulating levels of the anti-angiogenic protein sVEGFR-1, with antagonist activity to both 
VEGF and PlGF, is reported to be increased in the placenta (Maynard, Min et al. 2003, 
Tsatsaris, Goffin et al. 2003) and serum (Zhou, McMaster et al. 2002, Koga, Osuga et al. 
2003) of women with PE, and is associated with severity of the disease. sVEGFR-1 was 
detected long before the onset of the clinical manifestations of PE (Hunter, Aitkenhead et al. 
2000, Maynard, Min et al. 2003, Tsatsaris, Goffin et al. 2003, Levine, Lam et al. 2006). In 
fact, evidence of low PlGF levels in the first trimester, before an increase in sVEGFR-1 
levels, is stated as a predominant risk factor pertaining to this disorder (Levine, Maynard et al. 
2004, Thadhani, Mutter et al. 2004). 
Maternal circulation levels of VEGF have been reported by different investigators with 
conflicting results including increase, decrease or no change in the levels of VEGF in women 
with healthy pregnancies compared to pregnancies complicated by PE (Baker, Krasnow et al. 
1995, Sharkey, Cooper et al. 1996, Kupferminc, Daniel et al. 1997, Lyall, Greer et al. 1997). 
In both PE and acute pyelonephritis (AP), the most common septic shock during pregnancy,  
circulating levels of PlGF are reported to be dramatically reduced (Polliotti, Fry et al. 2003, 
Chaiworapongsa, Romero et al. 2009) and have been associated with inflammation. 
Excessive inflammatory cell activation, beyond the robust inflammatory response, observed 
during normal pregnancies, has been proposed as a driving force that contributes to the 
endothelial dysfunction that was seen in PE (Freeman, McManus et al. 2004). This was 
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further supported by expression array studies, indicating widespread up-regulation in the 
expression of cytokines and their receptors in the placentas of PE complicated pregnancies 
(Pang and Xing 2003). Abnormal production of cytokines and an asymmetry between Th1 
type cells that produce pro-inflammatory cytokines, such as, TNF-α, IL-1β, IL-12 to that of 
Th2 type cells cytokines that produce IL-4, IL-6, IL-10 yield to vascular damage and PE 
(Conrad, Miles et al. 1998, Ellis, Wennerholm et al. 2001, Freeman, McManus et al. 2004). 
Increased circulating levels of the pro-inflammatory cytokine TNF-α, and its soluble TNF 
receptor 1 [sTNF-R1], are detected in PE as well as AP (Chaiworapongsa, Romero et al. 
2009) and correlate with the severity of the disease (Schipper, Bolte et al. 2005). TNF-α 
induced the release of sVEGFR-1 from cultured placental explants (Ahmad and Ahmed 
2004).  
A very recent study demonstrated that continuous administration of TNF-α for two weeks at 
mid-gestation to a cytokine-induced model of pregnant baboons caused changes that are seen 
in human PE, i.e. elevation in blood pressure and proteinuria (Ueda, Hirai et al. 1996). The 
treated pregnant animals also developed elevated plasma, and placental mRNA expression of 
sVEGFR-1 and soluble endoglin (sEng), a soluble form of transforming growth factor 
receptor TGF-β, compared to pregnant saline controls or in non-pregnant TNF-α treated 
animals. These results identify a link between cytokines, placental dysfunction and 
endothelial dysfunction resulting in the onset of PE-like symptoms. Furthermore, Sunderland 
and group postulate that hypertension and proteinuria in the setting of increased sVEGFR-1 
can be caused by an increase in TNF-α alone (Sunderland, Thomson et al. 2011). 
Although extensive animal studies and epidemiological studies have been performed 
suggesting multiple factors leading to PE, to our knowledge studies assessing the impact of 
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inflammatory cytokines on angiogenic factors, such as the effect of TNF-α on PlGF, and key 
factors in PE are none.  
1.8.5.3  Role of PlGF in inflammatory disorders 
Inflammation is increasingly recognised as a central component of the pathophysiology of 
several diseases. Inflammation manifested with the elevated levels of inflammatory cytokines, 
activation of neutrophils, monocytes and ECs (Pober and Sessa 2007). Inflammation is a 
complex stereotypical set of reactions expressed in response to the damage of the cells and 
vascularised tissues. Angiogenic mediators, including growth factors, cytokines, matrix 
components and other contributors, such as hypoxia, have been implicated in capillary 
formation. Additionally, circulating levels of angiostatic activating agents, namely anti-
inflammatory cytokines and other growth factors, contribute towards sustenance of controlled 
angiogenesis (Auerbach and Auerbach 1994, Szekanecz and Koch 2001, Szekanecz and Koch 
2007). Perturbing this equilibrium between angiogenesis and inflammation may lead to 
inflammatory diseases, such as PE (Sharma, Satyam et al. 2007), rheumatoid arthritis 
(Folkman 1995), psoriasis (Braverman and Sibley 1982) or Crohn‟s disease (Kanazawa, 
Tsunoda et al. 2001). The process of inflammation in association with angiogenesis is 
essential for tissue repair (Risau 1994, Carmeliet and Jain 2000, Streit, Velasco et al. 2000). 
Several pro-angiogenic factors that contribute to the inflammatory vascular response  
including PlGF (Clauss, Weich et al. 1996, Luttun, Autiero et al. 2004), VEGF (Detmar, 
Brown et al. 1994), FGF (Kanazawa, Tsunoda et al. 2001), and angiopoietins (Kuroda, 
Sapadin et al. 2001) have been reported.  
In rheumatoid arthritis (RA) the inflamed synovium has detectable levels of growth factors, 
inflammatory cytokines, chemokines, adhesion molecules as well as matrix-degrading 
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proteases (Bodolay, Koch et al. 2002). PlGF and VEFGR-1 were detected on inflammatory 
mediators and ECs in the inflamed synovium in animal models mimicking human arthritis 
(Courtenay, Dallman et al. 1980). Excessive or insufficient angiogenesis enhances a number 
of inflammatory processes, and the two are often co-dependent (Jackson, Seed et al. 1997). 
The activated endothelium is an integral part of the inflammatory response, and is due to the 
apparent co-dependency of inflammation and angiogenesis; compounds that block the 
angiogenic response may also prove beneficial for inflammatory diseases.  
1.9  Fibroblast Growth Factors [FGF] 
Like PlGF, FGFs are pleiotropic factors belonging to the RTK class IV of angiogenic factors 
and were among the first molecules discovered to exert proliferation, migration and 
differentiation of vascular cells, both in vitro as well as in vivo (Bikfalvi, Klein et al. 1997). 
FGFs manifest their biological effects on different cell types, including ECs. The FGF family 
consists of 23 members (Nishimura, Utsunomiya et al. 1999) that share around 55% 
homology of the amino acid residues, ranging between 18- to 30-kDa proteins with a high 
affinity for HS domains (Abraham, Whang et al. 1986, Liekens, De Clercq et al. 2001). HS is 
critical for the biological effect for some of the members of FGF (Spivak-Kroizman, Lemmon 
et al. 1994, Galzie, Kinsella et al. 1997). FGF-FGFR interactions and signalling require 
heparin sulphate proteoglycans [HSPGs] as co-receptors (Powers, McLeskey et al. 2000) and 
demonstrate developmental, tissue and cell-specific regulation. The prototypes; FGF-1 and 
FGF-2, are unique due to the lack of a conventional leader sequence. Consequently, secretion 
by the classical secretory pathway via endoplasmic reticulum does not occur (Basilico and 
Moscatelli 1992, Friesel and Maciag 1995).  
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1.9.1 FGF-2 [Basic FGF] 
FGF-2 is a potent angiogenic factor modulating cell proliferation and/or differentiation and 
survival in a variety of cell types, including those with stem cell properties, thus affecting 
various organ systems and biological processes (Kardami, Detillieux et al. 2007). 
1.9.1.1 Structure and Function 
The human FGF-2 gene is located on chromosome 4 (Mergia, Eddy et al. 1986), and consists 
of three exons separated by two introns. FGF-2 is a cationic mitogen weighing about 18,000 
kDa, measuring 155 amino acid [aa] residues in length (Abraham, Whang et al. 1986). FGF-2 
was one of the first angiogenic growth factors characterised and studied extensively (Presta, 
Moscatelli et al. 1986). FGF-2 has four alternate CUG [leucine] start codons that provide N-
terminal extensions of 41, 46, 55 or 133 aa, resulting in proteins of 22 kDa [196 aa], 22.5 kDa 
[201 aa], 24 kDa [210 aa] and 34 kDa [288 aa], respectively (Arnaud, Touriol et al. 1999).  
Human FGF-2 gene encodes multiple FGF-2 isoforms, ranging from 18, 000 to 24, 000 kDa 
(Florkiewicz and Sommer 1989).  Both low and high molecular weight subtypes demonstrate 
angiogenic activity in vivo, inducing cell proliferation, chemotaxis and production of 
urokinase plasminogen activator in cultured ECs (Presta, Moscatelli et al. 1986, Eliceiri, 
Puente et al.).  In general, the 155 aa/18 kDa or the low molecular weight [LMW] form is 
considered cytoplasmic [and secretable] (Bugler, Amalric et al. 1991, Florkiewicz, Majack et 
al. 1995, Delrieu 2000), whereas the high molecular weight [HMW] forms are considered 
nuclear in the target.  
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1.9.1.2 Receptor Binding 
To exert their biological activity, FGF‟s interaction with tyrosine kinase FGF receptors 
[FGFR] is essential. FGFRs contain two or three immunoglobulin-like domains and a 
heparin-binding sequence (Johnson, Lee et al. 1990). FGF-2 binds specifically to the distinct 
splice variant FGFR-1 isoform of the different FGFRs (Zhang, Ibrahimi et al. 2006). In vitro 
ECs from different origins express FGFR-1, whereas FGFR-2  is less frequently expressed 
(Presta, Dell'Era et al. 2005).  
1.9.1.3 Expression and Regulation 
FGF-2 secreted as a monomer and is either sequestered on matrix glycosaminoglycans or cell 
surface HS. The dimerization of the monomeric FGF-2 occurs in a non-covalent side-to-side 
configuration by the cell surface HS. This dimerised FGF-2 can activate FGF receptors (Herr, 
Ornitz et al. 1997, Okada-Ban, Thiery et al. 2000, Ornitz 2000).  
FGF-2 is expressed in several cell types, including platelets, visceral and vascular smooth 
muscle cells (SMC), epithelium lining of the colon, cardiac muscle cells, bronchus 
epithelium, megakaryocytes, neurones, and cerebellar Purkinje cells (Florkiewicz, Shibata et 
al. 1991). In addition, FGF-2 is also expressed in ECs  (Cordon-Cardo, Vlodavsky et al. 1990, 
Yu, Biro et al. 1993), fibroblasts [plus extracellular matrix], numerous embryonic mesodermal 
and neuroectodermal tissues (Cordon-Cardo, Vlodavsky et al. 1990), glomerular parietal 
epithelial cells and podocytes, mast cells, astrocytes, CD4 
+
 and CD8 T cells (Cordon-Cardo, 
Vlodavsky et al. 1990).  
1.9.2 Biological Effects of FGF-2 in Pathologies 
FGF-2 has been reported to be found in extracellular matrices and the extracellular circulation 
(Hanahan and Folkman 1996, Fannon, Forsten et al. 2000). Under normal conditions, the 
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levels of FGF-2 found are relatively low (Fannon, Forsten et al. 2000). However, these levels 
are substantially elevated in cases of disease and cancer (Riley, Savage et al. 1993, Fannon, 
Forsten-Williams et al. 2003). For example, high levels of FGF-2 have been found in the 
circulation of ECs in pathologies, such as Kaposi‟s sarcoma and hemangiomas, implicating 
the autocrine role of FGF-2 (Presta, Dell'Era et al. 2005). FGF-2 has also been associated with 
tumour angiogenesis and a wide spectrum of cancers (Chodak, Hospelhorn et al. 1988, 
Nguyen, Watanabe et al. 1994, Meyer, Yu et al. 1995, Toi, Taniguchi et al. 1996). The 
temporal and spatial distribution of FGF-2 is fundamental, not only for normal development 
but for disease control as well (Fannon, Forsten et al. 2000, Lalani, Wong et al. 2005, Lee, 
Silva et al. 2011), that can be regulated by HSPGs. Isolated ECs from FGF-2 null mice 
exhibited defects in cell migration (Pintucci, Moscatelli et al. 2002), resulting in delays in 
wound healing (Ortega, Ittmann et al. 1998).  
FGF-2 is one of the most widely used pro-angiogenic growth factors for the restoration of 
cardiac function (Kardami, Detillieux et al. 2007, Liao, Porter et al. 2007). Cardiomyocytes 
express functional FGF-2 receptors and, upon activation by FGF-2, trigger multi-signalling 
cascades resulting in cytoprotection, DNA synthesis, and negative inotropic effect (Ishibashi, 
Urabe et al. 1997, Padua, Merle et al. 1998). Several pre-clinical and animal studies were 
carried out to investigate the cardio-protective role of FGF-2, which are summarised in Table 
1.3. FGF-2-mediated angiogenesis is dependent on VEGFR-1 [Flt-1] activity (Kanda, Miyata 
et al. 2004). Kanda and colleagues demonstrated that blocking VEGFR-1 inhibited FGF-2-
mediated tube formation in cultured HUVEC (Kanda, Miyata et al. 2004). The biological 
implications of FGF-2 are vast and play a significant role in vascular development as well as 
an exogenous therapeutic tool. Angiogenesis is a complex process that is regulated by several 
pro- and anti-angiogenic factors. FGF-2 and PlGF share Janus-like roles in pathological and 
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therapeutic angiogenesis, such as inducing wound healing, leukocyte recruitment, collateral 
growth post-MI. They have been identified as contributors to the progression of 
atherosclerosis (Figure 1.12) (Luttun, Tjwa et al. 2002, Khurana, Moons et al. 2005, Virag, 
Rolle et al. 2007, Liu, Tang et al. 2013). 
    
 
Table 1.4 Role of FGF-2 in improving cardio-protective function in CVD 
The cellular activities in response to the paracrine and autocrine interactions of these 
angiogenic growth factors remain unclear. However, all of these findings suggest that a subtle 
balance exists between the beneficial effects of angiogenic therapy (including 
revascularisation, cardiac protection and wound healing), versus detrimental effects requiring 
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anti-angiogenic therapy (including inflammatory angiogenesis leading to rheumatoid arthritis, 
atherosclerosis or tumour angiogenesis) exerted by PlGF, FGF-2 and their respective 
receptors.   
             
Figure 1.12 Janus-like role of FGF-2 in the atherosclerotic lesions of coronary artery 
disease. In a normal vessel wall, the circulating or autocrine FGF-2 binds to its receptor on 
the surface of ECs (ECs). This process involved in the resistance of ECs to oxidative stress 
improves endothelial function and promotes EC survival. When expressed at high 
concentrations because of protein delivery, FGF-2 induces collateral growth, which helps 
restore blood circulation to the infarcted areas. In atherosclerotic lesions, FGF-2 is released 
by activated inflammatory cells, ECs and vascular smooth muscle cells (VSMCs). The role of 
these cells in advanced lesion development is undetermined. FGF-2 may participate in the 
stimulation of early stage angiogenesis of microvessels entering from the adventitia. FGF2 
may induce the proliferation, migration and osteoblastic differentiation of VSMCs. FGF2 may 
also cause intimal thickening and promote plaque vulnerability. Endothelial FGF receptor 
(FGFR) signalling has a dual role in the cardiovascular system (Liu, Tang et al. 2013).
 
1.10 Signal transduction of pro-angiogenic growth factors 
Therapies to maintain the balance between the angiogenic stimulators and inhibitors have 
been a fundamental goal of several research groups and pharmaceutical industries to try to 
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help alleviate disease.  One of the major ways to achieve this is by manipulating the 
angiogenic growth factor ligands and/or receptors that elicit signal transduction pathways, in 
order to inhibit or propagate induction of angiogenesis or arteriogenesis in pathologies. The 
discovery of the downstream signal transduction pathways for RTKs has led to the 
development of many newly targeted agents. The three major signal transduction pathways 
for angiogenic growth factors are the Ras/Raf/MAPK pathway, PI3K/Akt/mTOR pathway, 
and PKC pathway (Figure 1.13). These multiple signalling pathways can work independently 
or in concert to elucidate the signal transduction, resulting in cellular activities. Several 
studies focussed on manipulating angiogenesis by regulating the signalling pathways that are 
unique to the growth factor ligands or their respective receptors.  
In homoeostasis, a fine balance exists between pro- and anti- angiogenic factors that tightly 
regulate angiogenesis (Bergers and Benjamin 2003). Tumour angiogenesis or pathological 
angiogenesis results from an uncontrolled excess of pro-angiogenic factors (e.g. hypoxia and 
chemo-gradient of growth factors) that stimulate angiogenesis. Common signalling targets 
that regulate cell proliferation and subsequent angiogenesis are crucial for metastasis and their 
identification could, therefore, aid in controlling the disease progression 




Figure 1.13 Major signal transduction pathways for angiogenic growth factors RTK include 
the Ras/Raf/MAPK pathway, PI3K/Akt/mTOR pathway and PKC pathway. The receptors and 
their signal transduction pathways are potential therapeutic targets for anti-angiogenesis 
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1.11 Inflammatory Angiogenesis 
There is a growing body of experimental evidence linking systemic inflammation and 
endothelial dysfunction (Table 1.5; Figures 6.1 and 6.13). When exposed to certain 
pathogenic pro-inflammatory stimuli, the endothelium expresses leukocyte chemotactic 
factors, adhesion molecules and inflammatory cytokines. Inflammation is a complex set of 
reactions expressed in response to damage to the cells and vascularised tissues. During 
inflammation, angiogenesis is initiated by the activation of different cell populations, which 
release a variety of angiogenic factors that exhibit both pro-inflammatory and pro-angiogenic 
effects (DN 2010). 
The process of inflammation in association with angiogenesis is essential for tissue repair 
(Risau 1994, Carmeliet and Jain 2000, Streit, Velasco et al. 2000). Several pro-angiogenic 
factors that contribute to the vascular inflammatory response have been reported, including 
PlGF (Clauss, Weich et al. 1996, Luttun, Autiero et al. 2004), VEGF (Detmar, Brown et al. 
1994), FGF (Kanazawa, Tsunoda et al. 2001), and angiopoietins (Kuroda, Sapadin et al. 
2001). ECs are an active part of the inflammatory response and are known as inflammatory 
amplifiers. Adhesion molecules on the EC surface are exposed after receiving stimulatory 
signals from pro-inflammatory cytokines (Mai, Virtue et al. 2013). In contrast to the host 
defence manifested protective inflammation, chronic inflammation causes substantial tissue 
damage which triggers pathological angiogenesis; chronic inflammation promotes a 
continuous recruitment of inflammatory cells, thereby exacerbating inflammation and damage 
(Costa, Incio et al. 2007). On the other hand, angiogenesis itself can up regulate inflammation. 
It is well documented that the pro-angiogenic and anti-angiogenic factors represent the 
balance between the resting and activated vascular endothelium. Systemic inflammation and 
endothelial dysfunction related human studies  listed in Table 1.5. Disturbing this equilibrium 
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may lead to chronic inflammatory diseases, such as preeclampsia (PE) (Sharma, Satyam et al. 
2007), RA (Folkman 1995), psoriasis (Braverman and Sibley 1982) or Crohn‟s disease 
(Kanazawa, Tsunoda et al. 2001). Excessive angiogenesis or inhibition of angiogenesis 
enhances a number of inflammatory processes, and the two are often co-dependent (Jackson, 
Seed et al. 1997). Because of the apparent co-dependency of inflammation and angiogenesis, 
compounds that block the angiogenic response may also prove beneficial for inflammatory 
diseases. VEGF-R1, and its ligands VEGF and PlGF participate in an important role in 
monocyte chemotaxis and promote recruitment of circulating endothelial precursor cells from 
bone marrow (Hattori, Heissig et al. 2002, Holmes and Zachary 2004). PlGF can also 
contribute to inflammation by acting as a survival factor for monocytes and macrophages 
(Adini, Kornaga et al. 2002). 
A large number of diseases, such as RA, heart disease, tumour progression and metastasis, 
PE, obesity and trauma that is associated and not associated with any external stimuli or 
injury, are known to induce pro-inflammatory cytokines. Amplified tissue infiltration by 
macrophages is a dramatic and common feature of acute/chronic inflammation and 
angiogenesis. 
ECs express a broad spectrum of cytokines and chemokines, including TNF-α, IL-1β, IL-3, 
IL-5, IL-6, IL-8, IL-11, IL-15 (Krishnaswamy, Kelley et al. 1999). These are all pro-
inflammatory mediators in potentiating an inflammatory response, including inflammatory 
angiogenesis by inducing cytokine and growth factor secretion by ECs and non-ECs to the 
site of inflammation (Krishnaswamy, Kelley et al. 1999). Several cytokines and growth 
factors that are part of the inflammatory angiogenesis have pro-thrombotic and fibrogenic 
effects (Krishnaswamy, Kelley et al. 1999). 
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IL-1β and TNF-α, in particular, are effective in triggering the expression of pro-inflammatory 
genes in various types of cells (Kumar 2012).  
Table 1.5  Human studies of systemic inflammation and endothelial dysfunction 
 
Additionally, both IL-1β and TNF-α exhibit pro-coagulant activity by inducing endothelial 
expression of tissue factor, and they share overlapping functions in the acute as well as the 
chronic inflammatory response (Voronov, Carmi et al. 2014). TNF-α is probably the most 
studied candidate for initiating inflammatory angiogenesis. In physiological conditions, TNF-
α is hardly detected. However, in pathological disorders, TNF-α concentration amplifies to 
abnormally high levels (Lee, Zaske et al. 2011) (Table 1.6). Such high levels are toxic and 




Measurement/Assessment  Response Comment Ref 
Salmonella typhi 
vaccination 
Vascular Function -Acute 
inflammatory 
response 
- Increased levels 
of inflammatory 
response 
Short-term impairment of 
endothelium-dependent 
dilation in conduit and 




























Effect of oral aspirin (1.2 
g) pre-treatment on 
vaccine-induced 
endothelial dysfunction.  











1 hour exposure 
to TNF-α, IL-1β, 
or endotoxin 
Hand veins -Impaired 
endothelial 
function in hand 
veins of healthy 
subjects 
Endothelial dysfunction 
persisted for 48h and up 
to 7 days to recover  
(Bhagat, 
Moss et al. 
1996) 




          
Table 1.6  List of common pathologies presenting higher plasma levels of circulating TNF-
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 Study the impact of pro-inflammatory cytokines on endothelial  PlGF release in 
micro and macro-vascular endothelial cells. 
 Examine the role of endogenous PlGF on endothelial cell survival 
Chapter 5
 Delineate the underlying signalling mechanism governing FGF-2-mediated endothelial 
PlGF release
 Identify growth factors and cytokines regulating endothelial PlGF levels




 Examine the role of PlGF in FGF-2-mediated angiogenesis in vitro and ex vivo mouse 
PlGF gene knock out models









Chapter 3. Materials and Methods 
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Experimental Methods used in study
Biochemical/Molecular
Techniques






- Small interfering RNA  
- PlGF knock-out mice
 Angiogenic Assay 
- In vitro tube formation
- Aortic ring Assay
 Cell Viability - Scratch Assay, MTT, TUNNEL Assay
 Signalling studies    
- Adenoviral infection
3.1 Materials and Methods 
Equipment used for this study and its suppliers are documented in Appendix III. Protocols for 
production of all solutions and buffers are detailed in Appendix IV.  
Experimental methods 
Various experimental methods used in this study are listed in Figure 3.1. Detailed description 
and application of each method used can be found in this chapter. 
          
Figure 3.1 Experimental methods used in the current study. The methods are grouped 
according to the analysis required, listing out the method or technique used to achieve the 
functions exhibited by the cells.  
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3.2 Tissue and cell culture 
All cell and tissue culture media including supplements were purchased as sterile or filtered 
through 0.22 µm pore filter prior to use. Distilled water and Dulbecco‟s calcium and 
magnesium-free Phosphate Buffer Saline (PBS) were autoclaved before use. Tissue culture 
plastic equipment was purchased sterile. Glassware used was washed and autoclaved prior to 
use. Sterile media was stored at 4
o
C and used within 3 months.  
3.2.1 Growth medium and supplements for cell culture 
3.2.1.1 Composition of complete growth media for monolayer cells 
Roswell Park Memorial Institute (RPMI)1640  medium supplemented with 10% Fetal Bovine 
Serum (FBS) [for HUVEC, HDMEC or HMEC-1] or HAMS F-12, 10% FBS [Cancer cell 
lines]. All media were supplemented with 2mM L-Glutamine, 10 U/ml penicillin, 0.1 g/ml 
streptomycin, which was stored at -20
o
C and used within 3 months‟ time. 
3.2.2 Cultivation and maintenance of cell cultures  
Routine maintenance of cell cultures was carried out in a Class II cabinet. Cell cultures were 
maintained in humidified incubators in an atmosphere of 95% air, 5% CO2 at 37
o
C.  Cells 
were seeded in 80 cm
2 
tissue culture flasks in specific growth medium, and the medium was 
changed every 2-3 days. On reaching confluence, cells were sub-cultured by aspiration of the 
medium from the monolayer, followed by two washes with 5 ml PBS to remove serum. Cells 
were detached by treating the cells with trypsin/ Ethylene diamine tetra-acetic acid (EDTA) 
incubations of 2-4 minutes.  To inactivate the trypsin, 5 ml of the specific growth medium 
supplemented with FBS was added.  The cell suspension was transferred to a 15 ml conical 
tube and subjected to centrifugation at 80 g for 5 minutes. The supernatant was aspirated, and 
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the pellet suspended in 10 ml of growth medium. The cells were either split into new tissue 
culture flasks to maintain the stocks, or counted by haemocytometer in preparation for 
experiments requiring a specific number of cells per well before seeding either in T-75 cm
2
 or 
6, 12, 24 or 96 well tissue culture plates as per requirement. Details of cell seeding densities 
for human umbilical vein ECs (HUVEC) and human microvascular ECs (HMEC-1), the most 
commonly used cell types in this study, are mentioned in the figure legends below each of the 
experimental results. Each time the cells were detached with trypsin/EDTA and replated, they 
were assigned an ascending passage number. Table 3.1 illustrates the other cell types used in 
this study that was either a gift or purchased commercially. 
 
3.2.3 Isolation and maintenance of Primary Cell Culture and Cell lines 
3.2.3.1  Isolation of Human umbilical vein ECs [HUVECS] 
 HUVEC were isolated from the veins of umbilical cords by collagenase type-1 digestion as 
described elsewhere [1]. Umbilical cords were obtained from term deliveries that occurred in 
the Birmingham Women‟s Hospital NHS Trust. These umbilical cords were washed with 
PBS, and a 15-20 cm long section with no clamp trauma was excised. The umbilical vein in 
the cord was identified and cannulated with a blunt needle at one end. The other end was 
clamped prior to flushing the vein with PBS. This process of flushing the vein was repeated 2-
3 times to ensure the removal of any blood clots. The distal end of the cord was cannulated 
and clamped, followed by filling up of the vein by injection of 20 ml of type-1 collagenase [1 
mg/ml] made in Hank‟s buffered saline solution [HBSS]. The prepared umbilical cord was 
incubated at 37
o 
C for 10 minutes for the detachment of the ECs. Detached HUVECs in the 
type-1 collagenase  solution were collected by flushing Medium 199 [M199], buffered with 
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Earles salt‟s, supplemented with 2 mM L-Glutamine, 10 mg/ml streptomycin, 100 U/ml 
penicillin, 20 ng/ml Epidermal Growth Factor [EGF], 2.5 ng/ml FGF-2, 20% FBS into a 
sterile 50 ml tube. The cell suspension was centrifuged at 80 g for 5 minutes. Supernatant was 
discarded and the cell pellet re-suspended in 10 ml of M199 supplemented with 20% FBS. 
Cells were then seeded into a 1% gelatin pre-coated tissue culture flask. The flask is placed 
overnight in a humidified incubator with 37 
o
C, and an atmosphere of 95% air, 5% CO2 to 
allow the cells to attach. In order to remove erythrocytes, the medium was replaced on the 
following day, and the cells were grown to confluence. To assess and confirm the EC 
characteristics, immunofluorescence for the human von-Willebrand [vWf] factor was 
employed. Cells for experimental usage were between passage 2 and 6. 
 
3.2.4 Culturing of Human Microvascular ECs [HMEC-1] 
HMEC-1, a dermal microvascular cell line [a kind gift from Dr E Ades, Centers for Disease 
Control, Atlanta, GA] were cultured as previously described in detail (Wellicome, Thornhill 
et al. 1990). HMEC-1]. These were grown to confluence in T75 flasks in RPMI-1640 
supplemented with 2 mM L-Glutamine, 10 mg/ml streptomycin, 100 U/ml penicillin, 20 
ng/ml Epidermal Growth Factor [EGF], 2.5 ng/ml, 10% FBS and subcultured at a density of 
1.5 x 10
5
 on 24 well plates. Cells, on reaching confluence, were serum deprived in RPMI-
1640 medium containing 0.5% FBS overnight for subsequent experimental use. 
3.2.5 Cancer cell lines 
Cancer cell lines were subcultured in RPMI 1640 medium containing 10% FBS and plated at 
a density of 1.5x10
5 
cells/well. Prior to the day of conducting the experiment, cells were 
serum deprived in RPMI 1640 medium containing 0.5% FBS overnight. Cell supernatants 
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were collected and centrifuged at 85 g before storage at -80
o
C. Cancer cell lines used in the 
study are listed in Table 3.1 
 
Table 3.1 List of cancer cell source and cell types used in this study. 
 
3.2.6 Cell Cryopreservation 
A reserve stock of the cells was maintained through cryopreservation. Confluent monolayers 
of cells to be preserved were washed twice with PBS and trypsinised for 2-4 minutes, 
following the addition of 5 ml of complete medium. The cell suspension was centrifuged at 80 
g for 5 minutes, and the pellet was suspended in 1 ml of pre-cooled culture medium 
containing 10% FBS and 10% Dimethyl Sulphoxide [DMSO]. The cell suspension was 
transferred to sterile cryovials. The vials were labelled with cell type, passage number, and 
date of storage. Freezing of the cells was carried out in Mr. Frosty at a rate of –1
o
C/minute in 
100% isopropyl alcohol over a 4 hour period. The frozen vials were then transferred to racks 
in at –70
o
C and catalogued.   
Source Cell Name                                     Tumour type
Mammary Gland; 
Breast 
MDA-MB-231                                                  
Adenocarcinoma  (Cailleau et al., 1974)
MCF-7                                 
   
Invasive Breast Ductal 
carcinoma    (Soule et al., 1973)
BT-20                                                     
Invasive ductal 
carcinoma (Lasfargues &Ozzello,1958)
T-47D                                           Invasive ductal carcinoma          (Keydar et al., 1979)
Small Cell Lung 
Carcinoma
N417A                                                                  
Cancer Cell line (Kiefer et al., 1987)
N592                                                                                               Cancer Cell line (Kiefer et al., 1987)
N249                                                                                               Cancer Cell line (Pettengill et al., 1980)
Colon Carcinoma HT29                                                                  Adenocarcinoma (Fogh et al., 1979)
Choriocarcinoma JAR                                       Trophoblastic tumor of the placenta(Kameya e  l., 1975)
Reference
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3.2.7  Cryopreserved cell retrieval 
To retrieve the preserved cells, the cryo vials were thawed to 37
o
C incubated at room 
temperature. Once thawed, the cell suspension was immediately transferred to a tissue culture 
flask with specified serum-containing growth medium. Cells were incubated at 37
o
C in a 
humidified incubator in an atmosphere of 95% air, 5% CO2 for about 16 hours. This enabled 
the cells to attach to the flask. The cells were then washed with PBS to remove traces of 
DMSO and cell debris, and replaced with fresh growth medium. 
3.2 Stimulation of ECs 
HMEC-1 or HUVEC were cultured in 24 well cell culture plates at a density of 
1.5x10
5
cells/well and incubated at 37
o
C until they reached confluence. The mean time to 
achieve confluence was 24 to 30 hours and was dependent on passage number of the cells. 
Confluent cells were starved in appropriate growth medium overnight. Cells were stimulated 
in duplicate with various growth factors or inhibitors or both. All stimulations were performed 
in 500 µl for 24 hours unless otherwise indicated. Supernatants were collected and centrifuged 
at 85 x g before storage at -80
o
C. 
3.2.1 Analysis of Changes in Intracellular Signalling Pathways 
Various pharmacological inhibitors and activators were used to elucidate the mechanism of 
FGF-2 or TNF-α-mediated PlGF release from HMEC-1 or HUVEC. Confluent cells in 6 well 
cell culture plates at a density of 1 x 10
6
cells/well in 2 ml/well of the growth medium.  
Pharmacological inhibitors or activators were added 30-45 minutes before the treatment with 
FGF-2. At indicated time points cells were aspirated of growth medium and washed twice 
with 10 ml of ice-cold PBS/flask. Cells were subsequently subjected to lysis treating with 60 
µl/well of non-ionic radio immunoprecipitation buffer [RIPA] containing 1:1000 dilutions of 
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protease inhibitor and phosphatase inhibitors I and II. A sterile cell scraper was used to 
harvest the cell lysates which were collected into 0.5 ml eppendorf tubes. Duplicate samples 
were pooled to generate sufficient amounts of protein and allow ample protein for Western 
blotting. Samples were stored at -80
o
C for 1 hour and then thawed on ice before being 
centrifuged at 1300 rpm for 10 minutes to remove any insoluble proteins that may have been 
present.  Supernatants were aspirated, and the pellet was re-suspended in 50 ul of 1x RIPA 
buffer and assay for protein concentration. 
3.3 Adenoviruses 
3.3.1 Adenoviral infection of ECs 
HMEC-1 at 90% confluence were infected with the adenoviruses for a minimum of 12-16 
hours in M199 containing 5 % FBS and G/P/S at 37 C. Adenovirus containing medium was 
removed and replaced with fresh growth medium for a further 24 hours. Cells were then 
cultivated in M199 containing 5 % FBS and L-Glutamine, 10U/ml penicillin and 0.1 μg/ml 
streptomycin (G/P/S) for the appropriate time periods. Infection was validated by subjecting 
protein lysates of infected HMEC-1 to SDS-PAGE, and then Western blotted with appropriate 
antibodies diluted in TBS-T/0.5 % BSA (see Appendix II for antibody source and dilution 
used for Western blotting).  
PROTEIN BIOCHEMISTRY TECHNIQUES 





 96 well solid plates were coated with 100 l/well of capture 
antibody in PBS pH 7.4, covered with a plastic film and left in the dark overnight at room 
temperature (RT). The following day the plates were washed four times with PBS containing 
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0.05 % Tween [PBS-T] and then blocked for 1 hour using 200 l/well of 1 % BSA in PBS. 
After three PBS-T washes to remove residual BSA, samples were mixed well and added at 
100 l/well to the plates followed by incubation for 2 hours with agitation at RT. After 
washing, 100 l of biotinylated detection antibody constituted to working concentrations in 
PBS-T was added to each well and incubated for a further two hours at RT with agitation. 
After washing streptavidin-HRP [1:200] in PBS-T was added for 20 minutes in the dark and 
then washed off. The Hydrogen peroxide-colour substrate solution [R&D Systems, UK] was 
added to the plate [see manufacturer‟s instructions], incubated until sufficient colour change 
was observed and the reaction stopped using 2N H2SO4. Presence or absence of the protein of 
interest was determined by reading the optical density [OD] at 450 nm [adjusted at 540 nm] 
with a Multiskan Ascent 96 well plate reader and subtracting the blank value [sample diluents 
only] from the sample absorbance values. 
3.5 PlGF or VEGF ELISA 
Supernatants from HUVEC, HMEC-1 or cancer cell lines were incubated on 96 well plates 
and were coated with mouse anti-human PlGF or VEGF capture antibody in PBS [pH 7.4] 
[R&D Systems, UK]. 100 µl of recombinant human PlGF or VEGF standard in assay buffer 
[range 1- 2000 pg/ml] or cell supernatants were added and incubated at room temperature for 
2 hours. PlGF or VEGF release was detected with 100 l/well biotinylated mouse anti-human 
PlGF or VEGF detection antibody for 2 hours [0.4 g/ml] [R&D Systems, UK] and detected 
as described above. 
PlGF standards or cell supernatants were pre-incubated with increasing concentrations of 
sVEGFR-1 [0.01 to 100], to ensure that the R&D PlGF ELISA kit measured total PlGF. No 
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significant effect was seen on the level of PlGF measured in the ELISA indicating that both 
the sVEGFR-1 bound and free PlGF protein is being detected.  
3.6 Protein extraction  
The day before stimulation or transfection cells were fed with full media and seeded at a 
density of 5 x10
5
 cells/ml. Usually, ~ 5 x10
6 
cells [roughly 10 ml of cell suspension] were 
harvested and washed three times with 10 ml of cold PBS, centrifuging for 7 min at 1500 rpm 
and 4
o
C. The final wash was carried out in 1.5 ml Eppendorf, after the last wash all 
supernatant was aspirated on ice. The cell pellet was then either snap-frozen in liquid nitrogen 
and stored at -80
o
C for future use or lysed in between 50-500 µl of lysis buffer [9M urea, 50 
mM Tris pH7.5. 15 mM β-mercaptoethanol], unless otherwise stated. Following addition of 
lysis buffer, samples were vortexed vigorously for 1 min and then clarified by centrifugation  
3.6.1 Protein Quantification 
The protein concentration of the samples was quantified by the Bradford method of protein 
assay for equal loading of the samples on a Western blot gel. A protein standard curve was 
made using BSA standard protein [range from 0 - 1.4 mg/ml] dissolved in RIPA buffer. It was 
important that both the buffer with which the standard curve was created and used to re-
suspend the protein samples were identical. Thus, differences in protein concentrations 
observed between the samples were due to sample protein content and could not be attributed 
to buffer related artefacts. Protein samples were created in RIPA buffer to enable protein 
detection within the range of the standard curve. Following dilution, 5 µl/well of samples and 
standards were added in duplicate wells to 96 well plates followed by 25 µl/well of Bio-Rad 
Solution A and 200 µl/well of Bio-Rad Solution B. Plates were incubated for 15 minutes at 
room temperature before the optical absorbance was read at a wavelength of 595 nm with a 
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Thermo Lab Systems MultiScan Ascent microplate photometer. Optical absorbance values for 
protein samples were used to extrapolate protein concentration from the BSA standard curve. 
Protein samples loaded for the Western blots were equal in concentration as well as volume; 
this was achieved by diluting the sample with 2 x sample buffer to ensure equal loading of 
protein content and equalise volumes of each sample prior to applying onto the gel, to avoid 
lane artefacts. This step ensured that all of the samples were treated under identical conditions 
in the gel and any differences in protein expression observed by Western blotting are 
attributable to the changes in EC function rather than to gel loading or protein transfer errors.  
3.7 Western Blotting 
3.7.1 Polyacrylamide Gel Preparation and Running 
To separate the samples by SDS-PAGE, the appropriate percentage of running gel was 
prepared that was based on the size of proteins to be detected. The recipes for different 
percentage of running gel are listed in the appendix.  After the suitable running gel had been 
made, the mixture was immediately pipetted between two securely fastened glass plates up to 
a predefined mark determined by the height of the loading comb. A 50% methanol solution 
was applied immediately above this layer to prevent the formation of air bubbles in the 
running gel, and to generate a level running gel-stacking gel interface to ensure the samples 
would run in a parallel fashion. The gel was allowed to polymerise for 30 minutes before the 
methanol was removed and was replaced with 5% acrylamide stacking gel [2.7 ml 40% 
Acrl/Bis, 0.5 M Tris [pH 8.8] 200µl 10% SDS, 100µl 10% APS, 30µl TEMED and 24ml 
water] within which the loading comb was inserted. The stacking gel was given another 15 
minutes to polymerise before the apparatus was secured into the gel running tank. The tank 
was then filled with 1x running buffer [0.05 M Tris, 0.384 M glycine and 3.47 mM SDS] to 
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prevent the gel from drying out. Samples were boiled, cooled on ice and then centrifuged at 
1300 rpm for 1 minute. Samples were loaded into the lanes in accordance with a pre-prepared 
plan so that each lane had a maximal protein concentration of 20 ug/ml, 7 ul/lane of rainbow 
marker, plus 5 ul/lane of biotinylated marker were also boiled with 2 x sample buffer as 
described above and added to lanes flanking the samples. 2 x sample buffer was used to fill 
sample-free lanes to ensure that the sample buffer itself was not contaminated with protein. 
The gel was run for 30 minutes at 60 V and then run for a further 90 minutes at 110 V once 
samples had migrated from the stacking gel into the running gel. 
3.7.2 Semi-Dry Transfer of proteins onto Nitrocellulose Membrane 
Following separation, the gel was removed from the glass plates. The stacking gel and excess 
running gel were removed before the remaining gel was immersed in transfer buffer [5.81g 
Tris, 0.375 g SDS, 2.93 g Glycine, 200 ml 20% methanol and 800 ml dH2O]. Nitrocellulose 
membranes and stacking filter paper were cut to appropriate sizes and soaked in transfer 
buffer. The filter paper was placed in the transfer buffer upon which the nitrocellulose 
membrane, running gel and second filter paper were stacked [in that order]. Air bubbles were 
removed by rolling the layers with a pipette. Protein transfer was run for 2 hours at a constant 
current of 0.8 mA/ cm
2
]. 
3.7.3 Blocking Non-Specific Binding Sites on the Nitrocellulose Membrane 
Blocking the membrane prevents non-specific protein binding during subsequent stages of 
membrane handling and reducing non-specific binding of the primary and secondary 
antibodies. Following transfer, filter papers and gels were discarded while the nitrocellulose 
membrane was blocked in a blocking buffer consisting of 8% fat-free skimmed milk powder 
in TBS-T [20 mM Tris, 73.1 mM NaCl, 0.1% Tween-20® [pH 7.4]]. After 1 hour, the 
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blocking buffer was removed, and membranes were washed twice in TBS-T. By this stage, 
the non-specific milk proteins had bound to all available binding sites on the nitrocellulose 
membrane devoid of sample protein.  
3.7.4 Primary and Secondary Antibody 
Primary antibodies were diluted in 5% BSA solution containing sodium azide which prevents 
microbial growth in the nutrient-rich buffer. Primary antibodies were all used at a dilution 
listed in Table 3.2 and were raised in rabbit or mouse [except β-actin which was used at a 
dilution of 1:2000 and raised in mouse]. Membranes were probed with anti-total Erk1/2, 
phospho Erk1/2, c-Raf, β-actin or pan PKC primary antibody overnight at 4oC.  
  







  Source 
 actin mouse 1:20,000 Cell Signaling Tech, Herts, UK 
Akt rabbit 1:1000 Cell Signaling Tech, Herts, UK 
Akt [phospho ser-473] rabbit 1:500 Cell Signaling Tech, Herts, UK 
ERK1/2 rabbit 1:1000 Cell Signaling Tech, Herts, UK 
ERK1/2 [phospho thr-202/tyr204] rabbit 1:1000 Cell Signaling Tech, Herts, UK 
His-Tag mouse 1:1000 Autogen Bioclear, UK 
PLC [phospho tyr-783] rabbit 1:1000 Cell Signaling Tech, Herts, UK 
PlGF [172] rabbit 1:100 Gift – H. Weich 
RAS mouse 1:500 BD Transduction Labs, UK 
 Table 3.2 Antibodies used in Western Blotting for protein detection 
The following day, membranes were washed three times for 20 minutes each in TBS-T and 
were incubated with horseradish peroxidase [HRP] labelled secondary antibody or β-actin] at 
a 1:5000 dilution in 5% (w/v) skimmed milk powder in TBS-T. Table 3.3 illustrates the 
antibodies used for the purpose of the study, the species the antibody was raised in, the 
dilution used for western blotting and the source of the antibodies. A horseradish protein 
(HRP) conjugated biotinylated anti-biotin marker was added at a 1:1000 dilution to detect the 
biotinylated markers, which had also been transferred along with the sample protein to the 
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membrane. After 1 hour, the membranes were quickly washed twice in TBS-T before being 
washed a further three times for 20 minutes each in TBS-T.Secondary antibody conjugates. 
Antibody Dilution Experiment Source 
 







Table 3.3 Secondary antibody conjugates used for Western Blotting 
3.7.5 Enhanced Chemiluminescence Detection 
ECL solution was made using an equal volume of SuperSignal® West Pico luminal/enhancer 
and SuperSignal® West Pico stable peroxidase solution [Pierce Biotechnology Inc]. 
Membranes were incubated in ECL for 30 minutes before being wrapped in Saran wrap and 
secured in an autoradiographic cassette. The membrane was opposed to Kodak X-OMAT 5 
autoradiographic film for periods of time ranging from 5 minutes to 20 seconds in the dark 
room. The exposed film was first immersed in developer solution [Kodak] for 90 seconds and 
was secondly immersed in fixer solution [Kodak] before being washed with water and air-
dried. An automated film developing system was used in later experiments. 
3.7.6 Protocol for Stripping and Re-probing the membrane  
Membranes were immersed in stripping buffer [1.97 g Tris HCL [pH 6.7], 4 g SDS, and 1.4 
ml 2- mercaptoethanol and 200 ml dH2O] for 60 minutes at 30 
o
C to remove the membrane-
bound primary and secondary antibodies. Membranes were then washed twice for 10 minutes 
in TBS-T followed by a further 3 washes for 20 minutes each in TBS-T. Membranes were re-
blocked in 10% milk before the protocol from using the primary antibody was repeated. 
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3.8 Cell Viability by MTT assay 
To ensure that the cytokines and signalling inhibitors used in cell-based assays were not 
affecting cell viability [3-[4, 5-Dimethylthiazol–2-yl]-2, 5-diphenyltetrazolium bromide 
thizolyl blue] (MTT) assay was performed. MTT assay is a colorimetric assay that measures 
the mitochondrial activity, and the total mitochondrial activity is related to the number of 
viable cells.  This assay is broadly used to measure and detect any in vitro cytotoxic effects on 
cells (van Meerloo, Kaspers et al. 2011). 
The cell viability in this assay is based on the conversion of MTT, a tetrazolium salt, to an 
insoluble formazan product. This is largely achieved through the action of mitochondrial 
dehydrogenase enzymes in metabolically active cells. Cells were seeded at a density of 1.5 x 
10
4 
cells/well in 96-well plates, left to attach to the plate for 4 hours and then rested overnight 
in medium containing 2% FBS. The resting medium was aspirated from the cells and replaced 
with 100 l of fresh 2% FBS medium containing the growth factors at appropriate 
concentrations. After 24 hour incubation at 37 C, the growth factors were removed and 75 l 
of fresh 2% FBS medium was added. 25 l of MTT at a concentration of 5 mg ml
-1
 was added 
to each well and the plates were incubated in the dark at 37 C for 4 hours. MTT reagent was 
prepared by adding 3 ml of MTT to 9 ml of 10% FBS RPMI-1640. 100 µl of MTT reagent at 
a concentration of 5 mg/ml was added to each well following aspiration of conditioned media 
and HUVECs were incubated in the dark for 4 hours at 37 
o
C and 5% CO2. After removing 
the medium, 150 µl of 99.5% Dimethyl Sulphoxide [DMSO] was added to each well to 
solubilise the crystalline formazan and thus changes the shape of the absorbance spectrum of 
the solution to enable quantification by spectrophotometric analysis. Optical absorbance was 
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read at 540 nm with the Thermo LabSystems MultiScan Ascent microplate photometer and 
analysed.  
3.9 Molecular Biology techniques  
3.9.1 Total RNA Extraction 
RNA was extracted following stimulation of cells using the RNA Easy Mini Kit [Qiagen] 
according to the manufacturer‟s instructions. The concentration and quality of RNA were 
assessed using the Nanodrop spectrometer. The A260/280 of RNA samples was required to be 
approximately 1.8.  RNA stocks were diluted to 1 mg/ml for routine use. All RNA samples 
were stored at –80
o
C. 
3.9.2 cDNA synthesis 
The extracted RNA was subjected to digestion using DNase-1 enzyme on RNeasy mini 
columns [Qiagen]. Using the cDNA Synthesis Kit [Bioline], the total RNA [1 µg] was reverse 
transcribed with oligo-dT18 primers for 70 minutes at 48°C.  
Real-time PCR on a Corbett Research Rotagene RG-3000 was performed on the samples 
using SYBR green PCR SensiMix [Bioline] at 95°C, 10 seconds; 58°C, 15 seconds; 72°C, 15 
seconds. The real-time PCR machine was programmed to quantify fluorescence after 82°C, 
15 seconds, extended to 40 cycles. Using primers specific for human PlGF [sense, 5´-
GCGATGAGAATCTGCACTGT-3´; antisense, 5´-CTTTAGGAGCTGCATGGTGA-3´] or 
β-actin, cDNA samples and their standards were amplified as previously described (Malarstig, 
Tenno et al. 2003)(R&D systems).  
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In-house designed using  




Utilising the plasmid containing a C-terminal fragment of PlGF or β-actin cDNA, the mean 
threshold cycle (Farina, Sekizawa et al. 2008) for each sample was compared with standard 
curves produced using serial dilutions, to ensure that the primers could detect the targets over 
a large concentration range and to determine the detection limit/sensitivity as well. Relative 
PlGF expression was calculated following normalization using β-actin Ct value for the same 
sample. The Ct value for every gene of interest normalised using the β-actin Ct value for the 
same sample. Change in fold change calculated using the equation 2
-ΔΔct
.   
 
  
ΔΔCt  =  (ΔCt value of the treated cells) – (ΔCt value for the control) 
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3.10 Gene Inactivation Studies 
PlGF gene silencing studies were carried out by small RNA interference [sRNAi] by Amaxa 
for assessing PlGF gene function in HUVEC. PlGF ELISA assessed the degree of transfection 
by PlGF knock-down in HUVEC. 
3.10.1  Nucleofection 
To knock-down PlGF gene expression, HUVEC were transfected separately with PlGF 
siRNA [forward 5'-CCGGCUCGUGUAUUUAUUAUU-3'; reverse 5'-
AUAAAUACACGAGCCGGUU-3'], or control siRNA which does not target any sequence in 
the human genome.  The nucleofection technique is an electroporation based transfection 
technique. The day before, transfection cells were fed with complete medium and seeded at a 
density of 1.5 x 10
5
 cells/ml. HMEC-1 or HUVEC were transfected using Nucleofection Cell 
Line Kit T and a Nucleofector electroporator according to the manufacturer‟s instructions 
(AMAXA, Germany). 2 x 10
6 
cells were used per transfection. Cells were transfected with 5 
ug of siRNA using appropriate cell type-specific programme for HMEC-1 or HUVEC on the 
Nucleofector. Following transfection, cells were immediately transferred to a 12-well tissue 
culture plate and incubated in 1.5 ml of complete medium for 8 hours. Cells were 
subsequently diluted to 5x10
5 
cells/ml and cultivated to be used for cell function assays. 
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3.11 Functional Assays 
3.11.1 Tunel Assay – Dead End Fluorometric Assay 
3.11.1.2 Assay Principle 
Dead End Fluorometric assay was used to enable precise detection of apoptosis in situ in 
PlGF silenced HUVEC (PlGF siRNA) cells when compared to their respective control 
(control siRNA). The principle underlying this assay is the detection of DNA fragmentation in 
the apoptotic cells. Recombinant Terminal Deoxynucleotidyl Transferase, enzyme (rTdT) 
measures the fragmented DNA of apoptotic cells by catalytically incorporating labelled dUPT 











Figure 3.2 Schematic illustration of DNA strand breaks labelling for TUNEL assay with 
Br-dUTP utilising exogenous terminal deoxynucleotidyl transferase (TdT) 
(:http//www.google.com/images). 
      




HUVEC (control siRNA) and PlGF silenced HUVEC (PlGF siRNA) were plated at a density 
of 1x10
5
 on a poly-l-lysine-coated two-well microscope chamber slides for 6 or 12 hours. 
Instructions for performing the assay were followed according to the manufacturers‟ 
instructions (Promega). Cells were then fixed in 4% methanol free formaldehyde and 
subjected to the DeadEnd™ Fluorometric TUNEL System. This involved labelling of DNA 
strand breaks with fluorescein-12-dUTP for 60 minutes. Samples were immediately analysed 
using a fluorescence microscope. Protocol flow chart provided in figure 3.3. 
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Figure 3.3 Protocol overview of the DeadEnd™ Fluorometric TUNEL System used to 
detect cell apoptosis.  
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3.12 In Vitro Tube Formation  
Formation of tubular structures was studied using HUVEC cultured on growth factor-reduced 
Matrigel diluted 1:1 in ice-cold M199 as previously described (Ahmad and Ahmed 2004).  
Briefly, cells were seeded onto the Matrigel for 45 minutes and treated with FGF-2 (2 or 10 
ng/ml).  After incubation at various time points, cells were observed under a Nikon inverted 
microscope and results recorded at times specified using Image-Pro Plus image analysis 
software (Media Cybernetics). Mean total tube length was calculated from three independent 
experiments. 
3.12.1 Animal Preparation 
All procedures involving mice were performed according to the protocols approved by the 
University of Birmingham. Mice between 8-10 weeks of age for wild-type (WT) and PlGF-
KO mice on a Balb/c background were kindly provided by  at the 
. Validation of the PlGF-KO mice was carried out 
in the laboratories of . 
3.13 Aortic Ring Assay 
The aortic ring assay was performed as previously described (Blacher, Devy et al. 2001). 
Briefly, aortic explants were resected from PlGF-deficient mice (PlGF-KO) or wild-type 
(WT) mice. The descending thoracic aorta was very carefully isolated, then 1mm length aortic 
rings were cut and embedded into growth factor-reduced Matrigel and collagen mix, 
supplemented with 20 U/mL heparin on 48 well plate. The explant resections were treated 
with FGF-2 (2 or 10 ng/ml). Each experimental condition on the explant resections was 
performed in duplicates.  2.5 % of mouse serum was added to each condition (Carmeliet, 
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Moons et al. 2001). Aortic ring assay was performed with three biological replicates (n=3) 
and six technical replicates (n=6). 
Explant cultures were examined every second day. On day seven, vessels sprouting from 
aortic explants were examined using an inverted phase-contrast microscope. Results were 
recorded at times specified using Image-Pro Plus image analysis software (Media 
Cybernetics). Quantification was achieved by measurement of the length and number of 
vessel-like extensions from the explants.  
 
3.14 Statistical Analysis 
The data in this thesis are expressed as mean [± Standard Error] of minimum 3 independent 
experiments unless otherwise indicated. A comparison between controls and samples and 
between individual samples was made with the use of a two-tailed unpaired Student‟s t-test 
with a 95% confidence interval.  P<0.05 was considered to be significant. All statistical 













Chapter 4 -Growth factors and cytokines 
regulating endothelial PlGF levels 





Development and growth following normal physiology depends primarily on oxygen and 
nutrients provided by blood vessels. Consequently, malfunctioning or dysfunction of these 
blood vessels contributes towards compromised organ function, leading to congenital and 
acquired diseases. Advancements of therapeutic strategies to either promote revascularisation 
of ischemic tissues, or to inhibit angiogenesis in cancer and inflammatory disorders with the 
goal to combat diseases have been a prime focus for over a decade. Administration of  
recombinant VEGF or anti-VEGF therapies (Losordo, Vale et al. 1998, Kastrup, Jorgensen et 
al. 2005, Stewart, Hilton et al. 2006), have been in use since 2004,  with its potential 
risks/side effects such as hypotension, bleeding, oedema formation  (Yang, Bunting et al. 
2000) and possible risk of inducing neoplastic and malignant disease (Lee, Springer et al. 
2000) out weighing its benefits.  
PlGF, a VEGF homolog and a key regulator in pathological angiogenesis (Carmeliet, Moons 
et al. 2001, Luttun, Tjwa et al. 2002), is detected in plasma and tumours, correlating to tumour 
staging, vascularity, recurrence, metastasis and in the survival of these tumours (Matsumoto, 
Suzuki et al. 2003, Chen, Hsieh et al. 2004, Parr, Watkins et al. 2005, Wei, Tsao et al. 2005, 
Ho, Chen et al. 2007). Anti-PlGF treatment both in vitro and mouse in vivo studies 
demonstrated inhibition of growth and metastasis in various tumours, including those resistant 
to VEGF[R] inhibitors [VEGF
R
Is] (Fischer, Jonckx et al. 2007). This study also ascertains the 
inhibitory effect of anti-PlGF on both angiogenesis and lymphangiogenesis, with a distinct 
feature of preventing angiogenic rescue program, with efficacy and safety unlike VEGF
R
Is 
therapies (Fischer, Jonckx et al. 2007). Elevated levels of PlGF have also been reported in 
several inflammatory disorders. PlGF has been reported to be indispensable for physiological 
vascular development (Carmeliet, Moons et al. 2001). The role of PlGF on proliferation, 




migration and permeability of ECs has been controversial (Park, Chen et al. 1994, Persico, 
Vincenti et al. 1999). Absence of PlGF induced regression of neovascular complexes, and had 
a minimal effect on vascular development and normal embryogenesis as demonstrated in 
PlGF knockout mice. Yet such a deficiency can reduce collateral vascular growth under 
pathologic conditions, such as ischemia, inflammation, and cancer (Carmeliet, Moons et al. 
2001). PlGF stimulates collateral growth in ischemic heart and limb with an efficiency 
comparable to that of VEGF, without affecting healthy vessels (Pipp, Heil et al. 2003, Luttun, 
2002 22), which makes PlGF the most wanted candidate to learn its functional aspects in 
order to manipulate as a therapeutic agent. Limited knowledge of the cell types producing 
PlGF and the factors regulating PlGF levels deters the efforts to combat several pro/anti 
angiogenic disorders. It is therefore essential to establish the source of PlGF and the factors 
regulating this pleiotropic cytokine.  
In this study we clearly demonstrate the specific and strong expression of PlGF at both the 
gene and protein levels in a wide range of ECs, unlike cancer cell lines. We also screened 
various growth factors and cytokines to evaluate their effect in modulating the levels of PlGF 
secreted by ECs. This study formed the basis of the later chapters to further investigate the 
underlying mechanisms regulating PlGF in ECs. FGF-2 and VEGF belonging to the class II 
and class V receptor tyrosine kinase family [RTK] were strong inducers, in contrast to the 
Th1 type pro-inflammatory cytokines, such as, TNF-α, that reduced secretion of PlGF from 
ECs.  
 




4.2 Results  
4.2.1 PlGF is selectively expressed in Endothelium 
As relatively little is known of the cell-specific regulation of PlGF expression, we screened a 
panel of tumour cell lines (including those derived from breast, colon and lung), as well as 
SMCs and ECs for VEGF and PlGF levels by ELISA [Figure 4, 4.2] and RT-PCR [Figure 
4.1B].   
In contrast to VEGF (Figure 4.2), PlGF expression was strikingly low or below detectable 
levels in most of the tumours, transformed and normal cells examined (Figure 4.1).  However, 
high levels of PlGF protein and mRNA levels were detected in a range of human 
microvascular and macrovascular ECs. PlGF expression was very low or below detectable 
levels in most of the tumour cell lines. In contrast, high levels of PlGF mRNA and protein 
levels were detected in ECs, re-affirming ECs to be an abundant source of PlGF (Yonekura, 
Sakurai et al. 1999). SMCs demonstrated significant levels of PlGF compared to the tumour 
cells, but very low levels when compared to ECs.  
  





Figure 4.1 PlGF selectively expressed in the endothelial cells.  PlGF protein  release  by 
ELISA (A) and PlGF expression by RT-PCR (B) from various tumour and normal cells: 
human breast (MDA-MB-231, MCF-7, BT20, T-47D), small cell lung carcinoma (SCLC: Hx-
82, N417A, N592, 249) colon (HT29), choriocarcinoma (JAR), melanoma (RPMI) cancer cell 
lines; embryonic kidney epithelial cells (HEK293); foetal lung fibroblasts (MRC-5), and 
aortic smooth muscle cells (HA-SMC). Human endothelial cells derived from aorta (HAEC), 
umbilical vein (HUVEC), pulmonary vein (PLVEC): and microvascular cells from lung 
(HuLEC), mammary adipose (HuMMEC), abdominal adipose (HuAMEC), Human pulmonary 
endothelial cells (HPMC), and the dermal microvascular endothelial cell line (HMEC-1).  
PlGF was measured by ELISA in cell supernatants following 24 h incubation in basal medium 
containing 5% FCS. (B) RT-PCR for PlGF in cancer cells and endothelial cells. Data are 




expressed in pg/ml of free and bound PlGF and are mean [± SEM] of three or more separate 
experiments performed in triplicates. RT-PCR data Courtesy Dr P Hewett. 
 
Interestingly, the same samples screened for VEGF levels demonstrated diametrical results, as 
previously reported in thyroid tumour cell lines (Viglietto, Maglione et al. 1995). This clearly 
demonstrates and re-confirms that ECs are most likey to be the prime source of PlGF, which 

















           
 
Figure 4.2 VEGF levels in endothelial and non-endothelial cells. VEGF release from 
various tumour and normal cells: human breast (BT-20, MCF-7, T-47D), colon (HT29), 
cancer cell lines; embryonic kidney epithelial cells (HEK293); foetal lung fibroblasts (MRC-
5), and aortic smooth muscle cells (SMC). Human endothelial cells derived from Human 
pulmonary endothelial cells (HPMC), umbilical vein (HUVEC), and the dermal 
microvascular endothelial cell line (HMEC-1).  PlGF was measured by ELISA in cell 
supernatants following 24 h incubation in basal medium containing 5% FCS. Data are 
expressed in pg/ml of free and bound PlGF and are mean [± SEM] of three independent 









4.2.2 Factors regulating the release of PlGF in cells 
After confirming that ECs are the prime source of PlGF, we sorted to study the factors that 
regulate the release of PlGF in HMEC-1 and primary cultures of Human macrovascular 
endothelial cells, HUVEC, and Smooth muscle cells [SMC]. Cells were treated with a range 
of growth factors and cytokines at specified concentrations. PlGF levels secreted by these 
cells 24 hours post treatment were measured in the cell supernatants by ELISA. Figure 4.3 
represents secreted PlGF levels from HUVEC [A] or HMEC-1 [B] in the presence of a range 
of cytokines that disclose to be agonist or antagonist of PlGF. Two–four folds increase in the 
levels of PlGF was observed in the presence of PMA and FGF-2 in both the cell types, 
compared to the control. In contrast, GM-CSF, TNF α and IL-1β had the opposite effect; 
inhibiting the levels of PlGF twofold.  




               
Figure 4.3 Factors regulating the release of PlGF from ECs. ECs were seeded at a density 
of 1.5X105 per well in 24 well dishes, serum starved overnight in 5% FCS containing 
medium. Supernatants were collected 24 hours post stimulation with growth factor or 
cytokine. Cell supernatants were analysed for PlGF levels in HUVEC [A], HMEC-1 [B], by 
ELISA. Data are expressed in pg/ml of free and bound PlGF and are mean [± SEM] of three 
separate experiments performed in triplicates. All the growth factors or cytokines used at a 
concentration of 10 ng/ml and PMA at 100nM. *P<0.05 vs. Control.  




The levels of PlGF released by SMCs in the presence of TNF α, PMA or FGF-2 demonstrated 




Figure 4.4 PlGF levels in stimulated SMCs. Cells were seeded at a density of 1.5X105 per 
well in 24 well dishes, serum starved overnight in 5% FCS containing medium. Supernatants 
were collected 24 hours post stimulation with growth factor or cytokine. Cell supernatants 
were analysed for PlGF levels by ELISA. Data are expressed in pg/ml of free and bound 
PlGF and are mean [± SEM] of three independent experiments performed in triplicates. All 
the growth factors or cytokines used at a concentration of 10 ng/ml and PMA at 100nM. 






























4.2.3 Growth factors regulating PlGF release in ECs 
PlGF, a homologue of VEGF (Maglione, Guerriero et al. 1991) has been demonstrated to play 
a synergistic role in pathologic angiogenesis, and is thought to „„amplify‟‟ VEGF-driven 
angiogenesis and activation of vascular ECs (Autiero, Waltenberger et al. 2003). PlGF could 
therefore represent an additional and perhaps safer target [given its binding specificity for 
VEGFR-1], for the treatment of neovascular disorders. Microvascular cells exhibited higher 
levels of PlGF when screened for PlGF in our study, complying with previous reports 
(Yonekura, Sakurai et al. 1999, Zhao, Cai et al. 2004).  
The effect of pro-angiogenic growth factors on PlGF release from ECs has been studied by 
measuring the levels of PlGF from HUVEC in response to treatments with a range of growth 
factors. VEGF is the most predominant growth factor regulating angiogenesis (Roy, Bhardwaj 
et al. 2006). Splice variant isoform VEGF-A165 induced PlGF release from ECs, in 
concurrence with earlier reports (Zhao, Cai et al. 2004), and seemed to be more potent than 
VEGF-A121, which was reported to be remarkably similar to PlGF structurally (Iyer and 
Acharya 2002).  VEGF-A165 seemed to be more potent agonist of PlGF, wherein, 10ng/ml of 
VEGF-A165 induced a three-fold increase in the levels of PlGF, compared to two-fold increase 
by VEGF-A121 at 50ng/ml (Figure 4.5A). VEGF–E, a highly related protein encoded by Orf 
virus, mediating angiogenesis preferentially via the VEGFR-2 signalling (Ogawa, Oku et al. 
1998, Meyer, Clauss et al. 1999, Wise, Veikkola et al. 1999), seemed to have reduced the 
release of PlGF by two-fold compared to the control. Ubiquitous angiogenic factor FGF-2 
induced an increase in the levels of PlGF by three-five-fold in a concentration dependent 
manner, similar to that of VEGF-A165. Similarly, EGF, a known inducer of cancer risk, 
(Herbst and Shin 2002) inhibited PlGF levels (Figure 4.5B). 





Figure 4.5 PlGF levels in response to growth factors. HUVEC were seeded at a density of 
1.5X105 per well in 24 well dishes, serum starved overnight in 5% FCS containing medium. 
Supernatants were collected 24 hours post stimulation with growth factors, VEGF, FGF-2 
and EGF at specific concentrations mentioned in the figure. Cell supernatants were analysed 
for PlGF levels by ELISA. Data are expressed in pg/ml of free and bound PlGF and are mean 
















































PlGF contributes to regulating the angiogenic switch, and its significant role in promoting 
aberrant angiogenesis in a variety of pathologies has gained acute attention in the past few 
years. However, little is known about the cell type specific expression of PlGF, and the 
mechanisms by which modulation of PlGF results to pathological angiogenesis are poorly 
understood. Studies over the years have demonstrated that several factors influence 
morphological and functional differences between the diverse ECs derived from 
microvascular endothelial beds. A variation in response to growth factors/cytokines pertains 
between these ECs, well documented by Aird (Aird 2007). 
In this study we not only establish ECs to be the prime source of PlGF producers, but also the 
factors regulating PlGF levels in ECs. We also analysed VEGF levels in the same panels of 
ECs and cancer cell lines. ECs extracted from both macro and micro vasculature, such as 
umbilical vein, dermis, lung, adipose and aorta expressed significant high levels of PlGF 
mRNA and protein levels in contrast to a panel of cancer cell lines. This data conforms to 
previous studies reporting ECs to be the principal cell types expressing PlGF (Yonekura, 
Sakurai et al. 1999, Zhao, Cai et al. 2004). PlGF protein was below detectable levels in most 
of the cancer cell lines derived from breast, colon, lung and kidney carcinomas. Cancer cells 
have been reported to have high levels of VEGF (Tran, Master et al. 2002). VEGF levels in 
the same panels of both ECs and cancer cell lines were found to be diametrical to the levels of 
PlGF, contemporaneous to thyroid tumours, where an increase in the VEGF levels and a 
decrease in the PlGF levels were reported (Viglietto, Maglione et al. 1995). Non-ECs, such as 
fibroblasts [MRC-5], had negligible levels of PlGF secreted, whereas PlGF secretion by 
SMCs was significant. Increase in the PlGF levels secreted by SMCs was three-five fold 
lower than ECs and twofold higher than the cancer cell lines screened. In contrast, the levels 




of VEGF released in both the cell types MRC-5 and SMCs was three to five-folds greater than 
the ECs. According to previous studies, PlGF was observed to stimulate SMCs synchronous 
to ECs during the induction of vessel growth in a more balanced manner than its homologues 
PDGF-BB or VEGF (Keyt, Nguyen et al. 1996), which opt to stimulate SMCs or ECs, 
respectively (Carmeliet and Conway 2001). This might be due to the common receptor, 
VEGFR-1 specific to PlGF, being present on both the cell types. In addition, our results show 
PlGF being produced by both the cell types; PlGF produced by ECs as well as SMCs 
indicates a possible existence of an autocrine regulation mechanism. However, further co-
culture and in vivo studies are warranted. PlGF is expressed by migrating keratinocytes and 
ECs, acting in a paracrine and autocrine fashion on VEGFR-1-expressing endothelium (Failla, 
Odorisio et al. 2000). Lack of PlGF resulted in delayed wound closure, indicating that it is 
required for optimal skin repair (Carmeliet, Moons et al. 2001). Over expression of this 
growth factor accelerates wound closure in diabetic mice (Cianfarani, Zambruno et al. 2006).  
Because both PlGF and VEGF-A share VEGFR-1 as their common receptor molecule 
(Korpelainen and Alitalo 1998, Nicosia 1998, Neufeld, Cohen et al. 1999), it is likely that the 
co expression of PlGF and VEGF-A might affect the binding of VEGF-A to its receptors and 
may thus modulate the cellular functions executed by VEGF-A or PlGF or VEGF/PlGF 
heterodimer. This would encompass the objective of the study to examine the role of PlGF or 
the factors modulating its production in ECs. Due to the evidence that HUVECs do not 
produce VEGF in vitro, we therefore committed to use HUVECs in this chapter to investigate 
the factors regulating PlGF secretion by ECs, which might dissect mechanisms underlying in 
a variety of pathologies. ECs treated exogenously with a range of cytokines and growth 
factors were assayed for PlGF by ELISA. VEGF, FGF-2, and PMA, a phorbol ester, 
pharmacological activator of PKC and tumour inducer (Furstenberger, Berry et al. 1981), 




induced PlGF release in these cells, supporting previous reports with respect to VEGF 
induction of PlGF (Yao, Yang et al. 2005). We demonstrate that VEGF-A165 and VEGF-A121, 
secretory and circulating splice variants of VEGF-A (Ferrara and Davis-Smyth 1997), 
induced PlGF production in ECs. Nevertheless, VEGF-A165 seemed to be more potent agonist 
of PlGF than its contemporary homologue VEGF-A121. VEGF165 has been reported to up 
regulate PlGF production from ECs (Yao, Yang et al. 2005), so does PlGF up regulate VEGF 
(Roy, Bhardwaj et al. 2005). Over expression of PlGF by adenovirus-mediated gene transfer 
increased both VEGF-A165 and VEGF-A121 protein in perivascular tissue, resulting in 
significantly enhanced angiogenesis (Roy, Bhardwaj et al. 2005). Recombinant treatment of 
VEGF-A121 in rat model of preeclampsia [PE] alleviated PE like symptoms including the 
plasma sVEGFR-1 levels, almost to the levels in the normal pregnant rat (Li, Zhang et al. 
2007). Gene expression studies in pregnant rat model of PE demonstrated VEGF-A121  
treatment reversed 125 of 268 sVEGFR-1 induced changes in gene expression of cluster 
genes related to angiogenesis, hypoxia, inflammation and coagulation (Gilbert, Verzwyvelt et 
al. 2010). The angiogenic cluster of genes reduced in this study did not show the status of 
gene encoding PlGF protein that is dramatically reduced in PE (Polliotti, Fry et al. 2003, 
Chaiworapongsa, Romero et al. 2009). Our study has shown that PlGF is the common factor 
induced by both of the ligands VEGF-A165 and VEGF-A121 which have been reported by 
above studies to be of therapeutic benefit in different pathologies. It might well be that this 
central key element PlGF is the potential target modulated, and maybe involved in the 
underlying mechanisms of these therapies. Taken together, these results indicate the existence 
of an autocrine mechanism involved in the release of these growth factors. VEGFR-2 specific 
ligand VEGF-E (Ogawa, Oku et al. 1998, Meyer, Clauss et al. 1999), which stimulates EC 
mitogenesis and permeability with a synonymous potency to that of VEGF-A (Ogawa, Oku et 




al. 1998, Meyer, Clauss et al. 1999), inhibited the levels of PlGF secreted by ECs. This 
probably might have been due to the interference of the signalling pathways, such as MAPK 
and PI3K, involved in PlGF production, which also seems to be induced by VEGF-E. 
However, PlGF was shown to be superior than VEGF or VEGF-E in their contributions to 
collateral vessel formation (Pipp, Heil et al. 2003). This study also suggests that cooperation 
between the two receptors VEGFR-1 and VEGFR-2, either on cellular or signalling levels, 
does not seem to be required for their effects on inducing collateral growth in vivo (Pipp, Heil 
et al. 2003). Though VEGF-E is a viral homologue of VEGF family (Meyer, Clauss et al. 
1999), the system would enable us to establish the VEGF family receptor specific driven 
angiogenesis, and a further insight into the potency of PlGF mediated angiogenesis, 
specifically via VEGFR-1 and the modulation of this system in the presence of VEGF-R2.  
FGF-2 and EGF demonstrated a contrast effect on PlGF levels. FGF-2 induced the production 
of PlGF by ECs in a concentration-dependent manner. FGF-1 induced PlGF secretion with 20 
percent lower potency than FGF-2 [data not shown]. FGF-2 also induced PlGF levels in 
SMCs about three-folds greater than control. FGF-2-mediated angiogenesis is dependent on 
VEGFR-1 activity in cultured HUVEC (Kanda, Miyata et al. 2004), which indicates the 
probability that FGF-2 might induce PlGF in vivo as well in order to be functional. 
Independent studies reported the beneficial effect of FGF-2 and PlGF in promoting 
angiogenesis, wound healing, restoring cardiac function (Harada, Grossman et al. 1994, 
Horrigan, Malycky et al. 1999, Iwama, Uemura et al. 2006, Kardami, Detillieux et al. 2007) 
and have also been named as key cytokines promoting inflammatory angiogenesis 
(Kanazawa, Tsunoda et al. 2001, Perelman, Selvaraj et al. 2003, Selvaraj, Giri et al. 
2003(Perelman, 2003 #450, Zittermann and Issekutz 2006). We demonstrated that FGF-2 is a 
potent inducer of PlGF in ECs, and this may be the prime reason for the complementary 




beneficial effect of FGF-2/PlGF in the above studies. The correlation between the two growth 
factors has been studied in detail in subsequent results chapters. This includes the underlying 
signalling mechanism for FGF-2-mediated PlGF release is studied in detail in succeeding 
chapter. 
EGF, a known inducer of cancer and angiogenesis (Ongusaha, Kwak et al. 2004), decreased 
the levels of PlGF. However, this inhibition was not concentration-dependent.  
GM-CSF, IL-1β and TNF α had an opposite effect, inhibiting the levels of PlGF twofold. 
Angiogenic and anti-angiogenic factors represent the balance and function of vascular 
endothelium. Deviation from this equilibrium may lead to chronic inflammatory diseases, 
such as preeclampsia [PE] (Sharma, Satyam et al. 2007), rheumatoid arthritis (Folkman 
1995), psoriasis (Braverman and Sibley 1982) or Crohn‟s disease (Kanazawa, Tsunoda et al. 
2001). Hollborn et al study report on PlGF secretion by human epithelial retinal cells [RPE] 
had a contrast result (Hollborn, Tenckhoff et al. 2006), when compared to our study. VEGF, 
PDGF and pro-inflammatory cytokines such as TNF α, IL-1β had no effect on PlGF release 
from RPEs. However, FGF-2 seemed to have decreased the levels of PlGF by about 50%, 
which was not acknowledged in the study. This might have been due to the low levels of 
PlGF expressed in this specific epithelial cell type. The secreted concentration could not be 
determined as the results being expressed in percentage of control (Hollborn, Tenckhoff et al. 
2006). It clearly indicates the cell type specific PlGF levels and their varying effect in the 
presence of growth factor and cytokines on PlGF production. Inflammatory cytokines are 
peptide mediators of EC activation as well as dysfunction (Sharma, Satyam et al. 2007). TNF-
α  is a potent Th1-type pro-inflammatory cytokine and has been reported to cause direct 
damage to ECs, increase EC permeability, up-regulate endothelial adhesion molecules 
[ICAM-1, VCAM-1, E-Selectin] and promote vasoconstriction, in the pathologies (Hunt, 




Chen et al. 1996). These results hint the effect of Th1 type cytokines, such as TNFα, on PlGF 
levels, which has been the centre of the succeeding results chapter in this study. 
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Recent studies have stated PlGF to have superior angiogenic activity than VEGF or FGF-2 
induced angiogenesis, with transiently improved neovascularisation and overall less 
successful outcomes (Wu, Claus et al. 2016) (Table 1.3). FGF-2 is ubiquitous, and therefore, 
thought to have greater angiogenic efficacy and safety than other angiogenic factors, such as 
VEGF, PDGF (Cao, Brakenhielm et al. 2003) (Table 1.4). Relatively high levels of PlGF 
mRNA and protein (Figures 4.1 – 4.2) are produced by ECs, suggesting a potential autocrine 
role for PlGF in pathological angiogenesis. FGF-2 increased PlGF release in HUVEC and 
HMEC-1 (Figure 4.3). Elevated VEGF levels are positively correlated with cancer 
progression (Savaskan 2013). Orthotopic mouse model studies reported that PlGF 
overexpression inhibited tumour growth, angiogenesis and metastasis by depleting VEGF 
homodimers (Xu, Cochran et al. 2006). Together, these reports lay emphasis on the beneficial 
and safe aspects of PlGF and FGF-2 for potential therapy. 
 
Binding of FGF-2 to FGFRs activates cellular responses by triggering multiple downstream 
signalling events  (Klint and Claesson-Welsh 1999). FGF-2 administration prevents ischemia 
or reperfusion injury in animal models via activation of the protein kinase C (PKC) and 
mitogen-activated protein kinase (MAPK) signalling cascades (Padua, Sethi et al. 1995, 
Padua, Merle et al. 1998, House, Melhorn et al. 2007). These include activation of the Ras-
dependent signalling pathway via the recruitment of Src proteins, and subsequent induction of 
the Ras-Raf cascade and activation of the Ras-independent pathway, by PI3K and/or 
PKC/PLD (Ahmed, Plevin et al. 1994, Alavi, Hood et al. 2003, Langford, Hurford et al. 
2005).  
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PlGF was found to be the most abundant of the other VEGF family members expressed in 
human dermal microvascular cells, at 100-fold greater than VEGF, which was the least 
abundant (Yonekura, Sakurai et al. 1999).  Well characterised endothelial cell line HMEC-1 
(Ades, Candal et al. 1992) grow in the absence of serum, compared to the primary vascular 
ECs which require 20-30 % serum supplemented medium (Ades, Candal et al. 1992). We 
observed increasing endothelial PlGF levels in response to the increasing serum 
concentrations (data not shown). Several factors endorsed the use of HMEC-1 for signalling 
studies in this chapter.  
1. Confirmation of crucial findings with HUVEC for instance; Endothelial PlGF levels 
having similar response to FGF-2 in HUVEC as well as HMEC-1 (Figure 4.3).  
2. Further investigation and experimental details of FGF-2-induced PlGF followed 
transcriptional regulation in HMEC-1 similar to findings in the next result chapter 
(Figure 6.1 – 6.2). 
3. Robust nature of the HMEC-1 to grow in growth medium supplemented with low 
serum (0.5%). 
4. Cells being easily available and could be used at higher passage numbers.  
5. Several and recent studies used HMEC-1 for endothelial cell signalling as well as 
functional studies (Weinkopff and Lammie 2011, Asteriti, Daniele et al. 2012, 
Pontillo, Espanol et al. 2015). 
Hence HMEC-1 was the chosen endothelial cell line to study, in an efficient way, the 
signalling pathway(s) governing FGF-2-induced endothelial PlGF. Pharmacological 
inhibitors, adenoviral-mediated overexpression systems and gene-silencing siRNA technology 
were used to delineate the signalling pathway(s) governing the release of PlGF in ECs. This 
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study demonstrates that under basal conditions, endothelial PlGF release involves 
Ras/Raf/MEK, PKC and PI3K pathways, while FGF-2-mediated PlGF release specifically 
requires MEK and PKC activation. HMEC-1 was used to study the signalling mechanism in 
this Chapter, primarily due to their robust nature, easy availability and more importantly due 
to the confirmation of crucial findings in FGF-2-induced PlGF results in HMEC-1 confirmed 
in HUVEC. 
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5.2 Results  
5.2.1 FGF-2-mediated PlGF release is concentration-dependent 
To investigate whether FGF-2-induced PlGF release was concentration-dependent, HMEC-1 
cell lines were treated with increasing concentrations of FGF-2 for 24 hours. A concentration-
dependent increase in the levels of PlGF release in cell supernatants was observed in response 
to the increasing concentrations of FGF-2. PlGF secretion reached statistical significance after 
addition of 1, 10 or 50 ng/ml of FGF-2 compared to the untreated cells. Treating HMEC-1 
with 10 ng/ml FGF-2 caused a significant (two- to three-fold) increase in PlGF levels in 
HMEC-1 (Fig 5.1) and was therefore chosen concentration for subsequent experiments.  
 
Figure 5.1 FGF-2 up-regulates PlGF release in a concentration-dependent manner.  
HMEC-1 were cultured in serum-reduced RPMI medium containing 0.5% FCS and incubated 
overnight. ECs were stimulated with concentrations of FGF-2 for 24 hours. The conditioned 
media was collected and assayed for PlGF by ELISA. The data represent the mean (± SEM) 
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5.2.2  FGF-2 induces PlGF expression in ECs in a time-dependent manner  
To investigate the kinetics of FGF-2-induced up-regulation of PlGF protein, HMEC-1 cells 
were treated with FGF-2, and PlGF levels were measured at various time points. Differences 
in the levels of PlGF release between FGF-2 treated and control cells became apparent after 8 
hours, and was two-fold greater in FGF-2 stimulated cells at 16 hours, reaching a plateau at 
24 hours (Figure 5.2A). Optimal time for subsequent experiments was therefore selected as 24 
hours, unless specified. Real-time PCR analysis on RNA from HMEC-1 treated with FGF-2 
for various time periods revealed that an increase in PlGF mRNA expression preceded the rise 
in PlGF protein secretion (Figure 5.2B). FGF-2-induced a four-fold increase in PlGF mRNA 
levels at 8 hours compared to its control, and returned to baseline levels by 24 hours. Cells 
were incubated overnight in low serum medium, followed by fresh medium with or without 
FGF-2 before collecting RNA samples at different time points for real-time PCR. This could 
explain the sudden increase in the mRNA levels at 8 hours. However, it is noteworthy that 
PlGF protein stimulation by FGF-2 is significant at 16 hours. Therefore, it appeared that FGF-
2 may regulate PlGF expression at a transcriptional level. The average doubling time for both 
HUVEC and HMEC-1 is between 24-30 hours. For subsequent experiments 24 hours‟ time 
point is chosen unless otherwise specified. 
Collectively, these results show that FGF-2-induced PlGF release is concentration-dependent 
through transcriptional activation of PlGF gene and de novo protein synthesis. Confirming 
these facts facilitated in proceeding to study in detail the signalling molecules involved in 
FGF-2-mediated PlGF release in ECs.  
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Figure 5.2 Kinetics of FGF-2-induced release of PlGF in cultured HMEC-1. [A] Time-
dependent PlGF protein release from HMEC-1 in response to FGF-2 [10 ng/ml] stimulation. 
Cell supernatants from conditioned medium were collected at indicated time points and PlGF 
levels measured by ELISA. [B] FGF-2-induced PlGF mRNA expression in a time-dependent 
manner. HMEC-1 were stimulated with FGF-2 (10 ng/ml) and mRNA subjected to 
quantitative real-time PCR for PlGF. PlGF mRNA values are normalized to β-actin gene 
expression and presented as mean (± SEM). Data are mean [±SEM] of at least three separate 
experiments performed in duplicate.  * p<0.05 vs Untreated.  
UNTREATED
FGF-2







U N T R E A T E D
F G F -2















































        Chapter 5 – PlGF Regulation by FGF-2 and Signalling systems mediating FGF-2-   




5.2.3 Role of PKC in FGF-2-induced PlGF release from ECs  
PKC is known to be involved in mediating FGF-2-induced EC function (Kent, Mii et al. 
1995). We therefore investigated the possibility that FGF-2-induced PlGF production was 
regulated by PKC. We used the pharmacological PKC inhibitors Ro32-0432 and GO6976 to 
determine the role of PKC in FGF-2-mediated PlGF release. FGF-2 induced PlGF protein 
release was completely blocked to the basal level when HMEC-1 were treated with Ro32-
0432 [Figure 5.3A] and GO6976 [Figure 5.3B] for 24 hours. A similar effect was elicited by 
these PKC inhibitors on PMA,  an activator of PKC (Furstenberger, Berry et al. 1981), that 
induced PlGF protein levels in ECs (Appendix II – PMA concentration graph). These data 
indicate the key role of PKC in PlGF production in ECs.  
5.2.3.1  Role of PKC isoforms in PlGF expression in ECs 
The PKC family consists of several distinct isozymes, each of which have specific structural 
and biochemical properties and regulatory mechanisms (Dekker and Parker 1994). Cultured 
ECs (HUVEC) express PKC isozymes α, β, δ, ε, ζ and δ (Haller, Ziegler et al. 1996). PKC is a 
central regulator of angiogenesis (Tsopanoglou, Pipili-Synetos et al. 1993).  We investigated 
the role of PKC in endothelial PlGF release by stimulating HMEC-1 with PKC activators. 
Thymeleatoxin [Thx], which is a selective activator of classical PKC isoforms [cPKC; α, β, 
and γ] (Ryves, Evans et al. 1991), Ingenol 3, 20-dibenzoate [IDB], which is a specific 
activator of novel PKC isoforms [nPKC; δ, ε, ε, and ζ], (Asada, Zhao et al. 1998) and á-APP 
modulator [á-APP] which is a selective activator of PKCα (Kozikowski, Nowak et al. 2003) 
were used for these studies. After 24-hours incubation in serum deprived conditions, PlGF 
levels were measured by ELISA in cell-conditioned medium. PKC activators, Thx and IDB 
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increased PlGF release by two- to three-fold (Figure 5.1C) compared to control. The á-APP 
modulator [á-APP] had the least effect on PlGF release.     
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Figure 5.3  PKC is involved in FGF-2 mediated PlGF release in HMEC-1. HMEC-1 were 
cultured in serum-reduced medium overnight and  incubated with PKC inhibitors (A) 
Ro320432 (1 µM), (B) GO6976 (1 µM), 45 minutes prior to addition of stimulants FGF-2 (10 
ng/ml) or PMA (100 nM). Cell supernatants were analysed for PlGF by ELISA.(C) PKC 
activators Ingenol 3, 20-dibenzoate (IDB) (1 µM), Thymeleatoxin (Thx; 10 µM) and α-APP 
(10µM)  induce PlGF release in ECs. HMEC-1 were treated with PKC activators; for 24 
hours and PlGF measured in cell supernatants. (D) Schematic illustration of PKC inhibition 
on FGF-2 signal transduction. Data are expressed as percentage release of PlGF 
measurements of 4 independent experiments performed in duplicate. *P<0.05 compared to 
the control. 
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5.2.3 PKC isoforms involved in FGF-2-mediated PlGF release 
To identify the PKC isoform[s] involved in FGF-2 stimulated PlGF release, HMEC-1 were 
infected with adenoviruses over-expressing dominant-negative PKC isoforms prior to 
stimulation with FGF-2 or PMA. Over-expression of dominant-negative isoforms α, δ and ε 
significantly decreased PlGF levels in the presence of FGF-2 or PMA (Figure 5.4). The 
decrease in PlGF levels was significantly greater for dominant-negative PKCα treated 
samples compared with dominant-negative PKCδ or PKCε treated samples.  
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Figure 5.4 PKC isoforms involved in FGF-2 mediated PlGF release. HMEC-1 were infected 
with expressing adenoviruses β -galactosidase [β-Gal] or recombinant adenoviruses 
encoding dominant-negative PKC isozymes of [A] PKC α,  [B] PKCδ or [C] PKCε for 24 
hours prior to incubation with 10 ng/ml FGF-2 or 100 mM PMA in basal medium containing 
0.5% FBS. PlGF was measured in cell supernatants by ELISA.(D)Pictorial depiction of PKC 
inhibitors effecting FGF-2 signal transduction. Results are the means [±SEM bars] of at least 
3 separate experiments [n=6] performed in duplicate. *P<0.05 compared to the control.  
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Figure 5.5 PKC isoforms involved in FGF-2 mediated PlGF release. PKC inhibitors 
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5.2.4 FGF-2- stimulated PlGF secretion from ECs requires PLD activity. 
Activation of PLCγ or PLD leads to the production of secondary messengers which 
phosphorylate PKC (Nishizuka 1995, Kook and Exton 2005). FGF-2 stimulates PLD 
signalling via PKC activation in ECs, independent of PLCγ (Ahmed, Plevin et al. 1994). We 
therefore investigated the role of these signalling molecules in FGF-2-mediated PlGF release 
from ECs. HMEC-1 were treated with U71322, a phosphatidylinositol-specific PLCγ (PI-
PLCγ) inhibitor or the PLD inhibitor, 1-Butanol or its isomer control, 2-Butanol, in the 
presence of FGF-2. PlGF levels in the control and FGF-2 treated samples appear to be 
secreted differentially following PI-PLCγ inhibition, compared to the treatment with 1-
butanol. PI-PLCγ inhibitor partially suppressed FGF-2-dependent PlGF protein levels (Figure 
5.6A), in contrast to the PlGF protein levels in the absence of FGF-2. However, this 
suppression in protein concentration was very small, suggesting that PI-PLCγ is not involved 
in FGF-2-mediated PlGF release from ECs. Basal and FGF-2-induced PlGF levels were 
radically reduced when PLD was blocked using 1-Butanol (0.4 % v/v) (Figure 5.6B), whereas 
treatment with 2-Butanol did not affect PlGF release. These data clearly demonstrate the loss 
of basal production of PlGF as well as FGF-2 stimulated PlGF secretion following inhibition 
of PLD, in contrast to the small reduction in FGF-induced production following to PLCγ 
inhibition.                      
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Figure 5.6 Role of PLD in PlGF release from ECs. HMEC-1 were cultured in serum-
reduced medium overnight and incubated with PI-PLCγ inhibitor (A) U71322 (0.1µM) or (B) 
1-butanol (0.04% v/v) or its isomer control, 2-butanol (0.04% v/v), for 45 minutes prior to 
addition of FGF-2 (10 ng/ml). Cell supernatants collected following 24 hour incubation and 
analysed for PlGF by ELISA. Data are expressed as means ± SEM of measurements of 3 
independent experiments performed in duplicate. *p<0.01 vs. control. 
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5.2.5 FGF-2 stimulates the release of PlGF via the Ras-Raf-MEK Pathway 
PKC isoforms activate Raf-1 (Cai, Smola et al. 1997, Schonwasser, Marais et al. 1998) and 
FGF-2 is reported to stimulate ERK1/2 MAPK phosphorylation in ECs (Yang, Wang et al. 
2008). We assessed the involvement of the Ras-Raf-MEK pathway (Figure 5.4A) on PlGF 
expression by examining ERK1/2, a down-stream effector of MEK1/2 (Bikfalvi, Klein et al. 
1997). Both MEK1/2 and ERK1/2 belong to the MAPK pathway that govern the processes of 
proliferation, differentiation and cell survival (Kolch 2000). Moreover, p38 MAPK negatively 
regulates endothelial cell differentiation in FGF-2 mediated angiogenesis (Tanaka, Abe et al. 
1999, Matsumoto, Turesson et al. 2002). We used the MEK inhibitor, PD98059 to examine 
the involvement of MAP kinase in FGF-2-induced PlGF release, as this inhibitor efficiently 
suppresses the activation of p42/p44 MAPKs. Inhibition of MEK attenuated FGF-2-mediated 
PlGF release by ECs to basal levels [Figure 5.8A]. PMA, an activator of ERK1/2 signalling 
pathway (Verin, Liu et al. 2000), also significantly decreased PlGF levels in the presence of 
the MEK inhibitor PD98059.  Blockade of p38 MAPK using SB203580 had no effect on 
FGF-2-mediated PlGF release (Figure 5.8B). These results indicate that MEK plays a 
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Figure 5.8  Role of Ras/MAPK signalling in FGF-2-induced PlGF release. HMEC-1 were 
cultured in serum-reduced medium overnight and pre-incubated for 45 minutes with 
pharmacological inhibitors (A) PD98059 (20 µM) or (B) SB203580 (20 µM) prior to the 
treatments with FGF-2 (10 ng/ml) or PMA (100 nM). Cell supernatants collected following 
24 hour incubation and were analysed for PlGF by ELISA. Data are expressed as means ± 
SEM of measurements of 3 or 4 independent experiments performed in duplicates. *p<0.01 vs 
control.  
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Figure 5.9 Diagrammatic representation of Ras-Raf-MAPK signalling pathway. Effect of 
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Ras is a highly conserved protein which serves as a convergence point for multiple signalling 
pathways. Ras is up-stream of the MAPK linear cascade and is involved in the 
phosphorylation of ERK (White, Nicolette et al. 1995, White, Vale et al. 1996). Ras has been 
reported to be involved in FGF-2-induced endothelial cell differentiation (Klint, Kanda et al. 
1999). To study the role of Ras in FGF-2-mediated PlGF release, cells were infected with an 
adenovirus expressing a dominant-negative mutant of Ras [AdRas
DN
], PlGF levels were 
measured in the cell supernatants. Over-expression of Ras
DN
 
in HMEC-1 inhibited PlGF 
release by 80% in both FGF-2 stimulated and untreated cells, indicating that Ras plays a 
pivotal role in endothelial cell PlGF release (Figure 5.10A). Furthermore, dominant-negative 
over expression of Ras
DN
 abrogated ERK1/2 phosphorylation in both the untreated and FGF-
2-treated protein samples (Figure 5.10B). This confirms that Ras activity is required for PlGF 
release via the downstream activation of ERK1/2. However, partial inhibition of ERK1/2 
activation subsequent to Ras blockade in the presence of the PKC activator PMA was 
observed. This indicates the involvement of PKC signalling pathway independent of ERK1/2 
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Figure 5.10 Ras involved in FGF-mediated PlGF release. (A) HMEC-1 were infected with 
adenovirus encoding dominant-negative Ras (AdRasDN) or β -galactosidase (β-Gal) control 
for 24 hours. Cells were treated with FGF-2 (10 ng/ml) or PMA (100nM) for 24 hours in 
basal medium containing 0.5% FBS. PlGF was measured in cell supernatants by ELISA. (B) 
Representative Western blot showing the effect of RasDN on ERK1/2 phosphorylation 
following FGF-2 or PMA stimulation. HMEC-1 infected with adenovirus encoding dominant-
negative Ras (AdRasDN) or β -galactosidase (β-Gal) control for 24 hours were stimulated 
with FGF-2 or PMA for 15 minutes.  25µg of cell protein per  sample was separated  by 10% 
SDS-PAGE. Activation of ERK1/2 was determined by Western-blot analysis using antibodies 
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that recognized phosphorylated ERK1/2 (pERK or p42/44). C – Control, F – FGF-2 (10 
ng/ml), P– PMA (100 nM). Data are expressed as means ± SEM of measurements of 3 or 4 
independent experiments performed in duplicates.  ** P<0.01 vs control. 
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5.2.6 Src Kinase activity is critical for PlGF release from ECs 
The preceding results confirmed that Ras-Raf-MAPK and PKC were critical for FGF-2-
mediated PlGF release from ECs. Src kinase has previously been reported to be involved in 
FGF-2/FGFR signalling (Klint, Kanda et al. 1999). Cells were treated with PP2, a potent 
inhibitor of the Src family of tyrosine kinases (Hanke, Gardner et al. 1996). Inhibition of Src 
kinase activity abrogated FGF-2-induced PlGF release in a concentration-dependent manner 
(Figure 5.11A). To elucidate the potential involvement of Src kinase on downstream 
signalling events, we assessed Raf and ERK1/2 phosphorylation in cells that were pre-treated 
with PP2 prior to stimulation with FGF-2 or PMA.  Western blotting of extracted proteins 
showed strong phosphorylation of Raf in FGF-2 treated samples compared with controls 
(Figure 5.11B). Conversely, Src kinase blockade abrogated Raf phosphorylation in both 
control and FGF-2 treated samples. However, Src inhibition had no effect on Raf activation in 
the presence of PMA, suggesting that PKC-mediated Raf activation is independent of Src 
kinase activity. These results indicate that Src kinase is important for activation of Raf-MAPK 
following FGF stimulated release of endothelial PlGF.  
Src inhibition in the presence of FGF-2 suppressed ERK1/2 phosphorylation. This indicates 
that multiple signalling cascades, including those regulated by MAPK and PKC, work in 
parallel to facilitate FGF-2-mediated PlGF release from ECs. 
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Figure 5.11 Src kinase involved in PlGF release from ECs. (A) HMEC-1 were cultured in 
serum-reduced medium overnight and pre-incubated for 45 minutes with the pharmacological 
Src inhibitor PP2 (0.1 -10 µM), prior to the treatments with FGF-2 (10 ng/ml) or PMA (100 
nM). Cell supernatants collected following 24 hour incubation and were analysed for PlGF 
by ELISA. Data are expressed as means ± SEM of measurements of 4 independent 
experiments performed in duplicates. (B) Representative Western blot showing the effect of 
Src kinase inhibitor, PP2 on ERK1/2 and Raf phosphorylation, following FGF-2 or PMA 
stimulation. HMEC-1 were pre-incubated with PP2 (10 µM) for 30 minutes followed by 
stimulation with FGF-2 or PMA for 15 minutes.  25µg of cell protein per treated sample was 
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run on a 10% SDS-PAGE. Activation of ERK1/2 was determined by Western-blot analysis 
using antibodies that recognized phosphorylated ERK1/2 (pERK or p42/44) or Raf (pRaf). 
The blots were re-probed with β-actin to demonstrate equal loading. C – Control, F – FGF-2 
(10 ng/ml), P– PMA (100 nM). *P<0.05 compared to the control. 
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5.2.7 PKC and MAPK dependent pathways governing FGF-2 regulation 
In order to confirm that PKC and MAPK regulate FGF-2-mediated PlGF release, we assessed 
whether PKC activation preceded MAPK phosphorylation. Raf and ERK1/2 activation were 
examined in the presence of diacylglycerol (DAG) kinase, which catalyses the 
phosphorylation of DAG. DAG is the physiological activator of PKC to phosphatidic acid 
(Houssa, de Widt et al. 1999) . Raf-1 activation was partially down-regulated under basal 
conditions, and in the presence of FGF-2 or PMA, suggesting possible cross-talk between the 
PKC and MAPK pathways (Figure 5.13). However, ERK1/2 phosphorylation was not 
affected by blocking DAG kinase, indicating PKC and MAPK are two independent pathways 
perhaps diverging from Raf-1 [Figure 5.7A]. To clarify the relationship between PKC and 




, either individually or in 
combination, and treated the cells with FGF-2 or PMA.  Cell lysates were subjected to 
Western blotting and probed for phosphorylated ERK1/2. PKCα 
DN 
alone did not affect 
ERK1/2 activation in the presence of FGF-2 (Figure 5.13). However, PMA induced ERK1/2 




 completely inhibited ERK1/2. 
Conversely, PKCα 
DN 
enhanced basal activation of ERK1/2, suggesting under unstimulated 
conditions there might be negative regulation of ERK by PKCα.  
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Figure 5.13 Representative Western blots showing the effect of DAG kinase inhibitor on 
ERK1/2 and Raf phosphorylation, following FGF-2 or PMA stimulation. (A) HMEC-1 were 
pre-incubated with DAG kinase II (10 µM) for 30 minutes followed by stimulation with FGF-
2 or PMA for 15 minutes.  25µg of cell protein per treated sample was separated by 10% 
SDS-PAGE. Activation of ERK1/2 was determined by Western-blot analysis using antibodies 
that recognized phosphorylated ERK1/2 (pERK or p42/44) or Raf (pRaf). The blots were re-
probed with β-actin to demonstrate equal loading. C – Control, F – FGF-2 (10 ng/ml), P– 
PMA (100 nM). (B) HMEC-1 were infected with adenovirus expressing β-gal or PKCαDN or 
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minutes.  25µg of cell protein per treated sample was run on a 10% SDS-PAGE. Activation of 
ERK1/2 was determined by Western-blot analysis using antibodies that recognized 
phosphorylated ERK1/2 (pERK or p42/44) or total ERK1/2. The blots were re-probed with 
ERK1/2 to demonstrate equal loading. C – Control, F – FGF-2 (10 ng/ml), P– PMA (100 
nM).  
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5.2.8 PlGF Release from ECs is regulated by PI3K  
We determined whether PI3K contributed to FGF-2-induced PlGF release by modulating 
PI3K activity with the pharmacological inhibitor, LY294002 (Davies, Reddy et al. 2000). 
LY294002 (Figure 5.14A) markedly decreased PlGF levels in both the untreated and FGF-2 
stimulated cells in a concentration-dependent manner. These data indicate that PI3K is 
required for both basal and FGF-2 mediated PlGF release.  The effect of PI3K blockade on 
MAPK signalling was investigated in cells treated with LY294002 in the presence of FGF-2.  
Cell lysates were subjected to Western blot analysis and monitored for the phosphorylated 
forms of ERK1/2 and Raf-1 (Figure 5.14B). PI3K inhibition did not affect ERK1/2 activation 
[Figure 5.14B], indicating that PI3K and MAPK independently regulate FGF-2-mediated 
PlGF release from ECs (Ferby, Waga et al. 1996, Scheid and Duronio 1996). However, PI3K 
inhibition partially abrogated Raf-1 phosphorylation in the presence of FGF-2. This suggests 
that Raf-1 phosphorylation is regulated by PI3K in ECs    
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Figure 5.14 Ras and PI3 kinase activity are required for PlGF secretion from ECs. HMEC-
1 were cultured in serum-reduced medium overnight and pre-incubated for 45 minutes with 
pharmacological inhibitor of PI3 kinase LY294002 at indicated concentrations prior to the 
treatments with FGF-2 (10 ng/ml). Cell supernatants collected following 24 hour incubation 
and were analysed for PlGF by (A) ELISA. Data are expressed as means ± SEM of 
measurements of 4 independent experiments performed in duplicates. (B)  A representative 
Western blot shows the effect of LY294002 on ERK1/2 and Raf phosphorylation following 
FGF-2 or PMA stimulation. HMEC-1 were pre-incubated with LY294002 (10 µM) for 30 
minutes followed by stimulation with FGF-2 or PMA for 15 minutes.  25µg of cell protein per 
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Western-blot analysis using antibodies that recognized phosphorylated ERK1/2 (pERK or 
p42/44) or Raf (pRaf). The same blots were re-probed with β-actin to demonstrate equal 
loading. C – Control, F – FGF-2 (10 ng/ml), P – PMA (100 nM). *P<0.05, compared to the 
control.  
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Figure 5.15 Multiple Signalling pathways FGF-2-mediated PlGF. Diagrammatic 
representation of signaling pathways that may be involved in FGF-2-mediated PlGF release 
from ECs. As indicated by the diagram and as described by the data, PKC and MAPK 
pathways are central for the FGF-2-induced PlGF release. It is possible that the crosstalk 
between the PI3K and ERK pathways is mediated in part by PKC (Ahmed, Plevin et al. 1994). 
PKC signaling also is reported to occur directly with PI3K and upstream of Ras. 
Furthermore, direct interaction between MEK and PKC downstream of Ras is reported. 
Likewise, ERK2 (p42) is reported to signal to Raf-1 via a positive feedback mechanism (Cai, 
Smola et al. 1997).  
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Numerous lines of experimental evidence implicated that a number of cytokines and growth 
factors modulate angiogenesis in vitro and in vivo via an autocrine and/or paracrine mode of 
action. VEGF (Ferrara and Davis-Smyth 1997), FGF-2 (Basilico and Moscatelli 1992, 
Bikfalvi, Klein et al. 1997, Paleolog 2002) and more recently PlGF (Carmeliet, Moons et al. 
2001) have been reported as potent angiogenesis inducers in physiological and/or pathological 
angiogenesis. Both VEGF and FGF-2 have a synergistic effect on angiogenesis (Asahara, 
Bauters et al. 1995, Kano, Morishita et al. 2005). Likewise, PlGF and VEGF have been 
demonstrated to play a synergistic role in pathological angiogenesis (Carmeliet, Moons et al. 
2001). In the following chapters I have shown that FGF- 2-stimulated up-regulation of PlGF 
in ECs is, in part, responsible for its angiogenic activity.  
 
FGF-2 induced a significant increase in PlGF mRNA levels compared to the control. PlGF 
protein levels, in response to FGF-2, followed a time and concentration-dependent 
mechanism. PlGF production in response to FGF-2 is via transcriptional activation of PlGF 
gene and de novo protein synthesis. In summary, up-regulation of PlGF protein was preceded 
by an increase of PlGF mRNA in a time-dependent manner in ECs when stimulated with 
FGF-2, unlike VEGF-induced PlGF release from ECs (Yao, Yang et al. 2005). 
 
In this study, further evidence of the intracellular signalling pathways governing FGF-2-
mediated PlGF release from ECs is detailed.  PlGF release in response to FGF-2 occurs 
primarily via the activation of MAP kinase and PKC. A significant body of pre-clinical 
evidence and patient data demonstrated proof of the concept that both FGF-2 and PlGF have 
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valuable and the significant roles during tissue healing, in ischemic injury (Harada, Grossman 
et al. 1994, Horrigan, Malycky et al. 1999, Iwama, Uemura et al. 2006, Callaghan, Chang et 
al. 2008), for improving cardiac function, promoting survival post MI (Kardami, Detillieux et 
al. 2007, Liao, Porter et al. 2007, Roncal, Buysschaert et al. 2008) and in their efficacy to 
advance therapeutic angiogenesis (Harada, Grossman et al. 1994, Unger, Banai et al. 1994, 
Luttun, Tjwa et al. 2002, Pipp, Heil et al. 2003, Kolakowski, Berry et al. 2006). 
FGF-2 strongly increased the phosphorylation of ERK1/2 and the MAPK inhibitor PD98059, 
which abrogated PlGF secretion induced by FGF-2 from ECs. In a similar manner, ERK1/2 
inhibition significantly decreased PMA-induced PlGF levels as well.  MEK1 and ERK1/2 
were required for FGF-2-mediated protection of ECs from the intrinsic (stress) pathway of 
apoptosis (Alavi, Hood et al. 2003).  MAPK activation by FGF-2 promoted cell proliferation 
and migration during cell development, and, like VEGF, inhibits endothelial cell apoptosis 
(Risau 1997)  
p38 has been reported to negatively regulate the endothelial cell response in FGF-2-stimulated 
angiogenesis (Matsumoto, Turesson et al. 2002), accompanied by prolonged ERK1/2 MAPK 
activation and increased endothelial cell survival (North, Moenner et al. 2005). Moreover, it 
has been suggested that a direct interaction exists between phosphorylated p38 and ERK1/2, 
resulting in ERK1/2 deactivation (Zhang, Shi et al. 2001). Here we show, using the p38 
inhibitor, SB203580, that p38 signalling is not involved in the release of PlGF protein from 
ECs. Activation of ERK1/2 and inhibition of p38 by FGF-2 is cardioprotective during 
ischemia-reperfusion injury in an isolated work-performing heart model of global low-flow 
ischemic mice (Dhalla 2010). Over expression of FGF-2 resulted in ERK1/2 activation, 
leading to protection from post-ischemic contractile dysfunction and MI (Dhalla 2010). 
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Additionally, FGF-2 also inhibits p38 activation during ischemia and reperfusion, leading to 
decreased cell death after ischemia-reperfusion injury (Dhalla 2010). These results indicate 
that activation of the MEK-ERK signalling pathway is necessary to mediate FGF-2-induced 
cardio-protection from both post-ischemic contractile dysfunction and myocardial infarction 
(Dhalla 2010). In addition to up-regulating VEGF expression, FGF-2 also amplified VEGFR-
2, a selective receptor for ECs in vivo (de Vries, Escobedo et al. 1992), via a PKC and 
ERK1/2 MAPK-dependent mechanism in bovine retinal capillary ECs (BREC) (Hata, 1999 
#613).   
Pharmacological down-modulation of PKC activity dramatically inhibited the FGF2-induced 
increase in PlGF secretion to basal levels. Similarly, PMA (PKC agonist) showed a 
significant decrease in the levels of PlGF in the presence of PKC inhibitors.  Selective down-
regulation of PKC α, δ and ε, by using validated PKC dominant-negative (PKC-DN) 
constructs over-expressed in adenoviruses, established the roles of PKCα, δ and ε in FGF-2-
induced PlGF release from ECs. á-APP modulator [á-APP], the specific activator, induced 
only marginal increase in PlGF when compared to the other PKC activators. In this respect, it 
must be observed that unlike FGF-2, VEGF-induced PlGF release from ECs was reported to 
be via a post-transcriptional mechanism involving the activation of PKCβ (Yao, Yang et al. 
2005).  
 
Pathophysiological studies in diabetic rats implicated PKCβ and PKCδ in hyperglycaemia-
induced vascular dysfunction (Inoguchi, Battan et al. 1992) and PKCε in muscle insulin 
resistance (WHO 2013). PKCα and PKCβ have been implicated in cardiac hypertrophy 
(Wakasaki, Koya et al. 1997).  In our study we found that PKCε isoform is involved in FGF-
2-induced PlGF release. Thus a greater understanding of the functional diversity and 
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pathophysiological regulation of PKC isoforms mediating growth factor-induced regulation, 
especially pertaining to vascular complications, is likely to have important clinical and 
therapeutic benefits (Xu, He et al. 2005). This data so far gives supportive evidence that PKC 
might be involved in the increased production of PlGF in disorders pertaining to pathological 
angiogenesis.  
An earlier study had reported that FGF-2-induced ERK1/2 phosphorylation is mediated by 
PKCε, which in turn enhanced anti-apoptotic proteins Bcl-XL and XIAP, thereby promoting 
survival/chemo resistance of lung cancer cells (Pober and Sessa 2007). Mounting evidence in 
animal models corroborated the PKCε isoform as a central signalling hub, mediating early 
and late pre-conditioning responses and cardioprotection during reperfusion (Ping, Zhang et 
al. 1997, Qiu, Ping et al. 1998, Ping, Zhang et al. 1999).  PKC ε was found to have a 
protective effect in myocardial preconditioning (Dorn, Souroujon et al. 1999).  PKC‟s role in 
the activation of the MAP kinase cascade involves complex interaction mechanisms due to the 
specificities of the various PKC isoforms involved. However, constitutively active isoforms 
PKC α, δ and ε have been reported to activate MEK/MAPK via Raf (Cai, Smola et al. 1997, 
Schonwasser, Marais et al. 1998). The involvement of Ras (Leevers and Marshall 1992, 
Thomas, DeMarco et al. 1992, Mitra, Weber et al. 1993) and c-Raf (Schaap, van der Wal et 
al. 1993, Schaafhausen, Yang et al. 2013) in the PMA-induced activation of MAP kinases has 
been reported with rather paradoxical results. Using a series of PKC knock-out mutants and 
mutants with constitutive kinase activity, Ueda et al showed that PKC δ is actually involved 
in the signalling pathway from PMA to Raf-MEK-ERK activation that operates in a Ras-
independent manner (Ueda, Hirai et al. 1996). FGF-2 administration prevents 
ischemia/reperfusion injury in animal models via activation of the protein kinase C (PKC) and 
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mitogen-activated protein kinase (MAPK) signalling cascades (Padua, Sethi et al. 1995, 
Padua, Merle et al. 1998, House, Melhorn et al. 2007).  
PKC activation by FGF-2/FGFR via phosphatidylinositol-phospholipase C (PI-PLCγ) has 
been reported in Chinese hamster ovary cells (Lundin, Ronnstrand et al. 2003).   FGF-2 
stimulates PLD signalling via PKC activation in ECs, independent of PLCγ (Ahmed, Plevin et 
al. 1994). However, in our study, blockade of PI-PLCγ enzyme by U73122 had only a modest 
effect on PlGF release induced by FGF-2. In contrast, PlGF secretion induced by FGF-2 was 
completely suppressed by PLD inhibition. These data are in line with previous reports 
(Ahmed, Plevin et al. 1994). Ahmed et al demonstrated in HUVEC that activation of PLD is 
dependent on prior activation of PKC (Ahmed, Plevin et al. 1994) indicating PKC to be 
upstream of PLD (Ahmed, Plevin et al. 1994). PLCγ or PLD activation leads to the 
production of second messengers that stimulate PKC (Nishizuka 1995, Kook and Exton 
2005). 
Blockade of DAG, a secondary messenger and activator of PKC (Al-Lamki, Wang et al. 
2005) using DAG Kinase inhibitor, did not lead to alterations in ERK1/2 activity. Yet 
inhibition of PKC eliminated FGF-2-induced ERK1/2 MAPK phosphorylation in BRECs 
(Forsten-Williams, Chua et al. 2005). Moreover, in the same study that the MEK inhibitor, 
PD98059, completely inhibited MAPK phosphorylation, FGF-2-induced VEGFR-2 
expression was only reduced by 70%, suggesting that although the majority of FGF-2-induced 
VEGFR-2 expression is via MAPK, other signalling pathways are also involved (Forsten-
Williams, Chua et al. 2005).  
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In this study, FGF-2-mediated PlGF release from ECs is via PKC and MAPK pathways 
independently. These pathways are indispensable for FGF-2-mediated PlGF release, most 
probably with Ras as the point of convergence for these two predominant pathways. 
This study demonstrates that PlGF release under basal conditions and in response to FGF-2 
from ECs involves multiple signalling cascades. PlGF release from ECs under basal 
conditions involved Ras/Raf/MEK, PKC and PI3K pathways, whereas FGF-2-mediated PlGF 
release was MEK and PKC specific. Statins reduced the expression of angiogenic growth 
factors FGF-2, HGF and TGF-β in mouse osteosarcoma by blocking Ras/MEK/ERK and 
Ras/PI3K/Akt pathways (Tsubaki, Yamazoe et al. 2011). Intracellular magnesium [Mg
+
]i 
concentration was increased in response to FGF-2 via tyrosine kinase/PI3K/PLCγ signalling 
pathways in HUVEC (Hong, Park et al. 2009). Low magnesium promotes endothelial 
dysfunction as a common pathogenic event associated in cardiovascular diseases, including 
hypertension, atherosclerosis, inflammation and thrombosis (Cines, Pollak et al. 1998, Maier, 
Malpuech-Brugere et al. 2004). It would therefore be interesting to study FGF-2 and PlGF 
levels in pathologies with low Mg
+
 that lead to endothelial dysfunction. 
Further work investigating the inter-dependency of the signalling pathways and the 
transcriptional factors regulating FGF-2-mediated PlGF release from ECs is warranted. There 
are moderately few of the anti-angiogenic agents for the treatment of not only CVD, but 
human cancers too, and many more of them are at various phases of clinical trials for 
therapeutic purposes. Resistance to apoptosis is a hallmark of carcinogenesis, and the 
initiation of apoptosis has been a vital focal point in the advancement of preventive drugs. 
Statins can induce apoptosis by regulating several signalling pathways, including the raf- 
MAPK1-ERK pathways (Carmeliet and Storkebaum 2002).  The pleiotropic effects of statins 
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are related to their interactions with diverse signalling pathways and targets; for instance, 
pravastatin suppressed cell proliferation of HUVECs through inhibition of cell cycle 
(Asakage, Tsuno et al. 2004) and cerivastatin is indicated to have inhibited endothelial cell 
migration (Vincent, Chen et al. 2001). Further dissection of the signalling pathways that play 
a vital role in improved cardiac outcome, such as PKC and MAPK in ECs in response to 
various endogenous growth factors and cytokines triggered by injury/ischemia, could further 
our understanding of the beneficial effect of statins on atherosclerosis and on cancer 
prevention as shown by clinical studies (Ivan, Kondo et al. 2001). However, most of these 
anti/angiogenic agents target the VEGF signalling pathway (Folkman 2007). There is 
experimental confirmation which indicates that the tumour vasculature could acquire drug 
resistance towards VEGF therapy by shifting to other growth factor-induced angiogenic 
signals (Hicklin and Ellis 2005). For example, anti-VEGF agents may perhaps lead to drug 
resistance in the RIP-Tag spontaneous mouse pancreatic islet tumour model by switching to 
FGF-2 and other factors-induced angiogenesis (Gullestad and Aukrust 2005). Thus, it is 
important to consider a combination therapy by blocking common enzymes in multiple 
signalling pathways triggered by a range of angiogenic factors. 
 
These results indicate the differential regulation of effector molecules in FGF-2-induced PlGF 
release from ECs in contrast to VEGF-stimulated PlGF (Yao, Yang et al. 2005). This would 
enable advancements in identifying novel therapeutic strategies to either promote 
revascularization of ischemic tissues, or to inhibit angiogenesis in cancer and inflammatory 
disorders. 
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Chapter 6 FGF-2-induced PlGF production in ECs: 
FGF-2-mediated angiogenesis is PlGF dependent 
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Despite considerable progress in the management of vascular insufficient ischemic diseases, 
such as CVD, PVD, MI and heart failure, a significant proportion of patients have symptoms 
refractory to medical treatment. Advanced disease with/without the existence of various co-
morbidities (Review) (Deveza, Choi et al. 2012) make these individuals unsuitable for 
conventional revascularisation techniques or surgical interventions, such as percutaneous 
coronary intervention (PCI), coronary artery bypass surgery (CABG) (Deveza, Choi et al. 
2012)  or percutaneous revascularisation (Di Stefano, Limbruno et al. 2004) to re-establish 
blood flow to the heart, brain or limbs (Review) (Deveza, Choi et al. 2012). Ischemic 
neovascularisation in the adult is a summation of three processes: vasculogenesis, 
angiogenesis and arteriogenesis (Lekas, Lekas et al. 2006, Silvestre, Mallat et al. 2008), with 
the aim of promoting tissue repair and remodelling of the blood vessels to address acute and 
chronic ischemic insults. Capillary network growth (angiogenesis) and/or collateral artery 
growth (arteriogenesis) form the key factors in the adaptive process of preserving tissue 
survival and organ function, saving limbs and lives following arterial occlusion in the 
vascular provinces of the body.  These processes represent the final targets of therapeutic 
neovascularisation aimed at providing an alternative treatment strategy. Driven by clinical 
demands, concerted efforts are being applied to investigate two distinct categories of vessel 
growth to reduce ischemia; angiogenesis and arteriogenesis (Heil, Eitenmuller et al. 2006) 
have augmented in recent years opening new lease on life for patients with ischemic disease 
(Reviews) (Di Stefano, Limbruno et al. 2004, Deveza, Choi et al. 2012).   
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Treatment modalities aiming to restore the impaired blood supply can either be a 
macrovascular repair (arteriogenesis; in the case of critical arterial stenosis or occlusion) or 
microvascular repair via angiogenesis, such as the event of an ischemic attack of the tissue. 
Several growth factors and cytokines drive the underlying mechanisms of these processes 
(van Royen, Piek et al. 2001, Takeda, Uemura et al. 2009, Wu, Wu et al. 2010) (Figure 6.1). 
PlGF (Carmeliet, Moons et al. 2001, Luttun, Tjwa et al. 2002, Iwama, Uemura et al. 2006, 
Kolakowski, Berry et al. 2006) and FGF-2 (Unger, Banai et al. 1994, Laham, Chronos et al. 
2000, Lazarous, Unger et al. 2000, Coenegrachts, Maes et al. 2010, Wu, Wu et al. 2010, 
Schmidt, Kharabi Masouleh et al. 2011) are reported to be both pro-angiogenic and pro-
arteriogenic without any deleterious side effects, such as hypotension, oedema, 
hemangiogenesis, proteinuria, impaired wound healing, haemorrhage and thrombosis or 
endocrine dysfunction; side effects which normally accompany VEGF therapy (Oura, 
Bertoncini et al. 2003, Takeda, Uemura et al. 2009) (Kamba and McDonald 2007). As a 
result, PlGF and FGF-2 have grabbed the attention of several research groups for their 
contribution towards the restoration of blood supply and cardiac function thereby enhancing 
survival rates. 
 
During acute myocardial infarction (AMI), the endothelium was reported to be the major site 
for elevated PlGF expression, rapidly producing PlGF within the infarcted myocardium 
(Iwama, Uemura et al. 2006) and positively correlated with >60% improvement in left 
ventricular ejection factor (LVEF). With the above results as a background, Takeda et al. 
studied the therapeutic effects of PlGF in a mouse model of AMI (Takeda, Uemura et al. 
2009). Three-day intraperitoneal administration of recombinant human PlGF via an osmotic 
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minipump enhanced both angiogenesis and arteriogenesis, resulting in the reduction of infarct 
size, improved cardiac function and increased survival rates post AMI (Takeda, Uemura et al. 
2009).  Co-administration of recombinant human (rh) sVEGFR-1 with rhPlGF lowered the 
survival rate of mice compared to rhPlGF treatment alone (Takeda, Uemura et al. 2009). 
Although the molecular mechanisms and factors that trigger and lead to angiogenesis and/or 
arteriogenesis are diverse, blood vessel growth is broadly accepted to be solely dependent on 
the function of ECs (Carmeliet 2000, M 2011). 
 
Consolidated data from our observations and that of previous reports (Yonekura, Sakurai et al. 
1999, Fischer, Jonckx et al. 2007, Dewerchin and Carmeliet 2012, Kim, Cho et al. 2012) 
demonstrate ECs to be likely as an important source of PlGF. PlGF and its receptor VEGFR-1 
have gained increasing attention for 'their contribution to pathologies. Several lines of reports 
established the critical role of PlGF in tumour angiogenesis and ischemic tissues through 
VEGFR-1 signalling on ECs, as well as in inflammatory-mediated mechanisms or enhancing 
recruitment of the endothelial progenitor cell (EPC) (Carmeliet, Moons et al. 2001, Luttun, 
Tjwa et al. 2002, Odorisio, Schietroma et al. 2002, Autiero, Luttun et al. 2003, Autiero, 
Waltenberger et al. 2003, Pipp, Heil et al. 2003, Rakic, Lambert et al. 2003, Li, Sharpe et al. 
2006). Therapies targeting revascularisation of ischemic tissues by enhancing capillary and 
collateral vessel formation in the heart and limb ischemic tissues with PlGF treatment (Luttun, 
Tjwa et al. 2002, Pipp, Heil et al. 2003, Kolakowski, Berry et al. 2006), and inhibition of 
tumour angiogenesis, arthritis and atherosclerosis using anti-VEGFR-1 (Carmeliet, Moons et 
al. 2001, Luttun, Tjwa et al. 2002) have been the focus for researchers throughout the past 
decade. PlGF, via VEGFR-1 alone (Terman, Khandke et al. 1994),  promotes monocyte 
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migration (Clauss, Weich et al. 1996), the release of NO (Bussolati, Dunk et al. 2001), wound 
healing (Iwama, Uemura et al. 2006) and prolongs survival and stability of capillary networks 
(Cai, Ahmad et al. 2003).  
 
Considerable interest has also arisen from numerous pre-clinical studies demonstrating the 
ability of FGF-2 to restore cardiac function post-MI (Kardami, Detillieux et al. 2007, Liao, 
Porter et al. 2007). Trans myocardial or extraluminal administration of FGF-2, in animal 
models, improved heart function, reduced infarct size and increased blood flow to areas of 
ischemia (Harada, Grossman et al. 1994, Unger, Banai et al. 1994). Additionally, FGF-2 
increased angiogenesis in the myocardium, improved systolic function (Harada, Grossman et 
al. 1994, Horrigan, Malycky et al. 1999, Iwatate, Miura et al. 2001) and improved collateral 
development in microembolised animal models (Iwatate, Miura et al. 2001). Loss of FGF-2 in 
mice impaired the process of MI repair (Schultz, Witt et al. 1999), whereas overexpression of 
FGF-2 preserved cardiac function by enhancing cell proliferation, scar contraction and 
ventricular function (Virag, Rolle et al. 2007). Endogenous FGF-2 contributes to the pro-
angiogenic effect of ACE inhibitors in cultured microvascular coronary ECs (Donnini, Solito 
et al. 2006) and elevated levels of FGF-2 accelerates wound healing (Callaghan, Chang et al. 
2008) by potentiating the recruitment of leukocytes (Zittermann and Issekutz 2006). Kanda et 
al reported that FGF-2-mediated angiogenesis is dependent on the activity of VEGFR-1 
(Kanda, Miyata et al. 2004), as incubation of HUVEC with anti-VEGFR-1 blocking antibody 
inhibited FGF-2-mediated tube formation (Kanda, Miyata et al. 2004). 
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Basing on the accumulated evidence from several sources that both FGF-2 and PlGF promote 
tissue healing and cardiac function following ischemic injury, post-MI, and as a therapeutic 
angiogenesis and/or arteriogenesis promoting agent, we hypothesized that FGF-2-induced 
angiogenesis is dependent upon the release of PlGF from ECs. Detillieux et al in his review 
suggested that the usefulness of FGF-2 in human therapy is dependent upon our ability to 
selectively augment its endothelial effects, and reduce smooth muscle effects (Pintucci, 
Steinberg et al. 1999, Detillieux, Sheikh et al. 2003), which can also be relevant to PlGF; 
PlGF has a direct impact on ECs, SMCs, macrophages and fibroblasts that express VEGFR-1 
(Dewerchin and Carmeliet 2012).  
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Figure 6.1 Factors involved in vasculogenesis, angiogenesis and arteriogenesis. Three types 
of vessel growth, angiogenesis, arteriogenesis and vasculogenesis, are represented. PlGF and 
FGF-2 are both angiogenic, and arteriogenic and stimulate both processes. Furthermore, this 
image emphasises the overlap between angiogenesis, arteriogenesis and vasculogenesis. It is 
currently unknown whether vasculogenesis is operative in the process of vessel growth in 
response to obstructive arterial disease. PlGF involved in mobilisation of progenitors from 
the bone marrow is perhaps necessary for vasculogenesis. Factors that induce angiogenesis 
via the proliferation of ECs, whereas factors stimulating arteriogenesis additionally induce 
proliferation of smooth muscle cells as well. Adapted from Van Royen et al. Cardiovasc Res 
2001;49:543-553 (van Royen, Piek et al. 2001). 
 
Although extensive work has been undertaken to examine the clinical significance of PlGF in 
animal models and human studies, via the loss of function and gain of function studies as a 
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disease-modifying candidate (Review) (Dewerchin and Carmeliet 2012), little is known about 
the factors that regulate endothelial PlGF. While we were investigating the factors that 
modulate PlGF expression in ECs, VEGF was reported to induce production of PlGF via a 
post-translational mechanism (Yao, Yang et al. 2005). The current chapter investgates 
whether the effects of FGF-2 on endothelial PlGF in an immortalised cell line (HMEC-1 
Figure 5.1, 5.2)) are comparable to a primary one (HUVEC). More importantly, this chapter 
substantially explores if FGF-2-stimulated angiogenesis required PlGF expression. 
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6.2.1 FGF-2 promotes PlGF production in HUVECs 
To determine the response of endothelial PlGF in the presence of angiogenic growth factors, 
HUVEC were treated with VEGF, FGF-2 or PMA for 24 hours. Cell supernatants were 
collected and assayed for PlGF release by ELISA. VEGF induced PlGF levels in agreement 
with the findings of Yao and colleagues (Yao, Yang et al. 2005). A two-fold increase in the 
PlGF levels was observed in the presence of FGF-2 (Figure 6.2), which was comparable to 
the effect of VEGF. As VEGF is readily produced by ECs (Figure 6.2), PMA, a PKC 
activator (Furstenberger, Berry et al. 1981), was used as a positive control as per the 
requirement. PMA at an optimal concentration of 100nM (approximately 62 ng/ml) was used 
in this study (PMA concentration graph in Appendix II). 
              
Figure 6.2 FGF-2-induced release of PlGF from ECs. HUVEC were seeded at a density of 
1.5 x 105 per well in 1% gelatin coated 24 well plate, and incubated overnight in RPMI 
containing 5% FCS. Cells were then stimulated with either VEGF [10 ng/ml], FGF-2 [10 
ng/ml], or PMA [100 nM]. Following a 24-hour incubation supernatants were collected and 
PlGF measured by ELISA. Data expressed in pg/ml of PlGF and are mean [± SEM] of at 
least three independent experiments performed in triplicate. *P<0.05 vs. control.  
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6.2.2 FGF-2-mediated PlGF release is concentration-dependent 
To investigate whether FGF-2-induced PlGF release was concentration-dependent, HUVEC 
were treated with increasing concentrations of FGF-2 for 24 hours. A concentration-
dependent rise in the levels of PlGF release in cell supernatants was observed in response to 
the increasing concentrations of FGF-2. PlGF secretion reached statistical significance after 
addition of 10, 50 or 100 ng/ml of FGF-2 compared to the untreated cells. The addition of 10 
ng/ml FGF-2 caused a significant (two- to three-fold) increase in PlGF levels in both HUVEC 









Figure 6.3 FGF-2 up-regulates PlGF release in a concentration-dependent manner. 
HUVEC were cultured in serum-reduced medium and incubated overnight. ECs were 
stimulated with increasing concentrations (1, 10, 50 ng/ml) of FGF-2 for 24 hours. The 
conditioned media was collected and assayed for PlGF by ELISA. The data represent the 
mean (± SEM) of at least 4 independent experiments, performed in duplicate. * p<0.05 vs. 
Control. 
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6.2.3 FGF-2 induces PlGF expression in ECs in a time-dependent manner  
To investigate the kinetics of FGF-2-induced up-regulation of PlGF protein, HUVECs were 
treated with FGF-2. PlGF levels were measured at various time points, starting instantly, i.e. 
from 0.25 hours up to 24 hours to monitor for detailed post-treatment effects of FGF-2 on 
endothelial PlGF. Differences in the levels of PlGF release between FGF-2 treated and control 
cells became apparent after 8 hours. The maximum difference between FGF-2 treated and 
untreated cells was observed at 16 hours (Figure 6.4A). The optimal time of 24 hours was 
therefore selected for subsequent experiments unless specified. Real-time PCR analysis of 
RNA from HUVEC treated with FGF-2 for various time periods revealed that an increase in 
PlGF mRNA expression preceded the rise in PlGF protein secretion (Figure 6.4B). Moreover, 
a significant increase was observed in FGF-2-induced PlGF mRNA levels at 8, 16 and 24 
hours compared to its control. Cells were incubated overnight in low serum medium, followed 
by fresh medium with or without FGF-2 before collecting RNA samples at different time 
points for real-time PCR. It is noteworthy to mention that PlGF protein stimulation by FGF-2 
is significant at 16 hours. Therefore, it appeared that FGF-2 may regulate PlGF expression at 
a transcriptional level. 
Experiments in this study concluded at 24 hours due to several reasons: 
1. HUVEC are fragile and sensitive primary culture cells that require full medium with 
high serum concentrations. In this study, HUVEC is grown in medium supplemented 
with 5% serum. Adding extra serum or fresh medium could bring about radical 
changes in cell functions. 
2. Opting to add a fresh medium for the experiments to run beyond 24 hours may 
contribute to artefacts in the results. 
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3. Most importantly, average doubling time for HUVEC and HMEC-1 is between 24-30 
hours.  
 
Bearing in mind these essential limitations regarding the cell types (HUVEC, HMEC-1) used 
extensively in this study, for subsequent experiments 24 hours‟ time point is chosen unless 
otherwise specified. 
To further confirm the transcriptional regulatory effect of FGF-2 on PlGF levels, cells were 
treated with actinomycin D, a transcription inhibitor (Sobell 1985) (Figure 6.5A), or 
cycloheximide, an inhibitor of protein biosynthesis (Figure 6.5B), for three or six hours in the 
presence of FGF-2. As these treatments abrogated PlGF expression, it confirmed our assertion 
that the requirement of transcription for PlGF release in response to FGF-2 was critical. As 
expected, the basal levels and FGF-2-induced PlGF protein levels reduced by actinomycin D 
and cycloheximide; inhibitors of de novo RNA synthesis and de novo protein synthesis, 
respectively.  This inhibition in PlGF suggests that PlGF production likely to be 
transcriptionally regulated. 
Collectively, these results show that FGF-2-induced PlGF release is concentration-dependent 
through transcriptional activation of PlGF gene and de novo protein synthesis. 
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Figure 6.4 Kinetics of the FGF-2-induced release of PlGF in cultured ECs. [A] Time-
dependent PlGF protein release from HUVEC in response to FGF-2 [10 ng/ml] stimulation. 
Cell supernatants from conditioned medium were collected at indicated time points and PlGF 
levels measured by ELISA. [B] FGF-2-induced PlGF mRNA expression in a time-dependent 
manner. HUVEC were stimulated with FGF-2 (10 ng/ml) and mRNA subjected to quantitative 
real-time PCR for PlGF expression analysis. PlGF mRNA values are normalized to β-actin 
gene expression and presented as mean (± SEM) of three separate experiments performed in 
duplicate.  * p<0.05 vs Control.  
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Figure 6.5 Kinetics of the FGF-2-induced release of PlGF in cultured ECs. HUVEC were 
pre-incubated with (A) actinomycin-D [1 µg/ml] or (B) Cycloheximide [1 µg/ml] and then 
stimulated with FGF-2 [10 ng/ml] for 6 hours. Cell supernatants from conditioned medium 
collected at indicated time points and PlGF levels measured by ELISA. Data are mean 
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6.2.4 Functional Studies 
 
6.2.4.1 FGF-2-induced in vitro tube formation is PlGF dependent 
FGF-2-mediated in vitro capillary morphogenesis of HUVEC is reported to require VEGFR-1 
(Kanda, Miyata et al. 2004). Previous work in our laboratory reported that PlGF enhances 
endothelial cell survival and sustained tube formation (Cai, Ahmad et al. 2003). To establish 
the requirement of PlGF for FGF-2-mediated endothelial tube formation, PlGF was knocked-
down by PlGF siRNA in HUVEC and the cells were subjected to in vitro tube formation 
assay.  
 
 6.2.4.1.1 Validation of PlGF gene silencing in HUVEC 
 
PlGF gene silencing by PlGF siRNA validation was achieved by measuring PlGF levels in 
PlGF gene silenced cells (PlGF siRNA) to control group (Control siRNA). HUVEC from both 
control group and PlGF siRNA samples were supplemented with 0.2 % or 20 % FBS for up to 
24 hours, and cell supernatants from conditioned medium collected at 6, 12 and 24 hours were 
subjected to PlGF ELISA for PlGF protein levels  (Figure 6.6). The PlGF siRNA completely 
attenuated PlGF expression (Figure 6.6) confirming the usage of PlGF gene silenced cells for 
loss of function.   
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Figure 6.6 Validation of PlGF gene silencing in HUVEC. PlGF expression attenuated in 
cell supernatants transfected with PlGF siRNA in HUVEC under 0.2 and 20 % serum 
conditions at various time points indicated. Cell supernatants assayed for PlGF by ELISA. 








        Chapter 6 – FGF-2-induced PlGF production in ECs: FGF-2-mediated angiogenesis is      




6.2.4.2 In vitro tube formation assays in PlGF gene silenced endothelial cells 
 
The siRNA-transfected cells were plated on growth factor-reduced Matrigel-coated wells, and 
FGF-2 was added to the appropriate wells. Endothelial tube-like structures were measured 
after 3 (Figure 6.7), 7 (Figure 6.8) and 24 hours (Figure 6.9) incubation.  
HUVEC treated with FGF-2 triggered a two-fold increase in capillary-like structures, at 7 and 
24 hours, compared to control wells. The ability of FGF-2 to form tubules was impaired in 
PlGF gene silenced cells (Figures 6.8, 6.9). Quantitative analysis showed an approximately 
two-fold decrease in total tube length in PlGF knock-down cells in the presence of FGF-2 at 7 
and 24 hours compared to the control (Figures 6.8, 6.9). Graphical representation of the tube 
formation assay in total tube length (µm/field) measured in five random fields is displayed on 
the respective images at 3, 7 or 24 hours. These results clearly indicate the requirement of 
PlGF for FGF-2-mediated in vitro tube formation.           
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Figure 6.7 PlGF is required for FGF-2-induced in vitro tube formation in ECs.  HUVEC 
transfected with Control or PlGF siRNA and plated onto a six-well plate in MCDB 131 
medium containing 5% FCS, and incubated overnight. The cells were trypsinised and 6x104 
per well were seeded on growth factor reduced-matrigel in a 24 well plate. FGF-2 [10 ng/ml] 
was added to the appropriate wells. Mean total tube length calculated in five random fields 
per well.(A)Photomicrographs for 3 hours and  (B) quantitative analysis demonstrating FGF-
2- induced endothelial cell capillary network attenuation in PlGF-silenced cells. Data 
expressed as the mean ±SEM of at least three independent experiments in duplicates. 
**p<0.05vs Control.   
3 hours
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Figure 6.8 PlGF is required for FGF-2-induced in vitro tube formation in ECs.  HUVEC 
transfected with Control or PlGF siRNA and plated onto a six-well plate in MCDB 131 
medium containing 5% FCS, and incubated overnight. The cells were trypsinised and 6x104 
per well were seeded on growth factor reduced-matrigel in a 24 well plate. FGF-2 [10 ng/ml] 
was added to the appropriate wells. Mean total tube length calculated in five random fields 
per well.(A)Photomicrographs for 7 hours and  (B) quantitative analysis demonstrating FGF-
2- induced endothelial cell capillary network attenuation in PlGF-silenced cells. Data are 
expressed as the mean ±SEM of at least three independent experiments in duplicates. 
**p<0.05vs Control. 
7 hours
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Figure 6.9 PlGF is required for FGF-2-induced in vitro tube formation in ECs.  HUVEC 
transfected with Control or PlGF siRNA and plated onto a six-well plate in MCDB 131 
medium containing 5% FCS, and incubated overnight. The cells were trypsinised and 6x104 
per well were seeded on growth factor reduced-matrigel in a 24 well plate. FGF-2 [10 ng/ml] 
was added to the appropriate wells. Mean total tube length calculated in five random fields 
per well.(A)Photomicrographs for 24 hours and  (B) quantitative analysis demonstrating 
FGF-2- induced endothelial cell capillary network attenuation in PlGF-silenced cells. Data 
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6.2.5 FGF-2-induced angiogenesis is PlGF-dependent: Mouse explant Aortic Ring 
Assay 
To further assess whether FGF-2-mediated angiogenesis is dependent on PlGF expression, the 
mouse aortic ring assay in plgf
-/-
 mice was performed. Aortic ring assay is a valuable model 
that bridges the gap and combines the advantages of in vivo and in-vitro models, giving 
further insight into endothelial migration and angiogenic sprouting (Nicosia 2009). Aortic 
rings were prepared as previously described (Lewis E.C 2009, Nicosia 2009) from the 
resected dorsal aortas from PlGF-deficient (plgf
-/-
), or from the age-matched corresponding 
wild-type (WT) mice, and embedded in collagen gels in the presence of FGF-2 (2 and 10 
ng/ml). After seven days, vascular sprouting around the aortic explants were examined using 
an inverted phase-contrast microscope [Figure 6.10A]. Endothelial outgrowth and tube 
formation were well established after seven days in FGF-2 treated WT, and this observation 
was taken as an indication to end the experiment. In contrast to FGF-2-induced microvessels 
in the WT aortic rings, plgf
-/-
 aortic explants had no significant angiogenic response following 
FGF-2 stimulation [Figure 6.10A]. Quantification of the total sprout lengths in each of the 
experimental conditions showed FGF-2 at both 2 and 10 ng/ml concentrations induced a 
three- and two-fold increase respectively in the sprout length in WT aortic explants, compared 
to its control. Notably, 2 ng/ml of FGF-2 induced 55% more of vessel sprouts compared to 10 
ng/ml of FGF-2 in WT aortic explants. This variation, when compared to in vitro tube 
formation (Figures 6.8, 6.9), could be explained due to the presence of the mixed population 
of native cells, i.e. SMCs and pericytes that may well interact through paracrine mechanisms 
(Lewis E.C 2009, Nicosia 2009) under the chemically defined culture conditions designed in 
this experimental settings. Also, with regards to the endothelial sprouting, the maximum 
migration, i.e. the furthest away distance migrated from each aortic ring, was also reduced in 
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cultures. Collectively, these data propose PlGF necessary for FGF-2-mediated 
angiogenesis.   
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Figure 6.10 FGF-2-mediated angiogenesis is dependent on PlGF expression [A] 
Representative photomicrographs of seven-day-old collagen gel cultures of mouse aorta. 
Mouse aortic explants extracted from wild-type (WT) and PlGF-knockout (Plgf-/-) mice were 
washed in PBS, sectioned into ~1 mm rings, and embedded in collagen in tissue culture wells. 
The tissues were coated with collagen with minimum air bubbles. After collagen 
solidification, the aortic ring cultures were maintained in the absence or presence of 
exogenous FGF-2. [B] Quantification of the total sprout length is expressed in µm. Data 
expressed as the mean ±SEM of four independent experiments repeating each condition in 
duplicate ***p<0.0001 vs control.  
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This is the first study to establish a direct link between the angiogenic activities exerted by 
FGF-2 and PlGF in ECs. The important contribution of the study is to demonstrate substantial 
evidence suggesting that FGF-2-induced angiogenesis requires PlGF. We believe that this 
evidence would add to the working concept of PlGF and FGF-2 contributed 
neovascularisation processes, and help to promote to improve therapies further.  
6.3.1 FGF-2 induces PlGF expression in ECs 
FGF-2-induced a significant increase in the secretion of PlGF protein levels in a 
concentration- and time- dependent manner, in macro- as well as micro- vascular ECs. These 
results are not consistent with findings of Yao and colleagues, which concluded that FGF-2 
did not modulate the level of PlGF release from HUVEC significantly (Yao, Yang et al. 
2005). In this study (Figure 2, page 1229, (Yao, Yang et al. 2005)), it was evident that FGF-2 
increased PlGF levels by approximately three-fold when compared to the control. 
Furthermore, differences in cell culture method and conditions perhaps contributed to this 
discrepancy (Appendix IV). Yao et al allowed HUVEC grown to confluence in EGM-2MV 
medium (with no documentation of cell numbers) in 12-well plates, and then switched to 
DMEM containing 10% calf serum (Yao, Yang et al. 2005). Moreover, only a fixed 
concentration of FGF-2 (25 ng/ml) was used (Yao, Yang et al. 2005).  On the other hand, in 
the current study a fixed number (1.5 x 10
5
) of ECs per well in a 24-well plate were incubated 
for 24 hours in 5% FBS-containing RPMI and analysed for PlGF levels. These culture 
conditions were maintained throughout the study unless mentioned otherwise. There is a 
possibility that the change of growth medium and high serum concentrations used in Yao 
study, known to induce PlGF levels (Chapter 7, Figure 7.6), may not have allowed FGF-2 to 
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elicit any further additional effect on PlGF levels in their study (Yao, Yang et al. 2005). 
Besides, we have examined in more detail the effect of FGF-2 on PlGF in ECs; we show a 
gradual increase in PlGF levels in response to increasing concentrations of FGF-2 in both 
HUVEC and HMEC-1. VEGF upregulation was reported to occur via a post-transcriptional 
mechanism (Yao, Yang et al. 2005). We observed FGF-2 induce a significant increase in 
PlGF mRNA levels compared to the control. Unlike VEGF-induced PlGF release from ECs 
(Yao, Yang et al. 2005), FGF-2-induced PlGF secretion was dependent on PlGF gene 
transcription. PlGF production in response to FGF-2 is via transcriptional activation of PlGF 
gene and de novo protein synthesis, i.e., up-regulation of PlGF protein was preceded by an 
increase of PlGF mRNA, in a time-dependent manner in ECs when stimulated with FGF-2. 
Intramyocardial delivery of FGF-2 in rat models reduced infarct size and improved cardiac 
function, when assessed at 4-24 hours post-MI (Jiang, Padua et al. 2002), which are within the 
time periods of FGF-2-induced PlGF levels in the current study. Although we demonstrate 
that the FGF-2 induced PlGF increase occurs via a transcriptional regulation mechanism in 
ECs, these results could be consolidated by identifying transcription factors that mediate the 
effects of FGF-2 on PlGF gene promoter. 
FGF-2 induces VEGF expression in vascular ECs through autocrine and paracrine 
mechanisms (Seghezzi, Patel et al. 1998). Though FGF-2 manifests variety of effects on EC 
function and gene expression, the findings in this study raises the possibility
 
that both FGF-2 
and PlGF may
 
regulate neovascularization in an autocrine and paracrine manner by 
modulating expressions of other potent angiogenic factors, such as VEGF.  
In the present study we demonstrate FGF-2 induced an increase in PlGF levels by up to two- 
to four-fold (200 - 400 pg/ml) when compared to the control (100 pg/ml). this was 
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demonstrated in macro- and micro- vascular ECs that may be sufficient to exert a biological 
effect. In AMI patients‟ plasma, PlGF levels ranged between 30 to 120 pg/ml, and higher 
levels of PlGF positively correlated with subsequent improvement in LVEF in the chronic 
phase; six months after the onset of AMI when compared to patients without improvement 
(Iwama, Uemura et al. 2006). These findings raise the possibility to speculate that FGF-2-
induced PlGF concentrations may enhance VEGF-driven angiogenesis through the unique 
cross-talk between VEGFR-1 and VEGFR-2. Moreover, PlGF concentration at 100 pg/ml 
stimulated DNA synthesis in VEGFR-1 expressing ECs (Landgren, Schiller et al. 1998). In 
agreement with a previous report (Yao, Yang et al. 2005), VEGF and the PKC activator PMA 
both up-regulated PlGF protein levels secreted from the ECs. Unlike FGF-2, VEGF up-
regulation of PlGF occurs via a post-transcriptional mechanism (Yao, Yang et al. 2005). Up-
regulation of PlGF mRNA and protein was observed during angiogenesis in a number of 
metabolic, inflammatory disorders and tumours,  including MI (Iwama, Uemura et al. 2006), 
diabetic retinopathy (Khaliq, Foreman et al. 1998), brain tumours (Nomura, Yamagishi et al. 
1998) and ischaemic retinal disorders (Yamashita, Eguchi et al. 1999). Based on these reports 
and our findings in this chapter, it is tempting to speculate that the increase in PlGF protein 
and mRNA levels noted in these pathologies is perhaps up regulated by FGF-2, as FGF-2 
expression has been reported in such disorders.(Riley, Savage et al. 1993, Fannon, Forsten-
Williams et al. 2003, Presta, Dell'Era et al. 2005).  
6.3.2 FGF-2-induced angiogenesis requires PlGF expression 
Pre-clinical studies and patient data provide proof of the beneficial effects of PlGF or FGF-2, 
on post AMI pathology in the infarcted myocardium. The proposed effect works by enhancing 
tissue healing following ischemic injury, improving cardiac function and subsequent increase 
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in the survival rates (Laham, Sellke et al. 1999, Jiang, Srisakuldee et al. 2004, Iwama, 
Uemura et al. 2006, Kardami, Detillieux et al. 2007, Takeda, Uemura et al. 2009) (Tables 1.3, 
1.4). Mice over-expressing PlGF in epidermal keratinocytes (under the keratin 14 promoter) 
exhibited a robust increase in dermal blood vessels, vascular permeability, in addition to 
increased inflammatory response (Odorisio, Schietroma et al. 2002, Oura, Bertoncini et al. 
2003). Conversely, a lack of PlGF resulted in an inhibited and abbreviated inflammatory 
response, in concert with reduced inflammatory angiogenesis and oedema formation 
(Carmeliet, Moons et al. 2001, Luttun, Brusselmans et al. 2002). PlGF contributes to 
regulating the angiogenic switch, and its significant role in promoting aberrant angiogenesis 
in a variety of pathologies has gained increasing attention in the past few years. Unlike 
VEGF, FGF-2 is a pro-angiogenic growth factor that is well-tolerated and free of significant 
adverse effects on the restoration of cardiac function (Lazarous, Unger et al. 2000, Kardami, 
Detillieux et al. 2007, Liao, Porter et al. 2007). A series of animal studies and observations in 
patients with AMI reported that the up-regulation of PlGF is essential to facilitate restored 
cardiac function, and attenuate the adverse effects seen in the post-ischaemic heart (Table 1.3) 
(Iwama, Uemura et al. 2006, Kolakowski, Berry et al. 2006, Roncal, Buysschaert et al. 2008, 
Takeda, Uemura et al. 2009). We demonstrated that FGF-2-mediated in vitro tube formation 
was dependent on PlGF, by knocking down PlGF gene utilising the gene silencing approach. 
Complete inactivation of PlGF gene for up to 24 hours was achieved in cells incubated with 
different serum concentrations.  A two-fold increase in PlGF levels under low serum 
conditions was observed when compared to high serum concentrations. These results indicate 
that PlGF is secreted by ECs in adverse or stressful conditions, probably to restore cell 
survival potential. This data is in line with previous studies from our laboratory, reporting 
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recombinant PlGF promoting long-term survival of ECs via PI3-kinase pathway (Cai, Ahmad 
et al. 2003).  
A significant decrease (about 40-50 percent) in FGF-2 stimulated tube formation was 
observed in the absence of PlGF demonstrating the requirement for PlGF in this process. 
Kanda and colleagues showed that an anti-VEGF-A antibody reduced FGF-2-induced 
capillary morphogenesis (Kanda, Miyata et al. 2004). The addition of PlGF-1 restored anti-
VEGF-A-mediated inhibition of capillary morphogenesis, proposing that VEGFR-1 signalling 
by endogenous VEGF-A may be required for FGF-2-mediated changes of EC shape (Kanda, 
Miyata et al. 2004). Although the Kanda et al. study compliments our results, there are few 
limitations in their study. We were unable to detect VEGF protein as well as mRNA in a 
range of ECs, including HUVEC, that were screened by ELISA and real-time PCR (Figure 
4.2). Experiments to determine the optimal concentrations of VEGF or FGF-2 to elicit cellular 
responses were not documented in Kanda et al study. Moreover, Kanda et al used a higher 
concentration of VEGF (20 ng/ml) or FGF-2 (20 ng/ml) (Kanda, Miyata et al. 2004), in 
comparison to this study which elicited cellular responses in ECs, including the significant 
increase in PlGF levels at a lower concentration of FGF-2 (10 ng/ml). Fujii and colleagues 
demonstrated, in severe hind limb mouse ischemic model, that VEGF up regulation of 
endogenous PlGF expression required in FGF-2-mediated therapeutic angiogenesis (Fujii, 
Yonemitsu et al. 2008). Both FGF-2 and PlGF work in close association with each other 
during FGF-2-mediated therapeutic angiogenesis (Fujii, Yonemitsu et al. 2008). However, 
this study demonstrates no effect of FGF-2 on PlGF expression in vitro (Fujii, Yonemitsu et 
al. 2008). Although in vivo data of Fujii and colleagues support our findings, we believe that 
the differences in vitro findings might have been due to variations in cell culture methods, 
such as source of cells, isolation procedures, and initial cell culture conditions that are known 
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to influence the response to pro-angiogenic factors (e.g. VEGF, FGF-2) (Suparna Sanyal 
2009). Some data, such as the growth medium and the passage number of the cells used were 
not documented (Fujii, Yonemitsu et al. 2008). In 2011, our group demonstrated a key finding 
that VEGF stimulates sVEGFR-1 expression from ECs in vitro and in vivo (Ahmad, Hewett et 
al. 2011), which raised questions about the findings of Kanda (Kanda, Miyata et al. 2004) or 
Fujii (Fujii, Yonemitsu et al. 2008) studies. 
The advancement of the current study demonstrating FGF-2-mediated in vitro tube formation 
assay requires PlGF was further consolidated by ex vivo aortic ring assay findings performed 
on WT and Plgf
-/-
 in the presence of FGF-2.  Pericytes and vascular SMCs residing at the 
interface between the endothelium and the surrounding tissue serve to be the potential pro- or 
anti-angiogenic target complementary to the endothelium (Nicosia 2009). 
This model provided invaluable information on the role of PlGF in FGF-2-mediated 
angiogenesis, as vessels that grow out from aortic ring assays recruit SMCs and pericytes are 
known to be the nearest possible comparison of neovessel formation in vitro settings to that of 
in vivo. Perhaps due to these causes FGF-2 at lower concentrations (2 ng/ml) induced almost 
double the number of sprouts in WT aortic rings when compared to 10 ng/ml treated WT 
aortic rings. Additionally, this response might have been due to a concerted effort of FGF-2 
induced VEGF expression (Seghezzi, Patel et al. 1998) which is supported by the recent 
findings from our laboratory of the concentration dependent up regulation of sVEGFR-1 by 
VEGF (Ahmad, Hewett et al. 2011). More so, reduced sprouting was observed in Plgf
-/-
 aortic 
rings in the presence of FGF-2, matching the findings of in vitro tube formation assay. 
Pericytes being the primary source of VEGF is stimulated by endothelial-derived NO 
(Reynolds, Grazul-Bilska et al. 2000). We therefore anticipated that a paracrine loop between 
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ECs producing NO and the pericytes which produce VEGF, in response to this NO may 
consequently coordinate and reinforce initial angiogenic activation. However, this was not the 
case; probably due to endothelial sVEGFR-1 expression being regulated by VEGF (Ahmad, 
Hewett et al. 2011). 
Although we have demonstrated our findings with substantial evidence, the limitations, such 
as inconsistency in the handling of the aortic rings and the amount of surrounding tissue, can 
influence the vessel outgrowth. Furthermore, a number of variables, including the type of 
angiogenic stimulation, age, gender and the genetic background of the animals used, may 
influence the result as well (Zhu, Iurlaro et al. 2003). To overcome these setbacks, increasing 
the number of replicates of the current aortic ring assay with minimising the above variables 
would be the step to move forward.  
Both endogenous and exogenous FGF2 induces VEGF expression in ECs via autocrine 
mechanism (Seghezzi, Patel et al. 1998). VEGF (Yao, Yang et al. 2005) and FGF-2 (Current 
study), enhance the expression of PlGF. Based on the above , we anticipated that FGF-2 
mediated angiogenesis in vitro as well as ex vivo in the absence of PlGF should sustain EC 
functions via FGF-2-induced VEGF (Seghezzi, Patel et al. 1998). However, the major factor 
perturbing this concept is the recent contribution from our laboratory that VEGF up regulates 
sVEGFR-1 in vitro as well as in vivo (Ahmad, Hewett et al. 2011). Collectively, these 
findings suggest that FGF-2 directly induces PlGF and indirectly, via FGF-2, induced up 
regulation of VEGF. VEGF, in turn, may modulate PlGF levels via transcription (Current 
study) and post-transcriptional mechanism (Yao, Yang et al. 2005) respectively, and therefore 
demonstrating that PlGF is required for FGF-2 mediated angiogenesis. Future studies to 
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analyse PlGF, FGF-2 and VEGF compromise in endothelial function due to sVEGFR-1 
secreted by VEGF in PlGF inactivation settings, is warranted.   
In animal models, FGF-2 administered post ischemia/reperfusion injury mediated acute 
protection against cardiac dysfunction and tissue damage involved activation of PKC and 
MAPK signalling pathways (Padua, Sethi et al. 1995, Padua, Merle et al. 1998, House, 
Melhorn et al. 2007). FGF-2 and VEGF use distinct intracellular pathways to activate 
angiogenesis (Hood, Frausto et al. 2003). VEGF and αvβ5 or FGF-2 and αvβ3 cooperate to 
promote differential regulation and activation of the Ras-ERK pathway (Hood, Frausto et al. 
2003). These distinct signalling molecules activated may play a role in the divergent vascular 
and survival responses elicited by FGF-2 and VEGF in inducing PlGF expression and its 
manifestation on cellular responses. Schematic illustration of PlGF, FGF-2 and VEGF 
interaction with the receptors activated to induce EC responses is represented in Figure 6.11. 
Elucidation of the expression of PlGF and its regulation in ECs may provide insights into the 
molecular mechanisms and the role of PlGF in aberrant angiogenesis, and its ability to 
reinstate normal vasculature in pathologies requiring neovascularisation, including cardiac 
restoration.  
Although PlGF exerts cellular responses via VEGFR-1 (Yla-Herttuala and Alitalo 2003), it 
was also reported that angiogenic response to PlGF is indirectly mediated by VEGFR-2 (Roy, 
Bhardwaj et al. 2005). It might be that the loss of PlGF may have reduced the availability of 
VEGF to promote VEGFR-2 driven angiogenesis. The findings are presented here to unveil a 
part of the complexity of FGF-2-mediated angiogenesis requiring PlGF, leading to the vital 
question of VEGF contribution in this process.  
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Figure 6.11 Schematic illustration of PlGF, FGF-2, VEGF and their receptors activated in 
EC functions. 1.  FGF-2 induces up regulation of VEGF expression in ECs in an autocrine 
mechanism contributing to angiogenesis (Seghezzi, Patel, et al. 1998). 2. FGF-2-mediated 
capillary morphogenesis of ECs requires signals via VEGFR-1 possibly via Akt (Kanda, 
Miyata, et al. 2004). 3. VEGF-induced PlGF up regulation occurs via a post-transcriptional 
mechanism involving PKC β (Yao, Yang, et al. 2005). 4. VEGF up regulated sVEGFR-1 
expression (Ahmad, Hewett, et al. 2011). 5. FGF-2-induced PlGF production in ECs occurs 
via transcriptional regulatory mechanism (Current study). 6. FGF-2-mediated angiogenesis 
is PlGF dependent (Current study). 
 
Additionally, as both VEGF and FGF-2 differentially regulate alpha integrin-mediated Ras-
ERK signalling to elucidate angiogenesis (Hood, Frausto et al. 2003), it is advantageous to 
delineate the signalling mechanism governing FGF-2 induced PlGF release in ECs. The 
distinct signalling pathways involved in the induction of PlGF by ECs via VEGF (Yao, Yang 
et al. 2005) or FGF-2 (Chapter 5) could promote a better understanding of the interactions 
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or/and interdependencies that exist between these potent growth factors, to modulate the EC 

















Chapter 7- TNF-α inhibited PlGF release and its 
effect on endothelial cell functions  
 
  






Chronic inflammation is a hallmark of several inflammatory disorders and plays a key role in 
the pathogenesis of endothelial dysfunction (Murdaca, Colombo et al. 2012). Angiogenesis in 
the pathology of chronic inflammation is a highly coordinated process, involving a complex 
network of chemical signals and cell interactions. A wide variety of cells involved in the 
inflammatory processes release numerous factors that act directly or indirectly on vascular 
ECs, resulting in “switching on” or “switching off” the angiogenic process (Folkman 1995, 
Carmeliet and Jain 2000).  
 
PlGF is an angiogenic stimulator and a strong pro-inflammatory mediator, which modulates 
the inflammatory process in a number of ways (Clauss, Weich et al. 1996, Bottomley, Webb 
et al. 2000, Selvaraj, Giri et al. 2003), for instance by the recruitment of inflammatory cells, 
pericytes and SMCs (Adini, Kornaga et al. 2002, Fischer, Jonckx et al. 2007, Dewerchin and 
Carmeliet 2012). Inflammatory mediators have a significant influence on the process of 
angiogenesis (Koch 1998, Ferrara, Gerber et al. 2003), where pro-inflammatory cytokines are 
known to be potent factors to induce and support angiogenesis  (Oura, Bertoncini et al. 2003, 
Yoo, Bae et al. 2005, Yoo, Yoon et al. 2009) (review (Voronov, Carmi et al. 2014). Of special 
relevance to angiogenesis, cytokines, in particular TNF-α and IL-1, named as “alarming 
cytokines” (Voronov, Carmi et al. 2014) significantly contribute to both acute and chronic 
inflammation resulting in  progressive healing (in acute stage) or towards the progressive 
destruction of tissues and organs (in chronic stage) (Feghali and Wright 1997, Kumar 2012). 
Additionally, these extremely potent inflammatory molecules with the potential to destroy or 
heal are also the primary mediators of septic shock (Feghali and Wright 1997). Sepsis is the 





leading cause of death in critically ill patients (Angus, Linde-Zwirble et al. 2001) and 
endothelial dysfunction is a key factor in its pathogenesis (Smadja, Borgel et al. 2012).  
 
Based on previous evidence, Matunga and group hypothesised that vascular endothelium is 
the principal target of the inflammatory response in sepsis, causing widespread vascular 
damage/disruption to the endothelium (Mutunga, Fulton et al. 2001). An increase in 
circulating ECs was observed in patients with sepsis but without shock, suggesting that 
endothelial damage precedes the clinical development of organ failure (Mutunga, Fulton et al. 
2001). The number of circulating ECs in sepsis is positively correlated with the severity of 
vascular injury (Mutunga, Fulton et al. 2001). Learning about the interactions between 
cytokines and ECs may, therefore, contribute towards our understanding of the mechanisms 
involved in endothelial shedding leading to progressive destruction/systemic pathological 











Figure 7.1 Endothelial dysfunction characterised by a shift in the activities of the 
endothelium towards reduced vasodilation, a proinflammatory state and prothrombic actions 
(Rajendran, Rengarajan et al. 2013). 
 
 





Vascular endothelium is known to be a specific target of TNF-α (Chia, Qadan et al. 2003, 
McKellar, McCarey et al. 2009, Zhang, Park et al. 2009). TNF-α signals via its receptor, 
TNFR1, and induces EC type II acute inflammation. Raised plasma levels of TNF-α are toxic 
(Lejeune, Lienard et al. 2006) and lead to vascular dysfunction. Effects of TNF-α and 
inflammatory cytokines are the key mediators of pathophysiology of endothelial/vascular 
dysfunction associated with several pathologies, including accelerated atherosclerosis, MI, HF 
(Zhang, Park et al. 2009, Kleinbongard, Heusch et al. 2010, Roubille, Martel-Pelletier et al. 
2013)  and chronic inflammatory disorders such as RA (Murdaca, Colombo et al. 2012), 
cancer and PE, and raises risk in trauma patients and obese individuals  (Zhang, Park et al. 
2009, Roubille, Martel-Pelletier et al. 2013). Among the list of common pathologies (Table 
1.6) presenting with higher circulating levels of TNF-α, heart disease (HD) show the highest 
levels of plasma TNF-α levels ranging between 1000-2000 pg/ml (Lee, Zaske et al. 2011), 
followed by RA as the second highest. Remarkably, a review by Piero Montorsi states that the 
atherosclerotic process begins during childhood (Vlachopoulos, Ioakeimidis et al. 2008). 
Moreover, women with PE and their children are reported to be at a higher risk of developing 
cardiovascular disease (CVD) at a later stage in life (Smith, Pell et al. 2001, Vatten, 
Romundstad et al. 2003), wherein TNF-α is reported to play a significant role. Individuals 
with chronic inflammatory diseases have been associated clinically with excessive 
cardiovascular risk and increased mortality when compared to the general population (Rosner, 
Ginzler et al. 1982, Peters, van der Horst-Bruinsma et al. 2004, Gelfand, Neimann et al. 2006, 
Mathieu, Motreff et al. 2010, Murdaca, Colombo et al. 2012, Nikpour, Gladman et al. 2013, 
Singh, Singh et al. 2014) (Table 6.1).  
 
 





Disease CAD Risk  
(RR or OR) 
Cardiovascular Mortality 
(RR) 
RA 1.5-2.0 (Solomon, Goodson et al. 
2006, Crowson, Liao et al. 2013) 
1.5 (Avina-Zubieta, Choi et al. 
2008) 
Systemic Lupus  
Erythematosus  
2.2-2.6 (Hak, Karlson et al. 2009, 
Magder and Petri 2012) 
1.7 (Bernatsky, Boivin et al. 2006) 
Psoriasis (severe) 1.5-7.1 (Gelfand, Neimann et al. 
2006, Samarasekera, Neilson et al. 
2013) 
1.1-1.6 (Gelfand, Neimann et al. 




1.9 (Peters, Visman et al. 2010, 
Mathieu, Gossec et al. 2011) 




1.2-1.4 (Fumery, Xiaocang et al. 
2014, Singh, Singh et al. 2014) 
1.0 (Dorn and Sandler 2007, 
Fumery, Xiaocang et al. 2014) 
Table 7 .1 Chronic inflammatory diseases and the relative risk of cardiovascular morbidity 
and mortality manifested by these diseases. RR – Relative risk; OR – Odds Ratio (Steyers 
and Miller 2014). 
 
TNF-α signaling through TNFR2 activates VEGFR2, promoting angiogenesis; this is a 
hallmark of chronic inflammation (Review) (Pober and Sessa 2007). VEGFA enhances acute 
inflammatory effects mediated by TNF-α. The exact mechanisms of signal transduction in 
these responses are not well understood. Pro-inflammatory signaling may involve an NF‑κB 
stimulation mediated by AKT amplification in some cell types. This pathway, however, this 
has not been observed in ECs (Pober and Sessa 2007). PlGF modulates the inflammatory 
process by up regulating VEGF (Bottomley, Webb et al. 2000) and VEGFR-1 (Yoo, Yoon et 
al. 2009) expression, in addition to increasing production of inflammatory cytokines, such as 
TNF-α in mononuclear cells (Selvaraj, Giri et al. 2003). An increase in inflammatory cells 
results in propagation of cytokines and chemokines, some of which are angiogenic, such as 
VEGF and PlGF (Artese, Rubini et al. 2002). The principle role of TNF-α in endothelial 





activation/dysfunction seems to rest on a subtle balance between angiogenic and 
inflammatory mediator response, leading to systemic protective effects in acute inflammation 
or systemic pathological effects in chronic inflammation (Kumar 2012).  
Hand veins, when exposed to TNF-α, IL-1β or endotoxin for an hour, were caused impaired 
endothelial function when compared to the hand veins of healthy subjects (Bhagat and 
Vallance 1997). Endothelial dysfunction persisted for up to 48 hours (Bhagat and Vallance 
1997).    Moreover, anti-TNF-α treatment improves endothelial dysfunction (Cardillo, 
Schinzari et al. 2006, Gonzalez-Gay, Garcia-Unzueta et al. 2006, Maki-Petaja, Hall et al. 
2006). It is, therefore, fundamental to unravel the possible correlations between circulating 
pro-inflammatory cytokines and the effects of these mediators on the endothelium resulting in 
inflammatory angiogenesis, unbalanced homeostasis, and major vascular dysfunction, leading 
to progressive destruction as a result of chronic inflammatory events.  
Although the association between angiogenesis and inflammation is not a new concept, an 
association of inflammatory mediators, such as TNF-α and endothelial PlGF, which may 
contribute to an imbalance between pro- and anti-angiogenic factors is poorly understood. In 
this chapter, the effect of TNF-α on endothelial PlGF and on in vitro angiogenesis has been 
examined.  
We believe that this evidence further supports the hypothesis that a conjoined target of 
angiogenesis and inflammation would reap more beneficial effect in developing therapies 
inhibiting endothelial dysfunction leading to cardiovascular disease / systemic vascular 
events. 






Figure 7.2 TNF-α - the key mediator of endothelial dysfunction and progressive destruction 
in chronic inflammation. Inflammation plays a key role in body defence mechanism against 
external stimuli, such as pathogens or foreign bodies. However, inappropriate and chronic 
activation of inflammatory processes is an underlying contributor to many common 
pathological inflammatory conditions. TNF-α and IL-1 are known to be extremely potent 
inflammatory molecules and share a common feature to drive acute/chronic inflammatory 
responses. TNF-α secreted by various cells, induces the expression of genes associated with 
inflammation, coagulation and proliferation, is abnormally increased in the circulation of 
several disorders and is known to target the endothelium. The vascular effects of TNF-α are 
alterations in endothelial metabolism/function, platelet aggregation and endothelial cell-
blood cell interactions and SMC function and proliferation (Bhagat and Vallance 1997). 
Abnormally levels of TNF-α drive the angiogenic and inflammatory response in several 
disorders (Table 1.7). Systemic vascular dysfunction (SVD) could be the minimum common 
denominator of the several such chronic inflammatory diseases, all of which are associated 
with high circulating levels of TNF-α, leading to progressive destruction.   
 
 





7.2  Results 
7.2.1 Endothelial PlGF protein release inhibited by TNF-α.  
The abnormal vascular remodelling process implies damage and dysfunction of ECs as well 
as smooth muscle cell (SMC) proliferation. (Dubey, Jackson et al. 1997, Dubeyl, Rosselli et 
al. 2000). To investigate whether the effect of TNF-α on PlGF release differs in different cell 
types, HUVEC, HMEC-1 and SMCs were treated with TNF-α (10 ng/ml) for 24 hours. Cell 
supernatants were analysed for the levels of PlGF. PlGF protein levels in the presence of 
TNF-α in both the endothelial cell types, HUVEC and HMEC-1, were decreased by about 
two-to-three fold compared to the control (Figure 7.3 A, B). Surprisingly, TNF-α had an 
opposite effect on SMCs and exhibited a three-fold increase in the levels of PlGF compared to 
the control (Figure 7.3 C). This is the first study to establish a direct effect of TNF-α on the 
levels of PlGF in cultured ECs.  
As TNF-α caused a similar significant reduction in the levels of PlGF release compared to the 
control in both the EC types [HUVEC, HMEC-1], we chose primary cultures cells, HUVEC 
for functional studies and HMEC-1 for signalling studies to maximise their respective benefits 
in their respective experimental boundaries. 
 
  





        
    
Figure 7.3 The effect of TNF-α on PlGF secretion in different cell types. Cells were 
cultured in 24 well plate, and incubated overnight with RPMI medium containing 5% FBS. 
Cells were stimulated with 10 ng/ml of TNF-α for 24 hours. Cell supernatants from (A) 
HUVEC, (B) HMEC-1 and (C) SMCs were collected and assayed for PlGF by ELISA. The 
data represents the mean [± SEM] of 3 independent experiments.  [*] P<0.05, [**] P<0.005, 



















































7.2.2 PlGF release in response to TNF-α is concentration dependent 
To investigate whether TNF-α mediated PlGF release was concentration-dependent, HUVEC 
were treated with increasing concentrations of TNF-α for 24 hours. A concentration-
dependent decrease in the levels of PlGF release in cell supernatants was observed in response 
to the increasing concentrations of TNF-α. PlGF secretion reached statistical significance 
from 10 or 100 ng/ml of TNF-α compared to the untreated cells. Treating HUVEC with 10 
ng/ml TNF-α caused a significant (two-fold) decrease in PlGF levels (Figure 7.4A). TNF- α 
concentration of 10 ng/ml was the chosen concentration for the subsequent experiments in this 
study unless mentioned otherwise. General observation of cell cultures and cell morphology 
under the microscope of the cells treated with TNF- α displayed no significant differences 
when compared to the untreated cells.  
It was imperative to know if TNF-α effect on PlGF levels is due to the regulatory mechanisms 
or cytotoxic effects of TNF- α on the cells. To elucidate this, cell viability test in the form of 
an MTT assay was performed (Figure 7.4B). Cells were subjected to identical culture 
conditions with increasing concentrations of TNF- α (0.1,1,10,100 ng/ml) as in the above 
experiment. HUVEC were not subjected to cytotoxicity effects in the presence of varying 
concentrations of TNF-α when compared to untreated cells.    
             
  





                         
 
Figure 7.4 TNF-α reduced PlGF release in a concentration-dependent manner. (A) 
HUVEC were cultured in serum-reduced medium and incubated overnight. Cells were 
stimulated with increasing concentrations ( 0,1,1,10, 100 ng/ml) of TNF-α for 24 hours. The 
conditioned media was collected and assayed for PlGF by ELISA. (B) Cell viability not 
effected by TNF-α. HUVEC were seeded in well in a 96 well plate and incubated overnight 
prior to stimulation. Cells were stimulated and incubated for 24 hours with various 
concentrations of TNF-α in serum reduced medium. Cell viability was assessed by MTT 
assay. The data represents the mean (± SEM) of at least 4 independent experiments, 
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7.2.3 TNF-α reduces PlGF expression in ECs in a time-dependent manner  
To investigate the kinetics of the TNF-α mediated PlGF down-regulation, HUVEC were 
treated with TNF-α and cell supernatants were collected at various time points and PlGF 
protein levels assayed by ELISA. Variations in the levels of PlGF release between TNF-α 
treated and untreated cells became apparent after four hours, and were found to be  significant  
(two-fold decrease)  at 8 hours (Figure 7.5 A). PlGF protein levels were noticed to reach its 
maximum at 24 hours.  The effect of TNF-α on PlGF mRNA expression in ECs was 
determined by real-time PCR performed on cDNA from HUVEC treated with TNF-α for 
various time periods. Consistent with the protein data, PlGF mRNA expression in the 
presence of TNF-α was significantly inhibited (Figure 7.5 B). TNF-α induced a two-fold 
decrease in PlGF mRNA levels at eight hours compared to its control. A decrease in mRNA 
levels was observed at 16 and 24 hours in TNF-α treated and respective control group as well. 
To confirm that the TNF-α inhibitory effect on PlGF levels was transcriptionally regulated, 
cells were incubated HUVEC with actinomycin D, a transcription inhibitor (Sobell 1985), for 
three or six hours in the presence of TNF-α. The data together demonstrated abrogated levels 
of PlGF (Figure 7.5 C), confirming the requirement of transcription for PlGF release from 
ECs. 
Collectively, these results suggest that TNF-α reduced PlGF release from HUVEC could be 
due to reduced de novo protein synthesis Twenty four hours was taken as an optimal time for 
subsequent experiments unless specified. 
  





           
Figure 7.5 Kinetics of TNF-α induced inhibition of PlGF release in HUVECs. [A] Time- 
dependent decrease in PlGF secretion in response to TNF-α [10 ng/ml] stimulation. Cells 
were seeded in a 24 well plate, incubated overnight and stimulated with TNF-α. Cell 
supernatants were collected at indicated time points and PlGF levels measured by ELISA. 
[B] TNF-α induced inhibition of PlGF mRNA expression in a time-dependent manner. 
Quantitative real-time PCR performed to analyse PlGF mRNA levels in HUVEC at 8, 16 
and 24 hour stimulation by TNF-α [10 ng/ml]. PlGF mRNA values were normalized to β-
actin gene expression. [C] TNF-α inhibited PlGF release is via de novo protein synthesis. 
HUVEC were pre-incubated with actinomycin-D [1 μg/ml] and then stimulated with TNF-α 
[10 ng/ml] for 6 hours. Data represntated are mean [±SEM] of at least three separate 
experiments performed in duplicate. [*] P<0.05, compared to the control. 
 





7.2.4 TNF- partially suppresses  growth factor-induced PlGF release from ECs. 
In Chapter 6 we established FGF-2-induced PlGF production in a concentration-dependent 
manner. To further investigate the antagonistic activity of TNF-α on PlGF release, HUVEC 
were treated with FGF-2 [10 ng/ml], or a range of serum concentrations in the presence of 
TNF-α (Figure 7.6). FGF-2-induced PlGF protein levels were suppressed in a concentration-
dependent manner in response to increasing concentrations of TNF-α, up to 10 ng/ml. 
Interestingly, 10 ng/ml of TNF-α inhibited FGF-2-induced PlGF levels (Figure 7.6A). A 
similar effect of TNF-α was observed on serum-induced PlGF release (Figure 7.6B). These 
















                                
Figure 7.6  TNF-α potentiates the inhibition of FGF-2- or serum-induced PlGF release in 
ECs. [A] HUVEC were plated at a density of 1.5x105 per well in 1% gelatin pre-coated 24 
well plate. Cells were stimulated with FGF-2 [10 ng/ml] or TNF-α [10 ng/ml] or both with 
increasing concentrations of TNF-α [0.1, 1, 10, 100 ng/ml] for 24 hours and cell supernatants 
assayed for PlGF.  [B] HUVEC stimulated with increasing concentration of serum in the 
presence of TNF-α [10 ng/ml], for 24 hours. Cell supernatants collected and assayed for 
PlGF. Data are mean [±SEM] of three separate experiments performed in duplicate.  * 
P<0.05 compared to Control [UN], ‡ P< 0.005 compared to FGF-2, § P< 0.01 compared to 
the preceding serum concentration. P<0.0001 between all the groups by one way Anova non-









































































7.2.5 Endothelial cellular functions impaired in TNF- α treated cells 
Growth factor and cytokine release induced due to oxidative/sheer stress has been reported by 
several studies in human and animal models in pathologies, namely tissue ischemia, coronary 
occlusion and placental insufficiency-intrauterine growth restriction [PI-IUGR] (Regnault, 
Orbus et al. 2002, Werner, Jandt et al. 2004, Gigante, Morlino et al. 2006). PlGF has been 
reported to be a significant factor in regulating the angiogenic switch in a variety of 
pathological states (De Falco, Gigante et al. 2002). Based on the new findings of stress 
induced PlGF levels in ECs and the possible role of PlGF in endothelial survival mechanisms, 
we further investigated the effect of TNF-α on PlGF expression and it‟s effect on cellular 
functions in ECs.  
7.2.5.1 TNF-α inhibits in vitro tube formation. 
To further investigate whether TNF-α inhibition on FGF-2-induced PlGF protein release 
limits angiogenesis, in vitro tube formation was studied in HUVEC. Cells were plated on 
growth factor-reduced Matrigel, in the presence of TNF-α or FGF-2 or FGF-2/ TNF-α. 
Quantitative analysis showed a significant increase in the total tube length, by about two-fold, 
when cells were stimulated with FGF-2 (Figure 7.7) [176.6 ± 9.867 µm/field, p<0.001, n=4].  
A significant reduction in the total tube length [74.20 ± 5.171 µm/field, p<0.003 n=4] in the 
presence of TNF-α was observed as compared to the control (Figure7.7). TNF-α blocked 
60 % of FGF-2-induced tube formation, and exogenous addition of FGF-2 in the presence of 
TNF-α restored tube formation by about 75% percent [133.4 ± 13.46 µm/field, p<0.03 n=4], 
compared to the total tube length in the presence of TNF-α (Figure 7.7). A graphical 
representation (Figure 7.7B) of the tube formation is shown in Figure 7.7A has been 
illustrated. These studies clearly demonstrated the inhibitory effect of TNF-α on endothelial 




















Figure 7.7  FGF-2 restores TNF-α suppressed in vitro tube formation. [A] HUVEC seeded 
at a density of 6x104 per well of a 24 well plate, pre-coated with growth-factor reduced 
matrigel. Cells were stimulated with TNF-α, or FGF-2 or TNF-α/FGF-2 at 10 ng/ml. Cells 
were observed at six hours after stimulation and results were recorded with a digital system. 
[B] Graphic representation of quantitative analysis of tube formation in figure 6.7A.  Data 
are expressed as the mean ±SEM of two independent experiments. Statistical comparison was 
performed using t-test* P>0.01, ** P>0.001 vs. compared to vehicle. 
  
             






7.2.5.2 Ability of PlGF to rescue TNF-α inhibited in vitro tube formation. 
PlGF restored anti-VEGF-A inhibited capillary morphogenesis in ECs (Kanda, Miyata et al. 
2004). We further investigated the role of PlGF to restore the endothelial capillary-like tube 
network inhibited by TNF-α in ECs. HUVEC were plated on growth factor-reduced Matrigel, 
in the presence of TNF-α or PlGF or PlGF/TNF-α for 6 hours and capillary-like tube network 
was analysed. The effect of TNF-α on tube formation at 3 hours showed no significant 
difference between the control and the treated cells. This was due to the effect of TNF-α on 
ECs manifested after 4 hours of treatment which was demonstrated in earlier experiments 
(Figure 7.8 A-B).  
Quantitative analysis showed a significant decrease in the total tube length, by about two-fold, 
when cells were treated with TNF-α (Figure 7.8 A-B) [69.56 ± 3.164, µm/field, p<0.006 n=7] 
compared to the control (Figure 7.8 A-B) [110.7 ± 12.12 µm/field, p<0.006, n=7]. Exogenous 
addition of PlGF, in the presence of TNF-α, restored tube formation completely to 100% 
percent [114.9 ± 7.100 µm/field, p<0.7708 n=7], compared to the total tube length in the 
untreated group. A graphical representation (Figure 7.8B) of the tube formation in Figure 
7.8A has been illustrated. These studies clearly demonstrated the inhibition of tube formation 












Figure 7.8  PlGF restores TNF-α suppressed in vitro tube formation. [A] HUVEC were 
seeded at a density of 6x104 per 24 well plate, pre-coated with growth-factor reduced 
matrigel. Cells were stimulated with TNF-α, or PlGF or TNF-α/PlGF. Concentration of TNF-
α 10 ng/ml, PlGF 50 ng/ml. Cells were observed at 6 hours after stimulation and results were 
recorded with a digital system.. [B] Graphic representation of quantitative analysis of tube 
formation in Figure 6.9A.  Data are expressed as the mean ±SEM of two independent 









7.2.5.3 Endogenous PlGF required for restoration of TNF-α-inhibited in vitro tube 
formation. 
Previous work in our laboratory reported the critical requirement of PlGF for long-term 
survival of ECs (Cai, Ahmad et al. 2003). We further investigated to know whether the 
complete restoration of TNF-α inhibited endothelial capillary network required endogenous 
PlGF, by performing PlGF gene knock down studies. PlGF was silenced in HUVEC by a 
siRNA approach. The uninfected and infected cells were plated on growth-factor reduced 
Matrigel in the absence or presence of TNF-α. PlGF silenced cells demonstrated a decrease in 
the total tube length by about 50 percent in the control group [Figure 7.9]. Wild type as well 
as PlGF knock-down cells treated with TNF-α had the same levels of total tube length in vitro 
tube formation decreased by 50 percent (Figure 7.9)  when compared to control non-
transfected cells. This demonstrated that both TNF-α and PlGF gene inactivation manifest 
similar levels of inhibitory effects on in vitro tube formation in ECs. Exogenous addition of 
PlGF in the presence of TNF-α to both uninfected and PlGF silenced cells had a diametrical 
effect (Figure 7.9). Addition of PlGF to TNF-α treated wild type completely rescued the TNF-
α inhibited tube formation, however this was not the case in PlGF silenced cells. Due to the 
complexity of the experimental readings total tube length measures have not been provided. 
However, a graphical representation (Figure 7.9B) of the tube formation in figure 7.9A has 
been illustrated. This clearly ascertains the fundamental requirement of endogenous PlGF for 
in vitro endothelial tube formation. 
  

















   
 
 
Figure 7.9 PlGF knock-down suppressed in vitro tube formation. [A] HUVEC seeded at a 
density of 6x104 per 24 well plate, pre-coated with growth-factor reduced matrigel. Cells 
transfected by non-specific control [control siRNA] or PlGF siRNA were stimulated with 
TNF-α, or PlGF or TNF-α/PlGF. Concentration of TNF-α-10 ng/ml, PlGF 50 ng/ml. Cells 
were observed at six hours after stimulation and results were recorded with a digital system.. 
[B] Graphic representation of quantitative analysis of tube formation in figure 6.10A. Data 
are expressed as the mean ±SEM of two independent experiments. Data are expressed as the 
mean ±SEM of two independent experiments. Statistical comparison was performed using t-
test* P>0.05 compared to vehicle. 
    
 





7.2.6 PlGF gene inactivation induced apoptosis in ECs. 
Apoptosis can be initiated by a wide variety of extrinsic signals such as cytokines, hormones, 
oxidized lipids or viral agents (Haunstetter and Izumo 1998). The direct effect of PlGF on the 
survival of tumour ECs and macrophages was mediated by the up-regulation of antiapoptotic 
gene, survivin, reported in mouse model (Adini, Kornaga et al. 2002).  Furthermore, 
Carmeliet and group demonstrated that murine anti-PlGF monoclonal antibody induced EC 
apoptosis in tumour models (Fischer, Jonckx et al. 2007). In order to study the role of PlGF in 
human EC survival, HUVEC were transfected with a control siRNA or PlGF siRNA. Cells 
were rested for 5-6 hours and were plated at a density of 1 x 10
5
 cells per well of a two well 
microscope chamber slide and incubated overnight. Cells were then treated with 0.2%  BSA 
or 20% FBS for 6 hours and analysed for apotosis. Apoptotic index was measured utilising 
the TUNEL assay by the detection of apoptotic nuclei, post fixation of the cells. The nuclei of 
viable cells were stained by DAPI (Figure 7.10A). The TUNEL positive cells incorporate 
fluorescein-labelled nucleotides into the 30-OH overhangs of DNA fragments, allowing the 
nuclei to be visualized in a green colour with the aid of a fluorescence microscope, to detect 
DNA fragmentation at a single-cell level (Figure 7.10A). A significant increase by about two-
fold in the percentage of TUNEL positive cells was observed in PlGF gene inactivated cells 
when compared to control siRNA [P<0.01]. Higher concentrations of serum supplemented 
[20% FBS] to the PlGF inactivated HUVEC could not prevent the occurrence of cell 
apoptosis, demonstrating the crucial requirement of PlGF for the survival of ECs. The 
percentage difference in TUNEL positive cells between the 0.2% BSA and 20% FBS treated 
PlGF gene silenced cells was approximately 10 %. In order to further analyse the conditions 
that affected PlGF gene knock-down in ECs, experiments were performed in the presence of 
20% FBS, to demonstrate the role of PlGF on EC survival at higher serum concentrations. 



















Figure 7.10 Apoptotic index in quantified in PlGF gene silenced cells. HUVECs were plated 
at a density of 1x105 on a poly-l-lysine-coated two-well microscope chamber slides treated 
for 6 hours with 0.2% BSA or 20% FBS. Cells were subjected to the DeadEnd™ Fluorometric 
TUNEL System involving labelling of DNA fragments at single-cell level with fluorescein-12-
dUTP for 60 minutes. Samples were analysed using a fluorescence microscope. [B] 
Graphical representation of A. *P<0.05 vs. Control siRNA. 
 
 





7.2.7 Loss of PlGF induced time dependent EC apoptosis 
We further studied the time-dependent apoptotic effect induced by the knock-down of PlGF 
gene. HUVEC were transfected with a vehicle or PlGF siRNA at a density of 1x 10
5
 cells per 
well of a two well microscope chamber slide with 20% FBS for 6 or 12 hours and analysed 
for apotosis. A significant increase in the percentage of TUNEL positive cells of about 2 fold 
at 6 hours and 3 fold at 12 hours of incubation times was observed in PlGF gene inactivated 
cells when compared to the control [P<0.01] (Figure 7.11). A bar graph representation of the 
experiment result demonstrates the percentage of TUNEL positive cells at both the time 
points of 6 and 12 hours, in vehicle or PlGF inactivated cells. Although the number of cells 
positive for TUNEL assay were more in the 12 hour compared to 6 hours in PlGF silenced 
cells, the difference was not significant. The experiment could not look at subsequent time 
points, due to the low number of attached cells beyond 12 hours.   
  

















Figure 7.11 Time dependent apoptotic index in PlGF gene silenced cells. HUVECs were 
plated at a density of 1x105 on a poly-l-lysine-coated two-well microscope chamber slides 
treated were incubated for 6 or 12 hours in 20% FBS containing growth medium. Cells were 
subjected to the DeadEnd™ Fluorometric TUNEL System involving labelling of DNA 
fragments at single-cell level with fluorescein-12-dUTP for 60 minutes. Samples were 
analysed using a fluorescence microscope. [B] A graphical representation of Dapi and Tunel 










7.2.8 Exogenous addition of growth factors does not rescue PlGF gene 
inactivation induced apoptosis 
To determine whether exogenous addition of growth factors reverse effect on the induced 
apoptosis on PlGF gene inactivated cells, HUVEC were transfected with a  control siRNA  or 
PlGF siRNA. PlGF gene inactivated cells were supplemented with PlGF (50 ng/ml) or VEGF 
(20 ng/ml) or PlGF/VEGF and analysed for apoptosis by TUNEL assay. Interestingly, 
exogenous addition of these growth factors had no effect on apoptosis induced by the knock 
down of PlGF gene (Figure 7.12), thus demonstrating that endogenous PlGF critical for EC 
survival.  
  






















Figure 7.12  Effect of exogenous angiogenic factors on apoptotic index in PlGF gene 
silenced cells. HUVECs were plated at a density of 1x105 on a poly-l-lysine-coated two-well 
microscope chamber slides treated with growth factors; PlGF (50 ng/ml) or VEGF (10 ng/ml) 
or VEGF+PlGF (10 + 50 ng/ml) for 6 hours in  20% FBS containing cell culture medium. 
Cells were subjected to the DeadEnd™ Fluorometric TUNEL System involving labelling of 
DNA fragments at single-cell level with fluorescein-12-dUTP for 60 minutes. Samples were 









7.2.9 Th1 type Pro-inflammatory cytokines regulate PlGF expression in a 
concentration-dependent manner in microvascular ECS 
To investigate the concentration-dependent effect of the pro-inflammatory cytokines on the 
levels of PlGF release from Human dermal microvascular endothelial cells (HDMEC), cells 
were treated with increasing concentrations of TNF-α, IL-1β or INFγ for 24 hours. PlGF was 
quantified in cell-conditioned medium by ELISA. All three cytokine types significantly 
suppressed the levels of PlGF compared to untreated cell medium; however, not all the 
cytokines showed a concentration-dependent effect. TNF-α had no effect on PlGF levels at 
concentrations up to 1 ng/ml. A concentration-dependent decrease in the PlGF protein levels 
was observed from 10 ng/ml and higher concentrations (Figure 7.13 A). INFγ significantly 
suppressed PlGF release at 0.1 ng/ml. Higher concentrations of INFγ [10, 100 ng/ml] had no 
further effect on PlGF levels (Figure 7.13 B). IL-1β [1, 10 ng/ml] had a dramatic decrease in 
endothelial PlGF protein release. A concentration-dependent decrease in the levels of PlGF 
was observed beyond 10 ng/ml of IL-1β (Figure 7.13 C).  
TNF-α  is a potent Th1-type pro-inflammatory cytokine and has been reported to cause direct 
damage to ECs, increase  EC permeability, up-regulate endothelial adhesion molecules 
[ICAM-1, VCAM-1, E-Selectin] and promote vasoconstriction, all of which are identified in 
the pathogenesis of chronic inflammatory disorders, such as PE (Hunt, Chen et al. 1996). In 
the present study we focused on examining the link between TNF-α on PlGF protein levels in 
ECs. TNF-α concentration at 10 ng/ml was used as a standard concentration for future 
experiments unless stated otherwise. 
 
 





      
 
 
Figure 7.13 Pro-inflammatory cytokines suppress the release of PlGF from ECs. Confluent. 
HDMECs were stimulated with increasing concentrations of [A] TNF-α, [B] INFγ, [C] IL-1β 
or [D] IL-6, IL-10 in 2% FBS containing MCDB131 medium for 24 hours. Conditioned cell 
supernatants were collected and PlGF levels were measured by ELISA. Data are expressed in 
pg/ml of free and bound PlGF and are mean [± SEM] of three or more separate experiment 
performed in triplicates. *P<0.001 vs control [C], ** P< 0.0001 vs C. Part of the data 
provided by Dr.Samir Sissoui. 
 



















































































7.2.10 Reduced endothelial PlGF in response to TNF- α in HMEC-1 
PlGF protein release from HMEC-1 showed similar response to TNF- α as by HUVEC 
(Figure 7.3) and HDMEC (Figure 7.13A). Detailed investigation on HMEC-1 to study the 
kinetics of TNF-α mediated PlGF down-regulation was done.  
 HMEC-1 were treated with TNF-α, cell supernatants were collected at various time points 
and PlGF protein levels assayed by ELISA. Variations in the levels of PlGF release between 
TNF-α treated and untreated cells became apparent after four hours, and were found to be  
significant  (two-fold decrease)  at 8 hours (Figure 7.14 A). PlGF protein levels were 
maximum at 24 hours.  The effect of TNF-α on PlGF mRNA expression in ECs was 
determined by real-time PCR performed on cDNA from HMEC-1 treated with TNF-α for 
various time periods. Consistent with the protein data, PlGF mRNA expression in the 
presence of TNF-α was significantly inhibited (Figure 7.14 B). TNF-α induced a two-fold 
decrease in PlGF mRNA levels at eight hours compared to its control. A decrease in mRNA 
levels was observed at 16 and 24 hours TNF-α treated and respective control as well. To 
confirm that the TNF-α inhibitory effect on PlGF levels was transcriptionally regulated, cells 
were incubated HMEC-1 with actinomycin D, a transcription inhibitor (Sobell 1985) for three 
or six hours in the presence of TNF-α. The data together demonstrated abrogated levels of 
PlGF [Figure 7.14], confirming the requirement of transcription for PlGF release from ECs. 
Collectively, these results show that TNF-α reduced PlGF release from ECs is due to reduced 
de novo protein synthesis. Twenty four hours was taken as an optimal time for subsequent 
experiments unless specified. 






Figure 7.14 TNF-α inhibited PlGF release is transcriptionally regulated. [A] Time-
dependent PlGF protein inhibition from HMEC in response to TNF-[10 ng/ml] stimulation. 
Cells were seeded at a density of 1.5x105 per well of a 24 well plate, serum starved overnight 
and stimulated with TNF-α. Cell supernatants were collected at indicated time points and 
PlGF levels measured by ELISA. [B] TNF-α induced inhibition of PlGF mRNA expression in 
a time-dependent manner. Quantitative real-time PCR performed to analyse PlGF mRNA 
levels in HMEC at 8, 16 and 24 hour stimulation by TNF-α [10 ng/ml]. PlGF mRNA values 
were normalized to β-actin gene expression. [C-D] TNF-α inhibited PlGF release is via de 
novo protein synthesis. HMEC were pre-incubation with actinomycin-D [1 µg/ml] and then 
stimulated with TNF-α [10 ng/ml] for 3 [C] or 6 [D] hours. Data are mean [±SEM] of at 
least three separate experiments performed in duplicate.  [*] P<0.05, compared to the 
control.   


































































































7.2.11 Effect of inflammatory cytokines on PlGF promoter activity in ECs 
To study if the reduced PlGF mRNA expression was due to the loss of PlGF promoter 
activity, 839 bp of the proximal PlGF promoter region was subcloned into pGL3-basic vector 
[pPlGFluc], a luciferase reporter gene. HMEC-1 were transiently transfected with pGL3-basic 
or with pPlGFluc and incubated with TNF-α, IL-1β or IL-6 for 48 hours. The level of 
promoter activity was measured by dual luciferase assay. We have shown earlier that the Th2 
type cytokine IL-6 had no effect on PlGF secretion by ECs (Figure 7.15). Pro-inflammatory 
cytokines TNF- α and IL-1β modulated PlGF promoter activity. A decrease by about 40% in 
the activity of PlGF promoter was observed in the presence of TNF-α or IL-1β (Figure 7.15). 
On the other hand, consistent to the effect of IL-6 on PlGF protein levels, IL-6 had no effect 
on PlGF promoter activity Additionally, IL-6 acted as a negative control in this experiment. 
These results were consistent with the reduction in PlGF mRNA and protein levels in the 





















Figure 7.15 PlGF promoter activity in the presence of cytokines. HMEC-1 were transfected 
with pPlGFluc [839 bp], on 12 well dish and incubated with 10 ng/ml concentration of the 
specific cytokines for 48 h.  Data are mean [±SEM] of two separate experiments performed in 







    
 





7.2.12  Signalling systems involved in TNF-α-induced PlGF protein reduction in 
ECs 
After confirming the response of HMEC-1 is similar to that of primary cultures in response to 
TNF-α, a further investigation into the potential signalling enzymes mediating TNF-α- 
inhibited PlGF release in ECs was undertaken. HMEC-1 were treated with various enzyme 
inhibitors. As mentioned previously, due to the unlimited proliferation capacity, easy 
availability and high working passage numbers, HMEC-1 were used for the signalling studies 
in this chapter. 
7.2.12.1 Signaling mechanism involved in TNF-α inhibited PlGF release by ECs 
TNF-α activates Src tyrosine kinase and, in response, induces Ca
2+
 influx in HUVEC 
(Tiruppathi, Naqvi et al. 2001). To investigate whether Src kinase is involved in TNF- α 
mediated inhibition of PlGF levels in ECs, HMEC were treated with Src kinase inhibitor, 
PP2. Cell supernatants were analysed for PlGF levels, following a 24 hours incubation. PlGF 
levels were significantly reduced under basal conditions and in the presence of TNF-α (Figure 
7.16). This demonstrates that Src kinase is critical for the production of PlGF from ECs. 
  














Figure 7.16  Role of Src tyrosine kinase on PlGF release in the presence of TNF-α. HMEC 
were pre-incubated with PP2 (10 µM), a specific Src kinase inhibitor for 30 minutes prior to 
stimulation with TNF-α (10 ng/ml) for 24 hours. Samples were analysed by ELISA for PlGF 
levels. Data are expressed as means ± SEM of measurements of 4 independent experiments 
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TNF-α-induced apoptosis (Wang, Liu et al. 2009) and VCAM-1 (Nizamutdinova, Jeong et al. 
2008) expression in human vascular endothelial cells (cell line ECV304) and HUVEC 
respectively via regulation of the PKC pathway. To establish whether PKC signalling is 
involved in TNF-α-mediated inhibition of PlGF levels, a pharmacological approach to inhibit 
PKC was used. HMEC were treated with PKC inhibitor, Go6976. Cell supernatants were 
analysed for PlGF levels, following a 24 hour incubation. PlGF levels were significantly 
reduced under basal conditions. In contrast, after treatment with Go6976, an increase by 25 
percent in the levels of PlGF in the presence of TNF-α was observed (Figure 7.17). This 
demonstrates that PKC is involved in basal secretion of PlGF from ECs and that Go6976 
partially rescued PlGF levels that were decreased in the presence of TNF-α. 
 
 
Figure 7.17 PKC inhibitor blocks the inhibition of PlGF release in presence of TNF-α. 
HMEC were serum deprived overnight incubated with PKC inhibitor Gö6976 (1 µM) 30 
minutes prior to addition of TNF-α (10 ng/ml). Cell supernatants were collected following 24 
hour incubation and analysed for PlGF by ELISA. Data are expressed as means ± SEM of 

























TNF-α-induced down regulation of surface molecules in HUVEC was reported to be 
independent of MEK and p38 MAPK pathways in HUVEC (Kalsi, Lawson et al. 2002). To 
investigate whether TNF-α-mediated decreased level of PlGF from ECs followed this 
mechanism, HMEC were treated with by PD98059, a MEK-1 inhibitor and p38 inhibitor SB 
203580. Cell supernatants were analysed for PlGF levels post incubation of 24 hours. PlGF 
levels were not affected by MEK-1 (Figure 7.18 A) and p38 (Figure 7.18B) inhibitors in the 
presence of TNF-α, demonstrating that the MAPK kinase pathways are not involved in TNF-α 

















                                
 
   
Figure 7.18 MAPK pathway is not involved in TNF-α inhibited PlGF release. Effect of 
MEK inhibitor on TNF-α treated PlGF release. HMEC were serum-deprived overnight 
incubated with MEK1 inhibitor (A) PD98059 (20 µM) or with (B) SB203580 (20 µM), p38 
MAP kinase inhibitor, 45 minutes prior to addition of stimulant, TNF-α (10 ng/ml). Cell 
supernatants collected following 24 hour incubation were analysed for PlGF by ELISA. Data 














































JNK (Jun N-terminal Kinase), also known as Stress Activated Protein Kinase (SAPK), 
belongs to the family of MAP kinases (Weston and Davis 2002), and has been reported to be 
involved in TNF-α activation in ECs (Garin, Abe et al. 2007, Lin, Chen et al. 2007). To 
confirm whether JNK kinase plays a role in TNF-α-mediated PlGF release, HMEC were 
treated with JNK inhibitor SP600125. PlGF levels under the basal conditions and in the 
presence of TNF-α were not affected (Figure 7.19), indicating that JNK kinase is not involved 
in PlGF release from ECs. 
 
                    
Figure 7.19- JNK kinase does not regulate TNF-α-mediated PlGF release. HMEC were pre 
incubated with SP600125 or control inhibitor at 10 µM for 30 minutes, prior to stimulation 
























                                                         
 
Nuclear factor-kappa B (NF-κB) mobilisation is a well-established transcription factor 
involved in transcriptional activation of TNF gene (Shames, Selzman et al. 1999).  NF-κB is 
sequestered in the cytoplasm by inhibitory proteins IκB, and subsequent phosphorylation by 
a cellular kinase leads to degradation and translocation of NF-κB to the nucleus (Schreiber 
1999). NF-κB activation by TNF antagonizes the TNF cytotoxicity (Xu, Bialik et al. 1998, 
Sumitomo, Tachibana et al. 1999). HMEC were treated with isohelenin, an inhibitor of the 
pro-inflammatory transcription factor NF-κB (Mazor, Menendez et al. 2000) in the presence 
of TNF-α and analysed for PlGF levels. Isohelenin induced a significant decrease in the PlGF 
levels under basal conditions; however, isohelenin had no effect in the presence of TNF-α 
(Figure 7.20). This indicated that the NF- κB is essential for the release of PlGF from ECs, 





Figure 7.20 TNF-α-mediated PlGF release independent of NF-κB pathway. HMEC were 
pre incubated with Isohelenin at 10 µM for 30 minutes, prior to stimulattion with TNF-α (10 
ng/ml) for 24 hours. Samples were analysed by ELISA for PlGF levels.  ***P<0.0001 
compared to the untreated. 
  






The prominent findings of the present study: 1. we demonstrate for the first time the direct 
evidence of TNF-α-suppressed endothelial PlGF expression, by combining the results from 
protein and mRNA analysis, complemented with reduced PlGF promoter activity. 2. TNF-α 
partially antagonises growth factor-induced endothelial PlGF. 3. TNF-α inhibited tube 
formation is partially/completely rescued by exogenous angiogenic growth factors. 4. Loss of 
PlGF function induced EC apoptosis could not be rescued by exogenous angiogenic growth 
factors. 5. The signalling pathways downstream of TNF/TNFR activation that lead to 
suppression of PlGF release seem to involve PKC. Our data establish a potential link between 
TNF-α effect on PlGF in ECs, which perhaps is one of the factors setting the stage for 
endothelial dysfunction.  
In this study, 24 hour exposure of ECs to TNF-α (10 ng/ml) significantly suppressed PlGF 
levels, compared to the control. This inhibition of PlGF levels was observed in primary micro 
(HDMEC) and macro (HUVEC) vascular ECs and cell line (HMEC-1). In PE, circulating 
levels of PlGF are reported to be dramatically reduced (Polliotti, Fry et al. 2003) and it has 
been associated with inflammation. Increased circulating levels of TNF-α and its receptor 
(sTNF-rI) are detected in PE and correlate with disease severity (Schipper, Bolte et al. 2005). 
On the other hand, PlGF deficiency resulted in a diminished and abbreviated inflammatory 
response (Cianfarani, Zambruno et al. 2006). Modulation of PlGF as a therapeutic target may 
therefore be beneficial for inflammatory diseases such as psoriasis, RA or tumour 
angiogenesis (Dubey, Jackson et al. 1997, Bottomley, Webb et al. 2000, Dubeyl, Rosselli et 
al. 2000, Carmeliet, Moons et al. 2001, Gigante, Morlino et al. 2006, Fischer, Jonckx et al. 
2007, Yoo, Yoon et al. 2009). 





In contrast to ECs, SMCs had elevated PlGF levels in response to TNF-α. Imbalance between 
“SMC/EC activators” and “SMC/EC inhibitors” has been suggested to be associated with 
occlusive disorders such as PE (Dubey, Jackson et al. 1997, Dubeyl, Rosselli et al. 2000). 
Though our observed findings are potentially limited by several considerations,  the results so 
far are tempting to hypothesise that the differential effect of TNF-α on PlGF levels, 
endothelial PlGF and SMC secreted PlGF could be a contributing factor associating PlGF to 
occlusion disorders, such as PE and atherosclerosis, characterised by EC dysfunction/damage, 
and SMC proliferation/migration (Dubey, Jackson et al. 1997, Dubeyl, Rosselli et al. 2000, 
Libby, Ridker et al. 2002, Dewerchin and Carmeliet 2012). Moreover, TNF-α concentration is 
observed to be abnormally high in such diseases, particularly in atherosclerosis when 
compared to other inflammatory disorders (Lee, Zaske et al. 2011).  TNF-α has a central role 
in EC apoptosis, and is linked to endothelial dysfunction resulting in SVD as a common 
denominator of several disorders (McKellar, McCarey et al. 2009, Lee, Zaske et al. 2011, 
Kumar 2012).  
We further demonstrate that IL-1β and INFγ also suppress PlGF levels in ECs. Similar to 
TNF-α, IL-1 (Figure 7.13) plays a distinct role in inflammatory mediated EC dysfunction 
(Barbieri, Zacchi et al. 2011). TNF-α and IL-1β exposure for even a short period of 1 hour 
was reported to impair endothelial function in hand veins of healthy subjects (Review) 
(Huang and Vita 2006). We observed that IL-6 and IL-10 have no effect on endothelial PlGF. 
IL-10 exerts a protective role (Mallat, Besnard et al. 1999) manifesting its anti-inflammatory 
effects on the vascular system through inhibition of leukocyte-EC interactions (Sprague and 
Khalil 2009), in addition to inhibition of pro-inflammatory cytokine and chemokine 
production by macrophages and lymphocytes as well (Sprague and Khalil 2009). TNF-α and 
IL-1β, with overlapping properties in the inflammatory process of acute and chronic 





inflammation showed a significant reduction in PlGF promoter activity; by contrast IL-6 had 
no effect what so ever. The effects of these cytokines on PlGF promoter activity were in line 
with their response on PlGF protein levels secreted by ECs. Further investigation is needed to 
focus in on the transcription factors regulating PlGF expression and characterization of the 
specific regions of the promoter responsible for down regulation of PlGF activity, when in the 
presence of the pro-inflammatory Th1 cytokines. This knowledge would further be 
transferable to study the causality factors of acute or chronic inflammatory mediated 
endothelial dysfunction. The present findings so far suggest that pro-inflammatory cytokines 
significantly suppressed endothelial PlGF secretion in vitro and this inhibition is 
transcriptionally regulated. Henceforth, we believe that this data revolutionises our 
understanding of inflammatory mediated effects on endothelial disruption to target disease 
specific angiogenesis. 
Although we were greatly tempted to examine further the effect of these inflammatory 
cytokines on PlGF levels in the interactions between ECs and SMCs, due to practical reasons, 
such as, limitations in resources and not to detract from our intentions to extensively study 
endothelial PlGF, we stepped progressively towards TNF-α regulation and its effects on PlGF 
in ECs alone. 
Anti-TNF-α therapy improved high density lipoprotein (HDL) cholesterol levels, as well as 
micro and macro vascular function in RA patients (Dimitroulas, Sandoo et al. 2012, Sandoo, 
van Zanten et al. 2012). TNF-α is anti-angiogenic (Sato, Fukuda et al. 1987), perhaps due to 
its inhibitory effects on eNOS protein expression. TNF-α is reported to suppress eNOS 
promoter activity and destabilised eNOS mRNA as well (Reviews) (Neumann, Gertzberg et 
al. 2004, Steyers and Miller 2014). NO reduction is considered to be the hallmark of 
endothelial dysfunction (Davignon and Ganz 2004, Zhang, Park et al. 2009, Steyers and 





Miller 2014), a common factor in several inflammatory disorders. The observed association of 
functional effect of TNF-α on NO availability and endothelial dysfunction has been 
established in pre-clinical and human models (Steyers and Miller 2014). NO release in 
HUVECs in response to PlGF (previous work from our lab) (Bussolati, Dunk et al. 2001), and 
the up-regulation of eNOS expression by FGF-2 (Mata-Greenwood, Liao et al. 2008), has 
prompted us to investigate the anti-angiogenic effect of TNF-α in response to these growth 
factors.  
Growth factor-induced PlGF levels were suppressed by TNF-α. TNF-α significantly 
suppressed serum- or FGF-2-induced PlGF levels, exhibiting the strong antagonist effect of 
TNF-α towards endothelial PlGF. Interestingly, TNF-α inhibited tube formation was partially 
rescued by exogenous FGF-2 and completely rescued by exogenous PlGF (Figures 7.7, 7.8). 
Furthermore, loss of function experiments with PlGF gene silenced ECs subjected to in vitro 
tube formation demonstrated truncated response. PlGF siRNA cells (untreated cells, or treated 
with TNF-α or TNF-α + PlGF) displayed reduced capillary network that matched to TNF-α 
inhibited capillary network in non-specific control siRNA group (Figure 7.9). Although TNF-
α-inhibited tube formation in the control group ECs (control siRNA) were salvaged when 
supplemented with exogenous PlGF, understandably PlGF silenced ECs could not be 
redeemed (Figure 7.9). These findings ascertain the critical role of PlGF for EC tube 
formation, and that the effect of total rescue manifested by PlGF on TNF-α-attenuated tube 
formation is a solitary contribution by PlGF alone. 
Unlike, VEGF, studies conducted earlier in our laboratory established PlGF sustained 
angiogenesis and survival of ECs by up-regulation of anti-apoptotic protein bcl-2 expression 
(Cai, Ahmad et al. 2003). Furthermore, Carmeliet and group demonstrated that murine anti-
PlGF monoclonal antibody induced EC apoptosis in tumour models (Fischer, Jonckx et al. 





2007). Mice have only one PlGF gene, when compared to humans that have two forms; PlGF-
1 and PlGF-2 differ in the ability to bind to neuropilin. Based on previous evidence and our 
current observations, we hypothesised that the dramatic reduction in capillary network 
demonstrated by PlGF gene silenced cells perhaps was due to EC apoptosis. Testing our 
hypothesis by loss of function experiments, TUNEL assay established this to be true. EC 
apoptosis is reported to be one of the factors contributing to endothelial dysfunction (Asai, 
Kudej et al. 2000, Tricot, Mallat et al. 2000); a leading cause in several pro- or anti-
angiogenic inflammatory disorders (Lee, Zaske et al. 2011, Kumar 2012, Steyers and Miller 
2014). PlGF is expressed by migrating keratinocytes and ECs, acting in a paracrine and 
autocrine fashion on VEGFR-1-expressing endothelium (Failla, Odorisio et al. 2000). Lack of 
PlGF resulted in delayed wound closure, indicating that it is required for optimal skin repair 
(Carmeliet, Moons et al. 2001). Over expression of this growth factor accelerated wound 
closure in diabetic mice (Cianfarani, Zambruno et al. 2006). In the TUNEL assay PlGF gene 
silenced cells demonstrated an increase in apoptosis rate in low serum conditions and in 
prolonged incubation time (12 hours). Exogenous supplementation of potent growth factors, 
such as, PlGF or VEGF or PlGF and VEGF together, did not rescue cell apoptosis in PlGF 
inactive cells, even when cells were grown in high serum concentration (20% FBS) contained 
endothelial growth medium.  The important finding that potent angiogenic factor VEGF, 
known for its survival feature being unable to rescue loss of PlGF-induced EC apoptosis, is 
perhaps due to the combined effects of PlGF being unavailable and the presence of sVEGFR-
1, a negative regulator of endothelial function. In 2011, our group made a vital contribution 
that unlike PlGF, VEGF-A stimulation of HUVEC increased sVEGFR-1 secretory protein and 
mRNA levels into the culture medium (Ahmad, Hewett et al. 2011). Pre-incubation of 
HUVEC with VEGFR-2 selective inhibitor SU1498, blocked the VEGF-A induced sVEGFR-





1 release (Ahmad, Hewett et al. 2011).  Additionally, recent work by Dr Sissaoui 
demonstrated an increase in PlGF release in response to VEGFR-1 knockdown suggesting a 
possible autocrine loop regulating PlGF and VEGFR-1 expression. Inactivation of PlGF gene 
therefore may have compound effect on endothelial function. It is difficult to explain the 
distinct contributions of VEGFR-1 and R2 with the current results, highlighting the need to 
study in detail how these receptors specifically contribute to PlGF induced endothelial 
apoptosis and subsequently endothelial dysfunction. 
Several lines of evidence have demonstrated the critical role of endothelial apoptosis leading 
to endothelial dysfunction being linked to a growing list of inflammatory disorders (Asai, 
Kudej et al. 2000, Tricot, Mallat et al. 2000). Tricot and group examined EC apoptosis by 
terminal dUTP nick end-labelling and ligase assay in  the luminal endothelium of 42 human 
carotid atherosclerotic plaques retrieved by endarterectomy (Tricot, Mallat et al. 2000). A 
systematic preferential occurrence of apoptosis was observed in the downstream parts of 
plaques, where low flow and low shear stress prevailed when equated to the upstream parts 
(Tricot, Mallat et al. 2000). Suggesting that local stress in vivo influences EC apoptosis 
conceivably postulates this as a major determinant of plaque erosion and thrombosis, as well 
as a possible link between EC apoptosis to human atherosclerosis and its relation to blood 
flow (Tricot, Mallat et al. 2000). It would have been interesting to measure the levels of PlGF 
and pro-inflammatory cytokines, in particular, TNF-α. IL-1β and INFγ that suppress 
endothelial PlGF (present study), to examine if a link persisted between these inflammatory 
and angiogenic mediators on EC apoptosis and subsequent EC dysfunction in such disorders. 
 
Obstructive sleep apnoea (OSA) has been linked to cardiovascular and cerebrovascular 
morbidity and mortality (El Solh, Akinnusi et al. 2007). Individuals with OSA have increased 





propensity for of 4.6 and 8-fold higher risk for coronary artery disease (Peker, Carlson et al. 
2006) and stroke (Palomaki 1991) respectively. Patients with OSA have high numbers of 
circulating apoptotic ECs correlated to abnormal vascular function (El Solh, Akinnusi et al. 
2007). Several factors, including increased oxidative stress with lowered antioxidant capacity, 
reduced endothelial NO production, activated inflammation, and increased EC apoptosis 
combine to contribute to unfavourable cardiovascular effects of OSA that may result in 
endothelial dysfunction and unstable plaque formation (Nakashima, Henmi et al. 2013). 
Moreover, in children with OSA syndrome (OSAS) an association between endothelial 
dysfunction and neurophysiological deficits has been established (Gozal, Kheirandish-Gozal 
et al. 2010), which compels future research to focus in further detail on inflammatory 
mediated EC apoptosis and endothelial dysfunction. 
 
An attempt was made to delineate the underlying signalling molecules governing TNF-α-
suppressed PlGF levels secreted by ECs using pharmacological inhibitors for specific 
signalling molecules. However, we could not find any known signalling enzymes that could 
overcome the inhibitory effect of TNF-α on PlGF production. Major signalling molecules 
such as, NF-κB, Src kinase, PKC, MAPK and JNK were examined in this process. 
As illustrated in this study, EC apoptosis induced by loss of PlGF, due direct or indirect effect 
of TNF-α presence we think perhaps this is the leading cause of endothelial dysfunction. 
Endothelial dysfunction is a central causality factor for several acute and chronic 
inflammatory disorders that have raised risk of CVD. Plasma levels of multimeric 
glycoprotein von Willebrand factor (VWF), produced by ECs (Hollestelle, Thinnes et al. 
2001) and a well characterised marker of stroke, vascular events, CVD (Review) (Spiel, 
Gilbert et al. 2008), are raised in different states of endothelial damage. Blockade of NO 





enhances release of VWF in humans and is useful marker of endothelial dysfunction (Review) 
(Spiel, Gilbert et al. 2008). Study of endothelial dysfunction in PlGF loss of function 
experiments by analysing VWF on PlGF siRNA EC/SMC functions, such as angiogenic 
assays, TUNEL or flow cytometry assays in vitro and in vivo PlGF KO disease models would 
identify whether the differential effect of TNF-α on PlGF secretion by ECs and/or SMCs that 
is more robust subsequently results to endothelial dysfunction perhaps the causality factor 
occlusive disorders, such as atherosclerosis.  
 
In summary, we believe that the current results demonstrate a potential link between TNF-α, 
IL-1β (cytokines mainly involved in leading to systemic pathological effects in chronic 
inflammation) and PlGF. Loss of PlGF induced EC apoptosis perhaps may be the causality 
factor in endothelial dysfunction, a common causality factor of several inflammatory 
disorders. 
 
The interplay between inflammation and angiogenesis is a mine field. However, we would 
like to believe that this data would enable and contribute towards our understanding of the 
several complex interactions between chronic inflammation and angiogenesis aiming to 
achieve more effective therapies.  






Figure 7.21 Loss of PlGF: An intermediary factor in the process of local Inflammation to 
systemic endothelial dysfunction. (1). Known Pathway – TNF-α has a central role in EC 
apoptosis, linked to endothelial dysfunction resulting in SVD in several disorders [17, 22, 
27]. Abnormal high levels of pro-inflammatory cytokines, TNF-α, IL1-β leads to several 
metabolic derangements, such as ROS, lipid abnormalities, decrease in bioavailability of NO, 
which sets the stage for EC apoptosis. EC apoptosis is reported to be one of the factors 
contributing to endothelial dysfunction [78, 79]. (2). Identified pathway - TNF-α, IL1-β 
inhibit PlGF via a transcriptional regulation mechanism. Loss of PlGF induced EC apoptosis 
(Present study). 
 












Chapter 8  General Discussion and future 
work 
  





In this thesis I identify the functional link between the regulation of endothelial PlGF 
expression in response to potent angiogenic factor FGF-2, and the inflammatory cytokine 
TNF-α. The effects of these interplays between angiogenic factors and cytokines in PlGF-
mediated angiogenesis and EC functions were examined in this study. Establishing the 
signalling pathways governing the regulatory mechanisms in PlGF secretion under the 
influence of FGF-2 and TNF-α could provide cues to compare the significant and temporal 
dynamic variances that might exist; for example, differential regulatory mechanisms in VEGF 
or FGF-2 induced PlGF in ECs and its effects on EC functions. My data would have major 
implications to further the understanding of the role of endothelial PlGF in dysregulation 
underlying inflammatory disorders of acute and chronic in nature, and subsequently the scope 
to improve therapeutic angiogenesis.  
Effects of various stimuli on endothelial PlGF regulation and EC functions.   
The molecular mechanisms and factors that lead to neovascularisation processes, angiogenesis 
and/or arteriogenesis, are diverse. However, blood vessel growth is accepted to be solely 
dependent on the function of ECs (Carmeliet 2000, M 2011). Being the interface between 
blood and tissue, ECs remain the main regulator of vascular homeostasis. Combined data 
from our observations in line with previous reports (Yonekura, Sakurai et al. 1999, Fischer, 
Jonckx et al. 2007, Dewerchin and Carmeliet 2012, Kim, Cho et al. 2012) demonstrate ECs to 
be an important source of PlGF. PlGF is redundant in normal physiology. However, it is 
identified as a key mediator and disease modifying agent for its predominant role in the 
angiogenic and inflammatory switch in several pathologies (Carmeliet 2000, Chen, Hsieh et 
al. 2004, Cianfarani, Zambruno et al. 2006, Dewerchin and Carmeliet 2012). A series of 




studies highlighted the role of PlGF in multiple pathologies, including tissue ischemia, cancer 
and inflammation (Dewerchin and Carmeliet 2012). PlGF had beneficial or harmful effects 
basing on the stage of disease progression.  
FGF-2-treated ECs amplified PlGF expression at both protein and mRNA levels (Current 
study), unlike PlGF production in response to VEGF that followed a post-transcriptional 
mechanism (Yao, Yang et al. 2005). It is also noteworthy that VEGF (25 ng/ml) amplified 
PlGF protein levels (Yao, Yang et al. 2005) at a higher concentration than FGF-2 (10 ng/ml)-
mediated PlGF expression in HUVECs. Also, the concentration of VEGF (100 ng/ml) used to 
characterise the signalling pathways involved in VEGF-mediated PlGF secretion (Yao, Yang 
et al. 2005) being ten times greater than FGF-2 (10 ng/ml). Differential effects of FGF-2 and 
VEGF on PlGF secretion in ECs existed (Table 8.1)  
Unlike VEGF, PlGF (Carmeliet, Moons et al. 2001, Luttun, Tjwa et al. 2002, Iwama, Uemura 
et al. 2006, Kolakowski, Berry et al. 2006) and FGF-2 (Unger, Banai et al. 1994, Laham, 
Chronos et al. 2000, Lazarous, Unger et al. 2000, Coenegrachts, Maes et al. 2010, Wu, Wu et 
al. 2010, Schmidt, Kharabi Masouleh et al. 2011) reported to be both pro-angiogenic and pro-
arteriogenic without any deleterious side effects, such as tumour growth  or heart, limb and 
ocular ischemia (Carmeliet and Conway 2001, Luttun, Brusselmans et al. 2002, Pipp, Heil et 
al. 2003, Rakic, Lambert et al. 2003, Dewerchin and Carmeliet 2012). Both FGF-2 and PlGF 
have been used as therapeutic agents in clinical trials to stimulate revascularization for the 
treatment of chronic ischemic conditions (Losordo, Vale et al. 1998, Laham, Sellke et al. 
1999, Ruel, Laham et al. 2002, Simons, Annex et al. 2002) (Tables 1.2 -1.3). 





Table 8.1 Differential regulation of FGF-2 and VEGF-induced PlGF levels in ECs 
 
In contrast, when VEGF was administered as a therapeutic angiogenic factor it was reported 
to have adverse effects, such as Endothelium-derived relaxing factor (EDRF)-mediated 
hypotension (Hariawala, Horowitz et al. 1996), tachycardia, decreases in cardiac output and 
stroke volume, changes in preload and after-load (Yang, Bunting et al. 2000), a high rate of 
failure to thrive/death and formation of endothelial cell-derived intramural vascular tumours 
in the implantation site (Lee, Springer et al. 2000). These results undermine VEGF as a 
therapeutic agent; in contrast, FGF-2 has been suggested as a safer option with therapeutic 
potential for neovascularisation trials (Laham, Sellke et al. 1999, Laham, Chronos et al. 2000, 
Lederman, Mendelsohn et al. 2002, Simons, Annex et al. 2002). We believe that findings of 
these differential effects in the regulatory mechanisms between VEGF and FGF-2 on PlGF 
levels would contribute to a better understanding of the roles of the growth factors, to 
effectively harness their potential as target therapeutic molecules.   
Research interest has been focused on the potential administration of PlGF and FGF-2 to 
alleviate conditions characterised by insufficient blood supply, such as MI, limb ischaemia 
FGF-2-induced PlGF (Current study) VEGF-2-induced PlGF (Yao. 2005)     
No changes in mRNA levels, post-
transcriptional modification
VEGF concentration used - 100 ng/ml
Partial suppression of VEGF-induced 
PlGF levels in the presence of ERK1/2 
inhibitor 
PKC isoforms involved - PKC-β
Src, Akt had no significant effect
Transcriptionally regulated with mRNA 
amplification
FGF-2 concentration used - 10 ng/ml  
ERK1/2 is completed abrogated FGF-2-
induced PlGF to the basal levels
PKC isoforms involved - PKC α, δ, ε
Src, Akt required for basal and FGF-2 
mediated PlGF secretion




and PVD (Table 1.3). The rationale of this study was to focus on the interaction between 
PlGF and FGF-2, centering on their overlapping beneficial functions and their potential as 
target molecules for neovascularisation therapies (Tables 1.2. 1.3) (Figure 6.1). We 
demonstrate that FGF-2 amplifies PlGF mRNA, yet PlGF up regulation by VEGF is reported 
to be a post-transcriptional modification (Yao, Yang et al. 2005). Up-regulation of PlGF 
mRNA and protein was observed in pathological angiogenesis in several disorders, including 
MI [5], diabetic retinopathy [41], brain tumours [42] and retinal ischaemic disorders [43].  
FGF-2-induced PlGF is mediated via MAPK and multiple isoforms of PKC. VEGF-induced 
PlGF involved PKC-β and partial activation of MAPK (Yao, Yang et al. 2005).  Similarly, in 
animal models, PKC and MAPK signalling cascades have been reported to be vital molecules 
in FGF-2-mediated prevention of ischemia/reperfusion injury (Padua, Sethi et al. 1995, 
Padua, Merle et al. 1998, House, Melhorn et al. 2007). A detailed involvement of PKC 
isoforms, especially PKC-α, β, δ and ε in cellular and pathophysiological conditions has been 
discussed in Chapter 5. We also demonstrated FGF-2 stimulates PLD signalling via PKC 
activation in ECs, independent of PLCγ (Ahmed, Plevin et al. 1994). Elevated PLD activity 
has been reported in several cancer tissues and is implied in tumour cell proliferation and 
survival (Pedrono, Saiag et al. 2007). As PLD is involved in FGF-mediated PlGF, and also 
cancer progression where FGF-2 as well as PlGF contribute to disease progression, the effect 
of inhibiting PLD as a common targeting molecule can be examined in vitro; this is an option 
to explore with future application of this current research. FGF-2 up-regulates VEGF 
expression in ECs through autocrine and paracrine regulation in endothelial and non-ECs 
(Seghezzi, Patel et al. 1998). However, recent work from our laboratory demonstrated VEGF 
to amplify sVEGFR-1 expression by the activation of VEGFR-1 gene promoter (Ahmad, 
Hewett et al. 2011). This link between VEGF and sVEGFR-1 (Ahmad, Hewett et al. 2011) 




raises the question of the role of VEGF in FGF-2 amplified PlGF and the EC functions in the 
current study, as FGF-2 is reported to amplify VEGF expression in ECs (Seghezzi, Patel et al. 
1998).  VEGF detection in a range of untreated ECs was undetectable (Figure 4.2).  
NO produced from eNOS plays an important role during physiological and pathological EC 
functions via regulation of anti-apoptosis, pro-angiogenesis and other mechanisms. eNOS 
-/- 
in 
mice impairs angiogenesis function in vivo [19,20]. FGF2, but not VEGF, stimulated eNOS 
expression in a time- and concentration-dependent manner in four different ovine foeto-
placental artery endothelial (oFPAE) cells (Zheng, Bird et al. 1999). FGF2 and VEGF differ 
greatly in the activation pattern of ERK (Mata-Greenwood, Liao et al. 2008). In oFPAE cells, 
FGF2 stimulated eNOS expression at all doses (1, 10, 100 ng/ml) tested, and this stimulation 
maximised with 10 ng/ml FGF-2 (Mata-Greenwood, Liao et al. 2008). Time course 
experiments in the same study demonstrated a significant increase in eNOS protein at 12 h 
and 24 h, with a maximal effect at 24 h (Mata-Greenwood, Liao et al. 2008). FGF2 provoked 
a sustained phosphorylation (5 min to 12 h), unlike VEGF which only stimulated transient (5 
min) ERK phosphorylation (Mata-Greenwood, Liao et al. 2008). This data of eNOS up-
regulation is in accordance with the kinetics (concentration and time) of FGF-2-induced PlGF 
in the current study. This clearly explains the effects of FGF-2-induced in vitro tube formation 
in ECs. However, in order to demonstrate endogenous PlGF regulation of eNOS, in our 
experimental model, HUVEC with inactivated PlGF or protein/tissue from plgf 
-/-
 mice, are to 
be subjected to detection of NO-eNOS activity by western blotting/ELISA for protein analysis 
or Northern blotting/QPCR to observe changes in mRNA levels. Although ERK is reported to 
mediate the release of NO/eNOS in ECs in response to PlGF (Shen and Chen 2008), FGF-2 
(Mata-Greenwood, Liao et al. 2008) and VEGF (Mata-Greenwood, Liao et al. 2008), 
differential regulation of ERK molecule, at least in FGF-2 and VEGF, was noted. Wherein, 




FGF-2 induced a stronger activation of ERK and sustained activation (up to 12 h), VEGF only 
induced a transient and weak activation (5-10 min) (Mata-Greenwood, Liao et al. 2008). In 
2006, we had demonstrated that VEGFR-1 is the signalling receptor for eNOS activation and 
in vitro tube formation (Ahmad, Hewett et al. 2006). Furthermore, Akt appeared to be the 
common mediator in VEGF-stimulated eNOS activation and in vitro angiogenesis for VEGF 
receptor (VEGFR-1 and VEGFR-2) pathways (Ahmad, Hewett et al. 2006). In the light of 
differential activation of multiple signalling pathways dictating FGF-2 and VEGF mediated 
eNOS phosphorylation (Yao, Yang et al. 2005), to learn if such differential mechanisms 
govern FGF-2 and PlGF induced NO-eNOS awaits confirmation in our experimental setting.  
This could be achieved by treating cultured HUVECs with FGF-2 (1 to 100 ng/ml) for a range 
of time points (up to 24 hours) or pre-treated with signalling inhibitors involved in FGF-2-
induced PlGF expression, such as ERK, PKC, PLD and PI3K.  Assessing for NO 
concentrations in these experimental conditions using Western blotting or QuantiChrom NO 
Assay Kit, would aid in understanding the details of the differential effects of these growth 
factors and their effects in vascular insufficient conditions, such as foetal growth restriction, 
PE or CVD.  We have shown the requirement of PlGF in FGF-2-mediated angiogenesis by in 
vitro tube formation and aortic ring assay models. FGF-2-mediated angiogenesis was 
truncated in aortic ring assay performed with tissue from plgf
-/-
 mice when compared to the 
wild type. The significant findings of this study lead to the proposition of the FGF-2/PlGF 
autocrine and paracrine loops that may regulate the angiogenic switch, and could contribute to 
ameliorate vascular complications in diverse angiogenic conditions including MI. FGF-2 also 
has been shown to induce the up regulation of endothelial VEGF in an autocrine manner 
(Seghezzi, Patel et al. 1998). Besides, systemic overexpression of VEGF-A in mice and 
HUVEC resulted in significantly elevated circulating sVEGFR-1 expression (Ahmad, Hewett 




et al. 2011). These findings raise the question whether the increase in PlGF levels is a direct 
effect of FGF-2, or a secondary effect of FGF-2-induced VEGF on PlGF, or both. If so, the 
inhibition of FGF-2 mediated angiogenesis in the absence of PlGF is the secondary effect of 
VEGF-induced sVEGFR-1, which demands further investigation in our experimental settings. 
It is beyond the scope of this study to extrapolate the explanation in the light of the 
involvement of VEGF.  More signalling and EC functional studies are needed to dissect the 
mechanisms for selectivity amplification of PlGF, by FGF-2 or VEGF, which are currently 
vague, a hypothesis that awaits further confirmation in our cell system. 
Signalling molecules mediating FGF-2-induced PlGF in ECs, PKC, ERK1/2 and PI-3K 
pathways contributed to PlGF up-regulation in ECs and human umbilical artery SMCs 
(HUASMCs) (Pan, Fu et al. 2010) in response to Ang II, establishing a role of PlGF in 
mediating Ang II-induced proliferation in vascular ECs and SMCs (Pan, Fu et al. 2010). 
Angiotensin II (Ang II), a significant contributor to the pathobiology of atherosclerosis and 
vascular disease, is a bi-functional growth factor stimulating proliferative and anti-
proliferative pathways simultaneously (Dimmeler, Rippmann et al. 1997). In ECs, Ang II 
mediates  inhibition of FGF-2-induced EC proliferation via stimulation of its receptor AT2 
(Stoll, Steckelings et al. 1995). This suggests that using these inhibitors to manipulate PlGF 
will, therefore, bring about changes in Ang II-mediated ECs and SMCs functions as well.  
 
 Although common signal transducing molecules mediating EC functions have been 
identified, the major challenge is to segregate one mechanism from another, as these growth 
factors and the pathways governing growth factor regulation could manifest autocrine, 
paracrine or intracrine effects on cellular responses. This could result in unwanted cellular 
responses, such as endothelial dysregulation or dysfunction leading to chronic inflammation. 




In order to effectively harness the potential of these growth factors, an improved 
understanding and identifying the crucial genes activated by the PlGF, FGF-2 and VEGF that 
elicit the signal transduction mediating the complex biological functions of VEGF and FGF-2 
amplified PlGF will be essential. 
 
Chronic inflammation is a hallmark of and a key factor in the pathogenesis of endothelial 
dysfunction (Murdaca, Colombo et al. 2012). Anti-cytokine therapy influences angiogenesis. I 
demonstrated with substantial evidence that inflammatory cytokines TNF-α, IL-1β and INFγ 
have an inhibiting effect on PlGF protein levels (Current study). TNF-α and IL-1β are 
extremely potent inflammatory molecules, besides being the primary mediators of septic 
shock (Feghali and Wright 1997). I showed that TNF-α suppression of PlGF is not only time- 
and concentration-dependent but also regulated at a transcriptional level. Vascular 
endothelium is known to be a specific target of TNF-α (Chia, Qadan et al. 2003, McKellar, 
McCarey et al. 2009, Zhang, Park et al. 2009) causing widespread vascular damage/disruption 
to the endothelium (Mutunga, Fulton et al. 2001). TNFR1 and TNFR2 activate inflammation 
as well as VEGFR2, promoting angiogenesis; a hallmark of chronic inflammation (Review) 
(Pober and Sessa 2007). Moreover, inflammatory response of PlGF involves recruitment of 
inflammatory cells, pericytes and SMCs (Adini, Kornaga et al. 2002, Fischer, Jonckx et al. 
2007, Dewerchin and Carmeliet 2012). In contrast to ECs, it was interesting to note that 
SMCs had elevated PlGF levels in response to TNF-α. It is tempting to speculate that the 
differential effect of TNF-α on PlGF levels in ECs and SMCs may contribute towards the 
imbalance of EC/SMC activators or inhibitors that have been suggested to be associated with 
occlusive disorders such as PE (Dubey, Jackson et al. 1997, Dubeyl, Rosselli et al. 2000). 
However, this hypothesis awaits further confirmation in our cell system. 





Our group previously reported that PlGF up regulates the anti-apoptotic enzyme bcl-2 and 
sustained tube formation in HUVEC (Cai, Ahmad et al. 2003). In the current study, TNF-α 
inhibited angiogenesis was restored by addition of exogenous FGF-2 and PlGF, in line with 
our findings previously (Cai, Ahmad et al. 2003). Infliximab, a chimeric monoclonal 
antibody, and approved treatment for inflammatory disorders, including, RA and Crohn‟s 
disease specifically neutralises the anti-inflammatory effect of TNF-α (Maini and Feldmann 
2002). Of special relevance to angiogenesis, infliximab reduced VEGF expression within the 
arthritic synovium and a reduction in the number of blood vessels in infliximab-treated 
patients. Hence anti-TNF-α therapy does not restore a long-lasting remission; instead its 
perpetuation continues the cytokine imbalance, leading to relapse of disease upon withdrawal 
of the therapy (Review) (Maini and Feldmann 2002).  
 
Women with PE have increased TNF-α level and reduced PlGF. These women and their 
children are reported to be at a higher risk of developing CVD at a later stage in life (Bellamy, 
Casas et al. 2007, Thomas 2014).  TNF-α, EC apoptosis and endothelial dysfunction are 
common denominators of several acute and chronic inflammatory disorders, associated 
clinically with excessive cardiovascular risk and higher mortality than the general population 
(Bellamy, Casas et al. 2007) (Table 6.1). In the current studies, TUNEL assay analyses 
showed that loss of PlGF induced EC apoptosis that could not be reversed by growth factors. 
We believe that the reduced formation of the capillary net in PlGF gene-inactivated cells is 
perhaps a secondary effect to EC apoptosis.  
 




The endothelium is the largest secretory organ in the body, with a surface area comparable to 
approximately six tennis courts. (Cooke 2000). Hence any subtle changes mark a noticeable 
impact. ECs are proposed to be an important source of PlGF, manifesting cellular activities in 
autocrine and paracrine regulation. Multiple approaches can achieve modulation of 
neovascularisation processes; either by blocking the action of pro-angiogenic intermediaries, 
such as the signalling molecules involved in FGF-2-mediated PlGF, or to improve anti-pro-
inflammatory cytokine therapies that may inhibit PlGF, or vice versa. In addition, future 
benefits may be gleaned by working with the common signalling molecules shared between 
neovascularisation and inflammation to inhibit or enhance their response in inflammatory 
angiogenesis. My study provides developments to understand PlGF regulation and subsequent 
involvement in the processes of inflammatory angiogenesis, either by delivering or blocking 
endothelial PlGF, via FGF-2 or inflammatory cytokines such as TNF-α, IL-1β or INFγ 
respectively. Pro-inflammatory mediators, such as TNF-α, suppress endothelial PlGF, and 
loss of PlGF leads to EC apoptosis (current study). Future work to examine whether TNF-α-
suppressed PlGF leads to EC apoptosis in a disease model is warranted. Moreover, EC 
apoptosis is known to contribute to endothelial dysfunction, assessing whether the loss of 
PlGF-induced EC apoptosis leads to endothelial dysregulation remains to be proved in our 
experimental model. Additionally, the signalling molecules mediating EC apoptosis in the 
presence or absence of inflammatory mediators needs to be designed, which would aid in 
understanding the mechanisms and the role of PlGF-manifested EC apoptosis and/or 
endothelial dysfunction in acute or chronic inflammatory disorders if exists.  
 
In addition to being identified as a pro-angiogenic and pro-arteriogenic factor (Dewerchin and 
Carmeliet 2012), PlGF is known to promote atherogenic neointima formation, macrophage 




accumulation, neovascularisation and EC activation (Khurana, Moons et al. 2005, Dewerchin 
and Carmeliet 2012). Short-term delivery of anti-PlGF antibody treatment to ApoE-deficient 
(apoE(-/-)) mice, appeared to act more efficiently during the early phase of atherogenesis, by 
reducing early atherosclerotic plaque size and inflammatory cell infiltration in the lesion 
(Roncal, Buysschaert et al. 2010). By contrast, in the same study CD4:TGFbetaRII (DN) x 
apoE(-/-) mice, a more severe atherosclerosis model, the anti-PlGF antibody was ineffective 
(Roncal, Buysschaert et al. 2010). 
 
Patients with ACS, including AMI, have high plasma PlGF level within 4-24 hours of 
symptom onset has positively correlated with >60% improvement in LVEF (Iwama, Uemura 
et al. 2006), in line with several studies that demonstrated the cardio-protective function of 
PlGF (Table 1.2). PlGF involvement in pathophysiology during the late symptomatic phase of 
ACS could differ from that during early disease (Kim, Cho et al. 2012). PlGF-mediated 
angiogenesis is amplified in response to hypoxic conditions involving cardiomyocytes and 
fibroblasts, which act in a paracrine manner on ECs contributing to myocardial angiogenesis 
(Torry, Tomanek et al. 2009). This process also involves PlGF promoted chemotaxis and 
recruitment of macrophages and monocytes enhancing tissue healing (Torry, Tomanek et al. 
2009). Consequently, PlGF is bi-functional; it could be beneficial or deleterious depends on 
the stage of disease progression. Based on the above-stated findings and the contributing 
factors of SMC and leukocyte recruitment in atherosclerosis, there is a suggestion that the 
differential effects of inflammatory cytokines that are up regulated to abnormal levels (Table 
1.6) in a disease state may aid to learn the hidden consequences during chronic inflammatory 
disorders, including atherosclerosis. Though the data is very preliminary in nature, the 
differential effects of TNF-α on EC and SMC secreted PlGF that is observed in this study, 




wherein endothelial PlGF was suppressed and SMC secreted PlGF was amplified (Current 
study), is a hypothesis that awaits further confirmation in our experimental model. Based on 
the evidence of the in vitro findings the study could be advanced to in vivo analysis.  
PlGF promotes VEGF-mediated angiogenesis in a number of ways. PlGF is thought to bind to 
VEGFR-1, and trigger the downstream signalling to enhance VEGF signalling via VEGFR-2 
(Luttun, Autiero et al. 2004).  PlGF displaces VEGF from VEGFR-1, thus making VEGF 
available for VEGFR-2 interactions (Carmeliet, Moons et al. 2001) or by forming VEGF-
PlGF heterodimers (Cao, Chen et al. 1996). The role of VEGF in PlGF-mediated cellular 
functions is vital. VEGF also enhances the expression of sVEGFR-1 in vitro as well as in vivo 
via autocrine regulation (Ahmad, Hewett et al. 2011). It is very puzzling and beyond the 
scope of the current study to extrapolate the exact role of VEGF and needs to examine VEGF, 
VEGFR-1 and sVEGFR-1 interactions in our experimental model.  
A number of soluble and cell-bound factors may stimulate or inhibit neovascularisation. 
Angiogenesis is a finely tuned note balancing between pro-angiogenic and anti-angiogenic 
mediators, like growth factors, cytokines, chemokines, cellular adhesion molecules and others 
(Cooke 2000, Szekanecz, Besenyei et al. 2010, Kim, Cho et al. 2012). Formation of vascular 
networks is a complex process and involves coordinated workings of multiple growth factors 
and their signalling peptides, which need a thorough understanding of their role in autocrine 
and paracrine regulation. With PlGF being non-redundant in pathological angiogenesis, 
henceforth it needs timely controlled regulation of PlGF to be taken into serious consideration 
to modulate PlGF and/or its receptor, VEGFR-1, as potential therapeutic tools. Our studies 
delineating the distinct signalling enzymes and their pathways involved in FGF-2-induced 
PlGF release and inflammatory mediator effect on suppressed endothelial PlGF that may well 
identify new therapeutic targets for the treatment of various pathologies.  




Chapter 9 Final Conclusion 
The current study and previous lines of evidence demonstrate PlGF to be the target for 
multiple molecules, including growth factors such as VEGF (Yao, Yang et al. 2005) and its 
isoforms (Current study Chapter 4), Ang II (Pan, Fu et al. 2010), and FGF-2 (Current study 
chapters 5 and 6). These growth amplify PlGF expression. Conversly, PlGF is also the target 
for inflammatory mediators like TNF-α, IL-1β or INFγ which suppress PlGF expression 
(Current study chapter 7). Therefore, manipulation of PlGF and its VEGFR-1 that mediate 
pathological angiogenesis is not only an ideal target, but a very decisive target that warrants 
careful examination in the regulation of its expression in different types of endothelial and 
non-ECs origin, on which PlGF and VEGFR-1 manifest their effect in multiple ways. The 
findings of this study, therefore, aid in understanding the modulation of PlGF in response to 
various stimuli, the potential benefit to target therapies and the possibility to alleviate disease.  
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Appendix III  
 Chemical Reagents and Suppliers 
1-Butanol:     Sigma, Poole, UK 
2-Butanol:     Sigma, Poole, UK 
5 x transcription buffer:   Promega, Southampton, UK 
6-keto-PGF1 ELISA kit:    R & D Systems, Abingdon, UK 
-APP:      Calbiochem, Nottingham, UK 
AAV helper free system:     Stratagene, UK 
Acetic acid [glacial]:     Sigma, Poole, UK 
Acrylamide solution [40 %]:   Bio-Rad, UK 
Agar select:     Sigma, Poole, UK 
Agarose:     Sigma, Poole, UK 
Ammonium persulphate:   Sigma, Poole, UK 
Angiokit:      TCS Biologicals, Buckingham,
 
UK 
Angiopoietin1:     R & D Systems, Abingdon, UK 
Angiopoietin2:     R & D Systems, Abingdon, UK 
BCA protein assay:    Bio-Rad, UK 
Bovine serum albumin:   Sigma, Poole, UK 
Bromophenol blue:    Sigma, Poole, UK 
Calcium chloride:     Sigma, Poole, UK 
Carbon dioxide:     Air products, Walton on Thames, UK 
Chloroform:     Sigma, Poole, UK 
Collagen:     Sigma, Poole, UK 




Colloidal Coomassie blue staining kit: Novex, San Diego, CA 
Competent DH5cells:   Gibco, Paisley, Scotland 
Cycloheximide:     Sigma, Poole, UK 
Denhardt's reagent:    Sigma, Poole, UK 
Dextran sulphate:    Sigma, Poole, UK 
Diethyl Pyrocarbonate [DEPC]:  Sigma, Poole, UK 
Diff-Quik staining solution:    Dade Behring Ltd, UK 
DMEM [phenol red free]:   ICN, Basingstoke, UK 
DMSO:     Sigma, Poole, UK 
DTT:      Pharmacia, Herts, UK 
ECL detection kit:    Amersham, Buckinghamshire, UK 
EDTA:     Sigma, Poole, UK 
EGF:      ReliaTECH, Braunschweig, Germany 
Ethanol [99.7-100 %]:   BDH, Poole, UK 
Ethidium bromide:    Sigma, Poole, UK 
FGF:      ReliaTECH, Braunschweig, Germany 
Foetal calf serum:    Gibco, Paisley, Scotland 
FURA2:     Sigma, Poole, UK 
Gelatin:     Sigma, Poole, UK 
GF109203X:      Calbiochem, Nottingham, UK 
Glycerol:     Sigma, Poole, UK 
Glycine:     Sigma, Poole, UK 
Goat serum:     Sigma, Poole, UK 




Gö6976:     Calbiochem, Nottingham, UK 
GW5074:      Calbiochem, Nottingham, UK 
Ham F12:     ICN, Basingstoke, UK 
Heparin:     Sigma, Poole, UK 
HEPES:      Sigma, Poole, UK 
Hispidin:      Calbiochem, Nottingham, UK 
Hybond N+ nylon membrane:  Amersham, Buckinghamshire, UK 
Hydrogen chloride:    Sigma, Poole, UK 
Hydrogen peroxide:    Sigma, Poole, UK 
Imidazole:      Sigma, Poole, UK 
Isohelenin:      Calbiochem, Nottingham, UK 
Isopropanol:     Sigma, Poole, UK 
Kaleidoscope prestained standards:  Bio-Rad, UK 
Kodak, X-Omat AR film:   Sigma, Poole, UK 
KT-5823:      Calbiochem, Nottingham, UK 
L-Glutamine:     Sigma, Poole, UK 
Leupeptin:     Sigma, Poole, UK 
L-NNA [N
G
-NO2-L-Arginine]:   Calbiochem, Nottingham, UK 
LY294002:      Calbiochem, Nottingham, UK 
Magnesium sulphate:    Sigma, Poole, UK 
Marvell dried milk:    Sainsbury's, Birmingham, UK 
Matrigel [growth factor-reduced]:    BD Biosciences, Cowley, UK  
Mayer's Haematoxylin:   Sigma, Poole, UK 




Hispidin:      Calbiochem, Nottingham, UK 
M199 medium:     ICN, Basingstoke, UK 
Methanol:     Sigma, Poole, UK 
Microcarrier beads:     Sigma, Poole, UK 
Mineral oil:     Sigma, Poole, UK 
MG262:      Calbiochem, Nottingham, UK 
MTT:      Sigma, Poole, UK 
Murine sVEGFR-1 ELISA Duoset:   R & D Systems, Abingdon, UK 
NP40:      Sigma, Poole, UK 
ODQ:       Calbiochem, Nottingham, UK 
Owrens buffer:    Sigma, Poole, UK 
PCR loading dye:    Sigma, Poole, UK 
Penicillin:     Gibco, Paisley, Scotland 
Pepstatin A:     Sigma, Poole, UK  
Phenol:chroroform:    Sigma, Poole, UK 
Phenylmethylsulfonyl fluoride [PMSF]: Sigma, Poole, UK 
Phosphate buffered saline tablets [PBS]: Sigma, Poole, UK 
Phosphatidic acid:    Calbiochem, Nottingham, UK 
PlGF-1:      ReliaTECH, Braunschweig, Germany 
PMA:      Calbiochem, Nottingham, UK 
Potassium chloride:    Sigma, Poole, UK 
PP2:      Calbiochem, Nottingham, UK 
Proteinase K:     Boehringer Mannheim, Sussex, UK 




Protein A-agarose:    Sigma, Poole, UK 
Protein G-agarose:     Sigma, Poole, UK 
QIAprep-spin Plasmid Kit:   Qiagen, Surrey, UK 
QIAquick extraction kit:   Qiagen, Surrey, UK 
Rapamycin:     Calbiochem, Nottingham, UK 
Restriction enzymes:    Amersham, Buckinghamshire, UK 
RNase A:     Sigma, Poole, UK 
Ro 320432:     Calbiochem, Nottingham, UK 
RPMI 1640:     Gibco, Paisley, Scotland 
Shrimp Alkaline phosphatase:   NEB, UK 
Silica gel:     Sigma, Poole, UK 
Sodium acetate:    Sigma, Poole, UK 
Sodium chloride:    Sigma, Poole, UK 
Sodium citrate:    Sigma, Poole, UK 
Sodium dodecyl sulphate:   Sigma, Poole, UK 
Soluble VEGFR-1 receptor-Fc:   R & D Systems, Abingdon, UK 
Sodium hydroxide:    Sigma, Poole, UK 
Streptomycin:     Gibco, Paisley, Scotland 
T4- DNA ligase:     NEB, UK 
TC-100 medium:    Gibco, Paisley, Scotland 
TEMED:     Bio-Rad 
Thymeleatoxin:    Calbiochem, Nottingham, UK 
Triethanolamine:    Sigma, Poole, UK 




Tris:      Sigma, Poole, UK 
Triton X-100:     Sigma, Poole, UK 
Trypsin:     Sigma, Poole, UK 
Tween-20:     Sigma, Poole, UK 
U0126:      Calbiochem, Nottingham, UK 
U73122:     Calbiochem, Nottingham, UK 
VEGF-A:     ReliaTECH, Braunschweig, Germany 
VEGF-E      ReliaTECH, Braunschweig, Germany 
VEGF-A:PlGF-1:     ReliaTECH, Braunschweig, Germany 
Xylene:     Surgipath, Cambridgeshire, UK 
 
All other cell culture reagents and chemicals were obtained from Sigma, Poole, UK. 
 
